STOCK TITAN

Vivos Therapeutics issues going-concern warning

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
10-Q

Rhea-AI Filing Summary

Vivos Therapeutics, Inc. (VVOS) reported nine-month revenue of $16.708 million, versus $13.619 million a year earlier; third-quarter revenue was $6.414 million versus $6.783 million. Nine-month net loss was $15.245 million versus $14.276 million, while third-quarter net loss was $1.971 million versus $5.400 million, with $2.906 million in other income.

As of September 30, 2026, cash and equivalents were $247,000, and operating activities used $12.334 million over nine months. Vivos said its approximately $0.2 million cash balance would not fund operations and strategic objectives for the next 12 months; without additional financing, substantial doubt exists about its ability to continue as a going concern. Management said financing would be needed through the first quarter of 2027.

On August 4, 2026, Streeterville exchanged $3.25 million of debt for common and non-convertible preferred stock, which carries a 9% annual dividend. On September 2, 2026, Streeterville exchanged $2,861,270 of debt for 11,445,080 common shares at an average $0.25 per share; those shares represented about 34% of post-exchange outstanding common stock, and Vivos received no proceeds. Streeterville note principal was approximately $2.3 million as of September 30, 2026, due June 10, 2027.

2 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

1 major · 4 points

Hollow bars mark forward-looking points. How the balance works

Positive

  • Moderate pointNine-month revenue was $16.708 million, versus $13.619 million in 2025.
  • Moderate pointThird-quarter net loss was $1.971 million, versus $5.400 million in 2025.

Negative

  • Major point. Forward-looking: it has not happened yet and may not happen.Substantial doubt: approximately $0.2 million cash cannot fund the next 12 months.
  • Moderate pointNine-month net loss was $15.245 million, versus $14.276 million in 2025.
  • Moderate pointThird-quarter revenue was $6.414 million, versus $6.783 million in 2025.
  • Moderate pointOperating cash used was $12.334 million, versus $11.451 million.

Filing Explained

The completed private placement creates an additional path to common-share issuance through preferred conversion and warrant exercise, separate from ATM shares already sold.

Form 10-Q is the unaudited quarterly report; this one says Vivos Therapeutics completed a private placement on June 30, 2026. The placement issued 3,608,495 Series A preferred shares, each convertible into one common share, plus warrants for the same number of common shares; the disclosed transaction included $1 million in cash and $1 million of previously funded bridge debt converted into the financing. If the preferred shares convert and warrants are exercised, additional common shares would be issued, reducing existing holders’ percentage ownership.

Separately, during the nine months ended September 30, 2026, Vivos sold 6,414,104 shares through its at-the-market program at an average of $0.45 per share, generating about $2.4 million net of commissions; $0.4 million remained available, but Vivos was not required to sell it.

Nine-month revenue $16.708 million Nine months ended September 30, 2026; $13.619 million in the 2025 period.
Third-quarter revenue $6.414 million Three months ended September 30, 2026; $6.783 million in the 2025 period.
Nine-month net loss $15.245 million loss Nine months ended September 30, 2026; $14.276 million loss in the 2025 period.
Third-quarter net loss $1.971 million loss Three months ended September 30, 2026; $5.400 million loss in the 2025 period.
Cash and cash equivalents $247,000 As of September 30, 2026.
Net cash used in operating activities $12.334 million Nine months ended September 30, 2026; $11.451 million used in the 2025 period.
Common shares issued in Streeterville debt exchange 11,445,080 shares Exchanged for partitioned notes on September 2, 2026, at an average exchange price of $0.25 per share.
Post-exchange outstanding common stock represented by exchanged shares Approximately 34% Shares issued to Streeterville in the September 2, 2026 exchanges.
going concern financial
"substantial doubt regarding the Company’s ability to continue as a going concern"
Going concern is the accounting assumption that a company will keep operating and meeting its obligations for the foreseeable future. The phrase matters most when a company or its auditors disclose substantial doubt about it, a formal warning that the business may not have enough resources to continue without raising money, restructuring, or selling assets. That language in a filing or press release signals elevated financial risk.
Employee Retention Credit financial
"reversed its previously recorded ERC liability"
A government-provided payroll tax credit that reimburses employers for a portion of wages paid to staff during qualifying downturns or disruptions, designed to encourage businesses to keep employees on the payroll. For investors, it matters because the credit improves a company’s cash flow and reduces payroll expenses—like a temporary government subsidy that boosts short-term profits and may change the company’s reported tax liabilities and cash reserves, which can affect valuation and risk assessments.
original issue discount financial
"includes an original issue discount of $0.7 million"
Original issue discount (OID) is the difference between a debt security’s face value and the lower price at which it is first sold, treated as additional interest that accrues over the life of the instrument. For investors it matters because OID raises the effective yield and changes taxable income and the holding’s cost basis over time — think of buying a $100 voucher for $90 and recognizing the $10 gain as earned interest as the voucher approaches maturity.
At-The-Market financial
"At-The-Market Equity Offering"
"At-the-market" is a method for companies to sell new shares of stock directly into the open market over time, rather than all at once. It allows companies to raise money gradually, similar to selling slices of a pie instead of the entire pie at once, which can help manage the sale's impact on the stock price. This approach gives investors a steady supply of shares while providing companies with flexible funding options.
Series B Non-Convertible Preferred Stock financial
"Series B Non-Convertible Preferred Stock is non-convertible"
beneficial ownership regulatory
"Streeterville’s beneficial ownership of the common stock is limited to 4.9%"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much revenue did VVOS report for the first nine months of 2026?

Vivos Therapeutics reported $16.708 million in revenue for the nine months ended September 30, 2026, versus $13.619 million for the same period in 2025. Service revenue was $12.141 million and product revenue was $4.567 million.

How many shares did VVOS issue to Streeterville in September 2026?

On September 2, 2026, Streeterville exchanged notes with $2,861,270 of outstanding principal for 11,445,080 shares of VVOS common stock at an average exchange price of $0.25 per share. The shares represented approximately 34% of post-exchange outstanding common stock, and VVOS received no proceeds.

What terms apply to VVOS Series B preferred stock?

The Series B Non-Convertible Preferred Stock is non-convertible, non-voting except in certain limited circumstances, and non-transferable. It has a liquidation preference over common stock and pays a 9% annual dividend, compounding daily and payable quarterly.

How much remained available under VVOS’s ATM program?

Approximately $0.4 million remained available for future sales as of September 30, 2026. During the nine months ended that date, VVOS sold 6,414,104 shares at an average price of $0.45 per share, receiving approximately $2.4 million net of commissions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false Q3 --12-31 0001716166 Yes Yes 0001716166 2026-01-01 2026-09-30 0001716166 2026-11-12 0001716166 2026-09-30 0001716166 2025-12-31 0001716166 2026-07-01 2026-09-30 0001716166 2025-07-01 2025-09-30 0001716166 2025-01-01 2025-09-30 0001716166 us-gaap:ProductMember 2026-07-01 2026-09-30 0001716166 us-gaap:ProductMember 2025-07-01 2025-09-30 0001716166 us-gaap:ProductMember 2026-01-01 2026-09-30 0001716166 us-gaap:ProductMember 2025-01-01 2025-09-30 0001716166 us-gaap:ServiceMember 2026-07-01 2026-09-30 0001716166 us-gaap:ServiceMember 2025-07-01 2025-09-30 0001716166 us-gaap:ServiceMember 2026-01-01 2026-09-30 0001716166 us-gaap:ServiceMember 2025-01-01 2025-09-30 0001716166 us-gaap:PreferredStockMember 2024-12-31 0001716166 us-gaap:PreferredStockIncludingAdditionalPaidInCapitalMember 2024-12-31 0001716166 us-gaap:CommonStockMember 2024-12-31 0001716166 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001716166 us-gaap:RetainedEarningsMember 2024-12-31 0001716166 us-gaap:ParentMember 2024-12-31 0001716166 us-gaap:NoncontrollingInterestMember 2024-12-31 0001716166 2024-12-31 0001716166 us-gaap:PreferredStockMember 2025-03-31 0001716166 us-gaap:PreferredStockIncludingAdditionalPaidInCapitalMember 2025-03-31 0001716166 us-gaap:CommonStockMember 2025-03-31 0001716166 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0001716166 us-gaap:RetainedEarningsMember 2025-03-31 0001716166 us-gaap:ParentMember 2025-03-31 0001716166 us-gaap:NoncontrollingInterestMember 2025-03-31 0001716166 2025-03-31 0001716166 us-gaap:PreferredStockMember 2025-06-30 0001716166 us-gaap:PreferredStockIncludingAdditionalPaidInCapitalMember 2025-06-30 0001716166 us-gaap:CommonStockMember 2025-06-30 0001716166 us-gaap:AdditionalPaidInCapitalMember 2025-06-30 0001716166 us-gaap:RetainedEarningsMember 2025-06-30 0001716166 us-gaap:ParentMember 2025-06-30 0001716166 us-gaap:NoncontrollingInterestMember 2025-06-30 0001716166 2025-06-30 0001716166 us-gaap:PreferredStockMember 2025-12-31 0001716166 us-gaap:PreferredStockIncludingAdditionalPaidInCapitalMember 2025-12-31 0001716166 us-gaap:CommonStockMember 2025-12-31 0001716166 us-gaap:AdditionalPaidInCapitalMember 2025-12-31 0001716166 us-gaap:RetainedEarningsMember 2025-12-31 0001716166 us-gaap:ParentMember 2025-12-31 0001716166 us-gaap:NoncontrollingInterestMember 2025-12-31 0001716166 us-gaap:PreferredStockMember 2026-03-31 0001716166 us-gaap:PreferredStockIncludingAdditionalPaidInCapitalMember 2026-03-31 0001716166 us-gaap:CommonStockMember 2026-03-31 0001716166 us-gaap:AdditionalPaidInCapitalMember 2026-03-31 0001716166 us-gaap:RetainedEarningsMember 2026-03-31 0001716166 us-gaap:ParentMember 2026-03-31 0001716166 us-gaap:NoncontrollingInterestMember 2026-03-31 0001716166 2026-03-31 0001716166 us-gaap:PreferredStockMember 2026-06-30 0001716166 us-gaap:PreferredStockIncludingAdditionalPaidInCapitalMember 2026-06-30 0001716166 us-gaap:CommonStockMember 2026-06-30 0001716166 us-gaap:AdditionalPaidInCapitalMember 2026-06-30 0001716166 us-gaap:RetainedEarningsMember 2026-06-30 0001716166 us-gaap:ParentMember 2026-06-30 0001716166 us-gaap:NoncontrollingInterestMember 2026-06-30 0001716166 2026-06-30 0001716166 us-gaap:PreferredStockMember 2025-01-01 2025-03-31 0001716166 us-gaap:PreferredStockIncludingAdditionalPaidInCapitalMember 2025-01-01 2025-03-31 0001716166 us-gaap:CommonStockMember 2025-01-01 2025-03-31 0001716166 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-31 0001716166 us-gaap:RetainedEarningsMember 2025-01-01 2025-03-31 0001716166 us-gaap:ParentMember 2025-01-01 2025-03-31 0001716166 us-gaap:NoncontrollingInterestMember 2025-01-01 2025-03-31 0001716166 2025-01-01 2025-03-31 0001716166 us-gaap:PreferredStockMember 2025-04-01 2025-06-30 0001716166 us-gaap:PreferredStockIncludingAdditionalPaidInCapitalMember 2025-04-01 2025-06-30 0001716166 us-gaap:CommonStockMember 2025-04-01 2025-06-30 0001716166 us-gaap:AdditionalPaidInCapitalMember 2025-04-01 2025-06-30 0001716166 us-gaap:RetainedEarningsMember 2025-04-01 2025-06-30 0001716166 us-gaap:ParentMember 2025-04-01 2025-06-30 0001716166 us-gaap:NoncontrollingInterestMember 2025-04-01 2025-06-30 0001716166 2025-04-01 2025-06-30 0001716166 us-gaap:PreferredStockMember 2025-07-01 2025-09-30 0001716166 us-gaap:PreferredStockIncludingAdditionalPaidInCapitalMember 2025-07-01 2025-09-30 0001716166 us-gaap:CommonStockMember 2025-07-01 2025-09-30 0001716166 us-gaap:AdditionalPaidInCapitalMember 2025-07-01 2025-09-30 0001716166 us-gaap:RetainedEarningsMember 2025-07-01 2025-09-30 0001716166 us-gaap:ParentMember 2025-07-01 2025-09-30 0001716166 us-gaap:NoncontrollingInterestMember 2025-07-01 2025-09-30 0001716166 us-gaap:PreferredStockMember 2026-01-01 2026-03-31 0001716166 us-gaap:PreferredStockIncludingAdditionalPaidInCapitalMember 2026-01-01 2026-03-31 0001716166 us-gaap:CommonStockMember 2026-01-01 2026-03-31 0001716166 us-gaap:AdditionalPaidInCapitalMember 2026-01-01 2026-03-31 0001716166 us-gaap:RetainedEarningsMember 2026-01-01 2026-03-31 0001716166 us-gaap:ParentMember 2026-01-01 2026-03-31 0001716166 us-gaap:NoncontrollingInterestMember 2026-01-01 2026-03-31 0001716166 2026-01-01 2026-03-31 0001716166 us-gaap:PreferredStockMember 2026-04-01 2026-06-30 0001716166 us-gaap:PreferredStockIncludingAdditionalPaidInCapitalMember 2026-04-01 2026-06-30 0001716166 us-gaap:CommonStockMember 2026-04-01 2026-06-30 0001716166 us-gaap:AdditionalPaidInCapitalMember 2026-04-01 2026-06-30 0001716166 us-gaap:RetainedEarningsMember 2026-04-01 2026-06-30 0001716166 us-gaap:ParentMember 2026-04-01 2026-06-30 0001716166 us-gaap:NoncontrollingInterestMember 2026-04-01 2026-06-30 0001716166 2026-04-01 2026-06-30 0001716166 us-gaap:PreferredStockMember 2026-07-01 2026-09-30 0001716166 us-gaap:PreferredStockIncludingAdditionalPaidInCapitalMember 2026-07-01 2026-09-30 0001716166 us-gaap:CommonStockMember 2026-07-01 2026-09-30 0001716166 us-gaap:AdditionalPaidInCapitalMember 2026-07-01 2026-09-30 0001716166 us-gaap:RetainedEarningsMember 2026-07-01 2026-09-30 0001716166 us-gaap:ParentMember 2026-07-01 2026-09-30 0001716166 us-gaap:NoncontrollingInterestMember 2026-07-01 2026-09-30 0001716166 us-gaap:PreferredStockMember 2025-09-30 0001716166 us-gaap:PreferredStockIncludingAdditionalPaidInCapitalMember 2025-09-30 0001716166 us-gaap:CommonStockMember 2025-09-30 0001716166 us-gaap:AdditionalPaidInCapitalMember 2025-09-30 0001716166 us-gaap:RetainedEarningsMember 2025-09-30 0001716166 us-gaap:ParentMember 2025-09-30 0001716166 us-gaap:NoncontrollingInterestMember 2025-09-30 0001716166 2025-09-30 0001716166 us-gaap:PreferredStockMember 2026-09-30 0001716166 us-gaap:PreferredStockIncludingAdditionalPaidInCapitalMember 2026-09-30 0001716166 us-gaap:CommonStockMember 2026-09-30 0001716166 us-gaap:AdditionalPaidInCapitalMember 2026-09-30 0001716166 us-gaap:RetainedEarningsMember 2026-09-30 0001716166 us-gaap:ParentMember 2026-09-30 0001716166 us-gaap:NoncontrollingInterestMember 2026-09-30 0001716166 2020-08-12 0001716166 VVOS:TheSleepCenterOfNevadaMember 2025-06-10 2025-06-10 0001716166 VVOS:TheSleepCenterOfNevadaMember us-gaap:CommonStockMember 2025-06-10 2025-06-10 0001716166 VVOS:AIMDetroitMember 2025-07-14 0001716166 VVOS:AppliancesMember 2026-07-01 2026-09-30 0001716166 VVOS:AppliancesMember 2025-07-01 2025-09-30 0001716166 VVOS:AppliancesMember 2026-01-01 2026-09-30 0001716166 VVOS:AppliancesMember 2025-01-01 2025-09-30 0001716166 VVOS:ToothPositionersMember 2026-07-01 2026-09-30 0001716166 VVOS:ToothPositionersMember 2025-07-01 2025-09-30 0001716166 VVOS:ToothPositionersMember 2026-01-01 2026-09-30 0001716166 VVOS:ToothPositionersMember 2025-01-01 2025-09-30 0001716166 VVOS:SleepTestingServicesMember 2026-07-01 2026-09-30 0001716166 VVOS:SleepTestingServicesMember 2025-07-01 2025-09-30 0001716166 VVOS:SleepTestingServicesMember 2026-01-01 2026-09-30 0001716166 VVOS:SleepTestingServicesMember 2025-01-01 2025-09-30 0001716166 VVOS:TreatmentCentersMember 2026-07-01 2026-09-30 0001716166 VVOS:TreatmentCentersMember 2025-07-01 2025-09-30 0001716166 VVOS:TreatmentCentersMember 2026-01-01 2026-09-30 0001716166 VVOS:TreatmentCentersMember 2025-01-01 2025-09-30 0001716166 VVOS:VIPMember 2026-07-01 2026-09-30 0001716166 VVOS:VIPMember 2025-07-01 2025-09-30 0001716166 VVOS:VIPMember 2026-01-01 2026-09-30 0001716166 VVOS:VIPMember 2025-01-01 2025-09-30 0001716166 VVOS:BillingIntelligenceServicesMember 2026-07-01 2026-09-30 0001716166 VVOS:BillingIntelligenceServicesMember 2025-07-01 2025-09-30 0001716166 VVOS:BillingIntelligenceServicesMember 2026-01-01 2026-09-30 0001716166 VVOS:BillingIntelligenceServicesMember 2025-01-01 2025-09-30 0001716166 VVOS:MyofunctionalTherapyServicesMember 2026-07-01 2026-09-30 0001716166 VVOS:MyofunctionalTherapyServicesMember 2025-07-01 2025-09-30 0001716166 VVOS:MyofunctionalTherapyServicesMember 2026-01-01 2026-09-30 0001716166 VVOS:MyofunctionalTherapyServicesMember 2025-01-01 2025-09-30 0001716166 VVOS:SponsorshipSeminarOtherMember 2026-07-01 2026-09-30 0001716166 VVOS:SponsorshipSeminarOtherMember 2025-07-01 2025-09-30 0001716166 VVOS:SponsorshipSeminarOtherMember 2026-01-01 2026-09-30 0001716166 VVOS:SponsorshipSeminarOtherMember 2025-01-01 2025-09-30 0001716166 us-gaap:FurnitureAndFixturesMember 2026-09-30 0001716166 us-gaap:FurnitureAndFixturesMember 2025-12-31 0001716166 us-gaap:LeaseholdImprovementsMember 2026-09-30 0001716166 us-gaap:LeaseholdImprovementsMember 2025-12-31 0001716166 us-gaap:ToolsDiesAndMoldsMember 2026-09-30 0001716166 us-gaap:ToolsDiesAndMoldsMember 2025-12-31 0001716166 us-gaap:SoftwareDevelopmentMember 2026-09-30 0001716166 us-gaap:IntellectualPropertyMember 2026-09-30 0001716166 VVOS:ReferralRelationshipsMember 2026-09-30 0001716166 VVOS:TheSleepCenterOfNevadaMember 2026-09-30 0001716166 VVOS:TheSleepCenterOfNevadaMember 2025-12-31 0001716166 VVOS:BioModelingMember 2026-09-30 0001716166 VVOS:BioModelingMember 2025-12-31 0001716166 VVOS:EmpoweredDentalMember 2026-09-30 0001716166 VVOS:EmpoweredDentalMember 2025-12-31 0001716166 VVOS:LyonDentalMember 2026-09-30 0001716166 VVOS:LyonDentalMember 2025-12-31 0001716166 VVOS:PatentsAndDevelopedTechnologyMember 2026-09-30 0001716166 VVOS:PatentsAndDevelopedTechnologyMember 2025-12-31 0001716166 VVOS:InternalUseSoftwareMember 2026-09-30 0001716166 VVOS:InternalUseSoftwareMember 2025-12-31 0001716166 us-gaap:TradeNamesMember 2026-09-30 0001716166 us-gaap:TradeNamesMember 2025-12-31 0001716166 us-gaap:OtherIntangibleAssetsMember 2026-09-30 0001716166 us-gaap:OtherIntangibleAssetsMember 2025-12-31 0001716166 VVOS:AirwayIntegratedManagementCompanyLLCMember 2025-06-09 0001716166 VVOS:AirwayIntegratedManagementCompanyLLCMember 2025-06-09 2025-06-09 0001716166 VVOS:AirwayIntegratedManagementCompanyLLCMember srt:MaximumMember 2025-06-09 2025-06-09 0001716166 VVOS:AirwayIntegratedManagementCompanyLLCMember 2026-09-30 0001716166 VVOS:AirwayIntegratedManagementCompanyLLCMember 2025-12-31 0001716166 VVOS:AirwayIntegratedManagementCompanyLLCMember srt:MinimumMember 2025-06-09 2025-06-09 0001716166 VVOS:AirwayIntegratedManagementCompanyLLCMember 2026-09-02 0001716166 VVOS:AvondaleCapitalLlcMember 2025-12-05 0001716166 VVOS:AvondaleCapitalLlcMember 2025-12-05 2025-12-05 0001716166 VVOS:AvondaleCapitalLlcMember 2026-01-01 2026-09-30 0001716166 VVOS:ShortTermAgreementMember 2026-09-30 0001716166 us-gaap:MeasurementInputDiscountRateMember 2026-01-01 2026-09-30 0001716166 VVOS:TheSleepCenterOfNevadaMember 2026-09-30 0001716166 VVOS:TheSleepCenterOfNevadaMember 2025-12-31 0001716166 VVOS:SecuritiesPurchaseAgreementMember VVOS:BiggerCapitalFundLPMember 2026-06-30 2026-06-30 0001716166 VVOS:SecuritiesPurchaseAgreementMember VVOS:BiggerCapitalFundLPMember 2026-06-30 0001716166 VVOS:SecuritiesPurchaseAgreementMember VVOS:BiggerCapitalFundLPMember us-gaap:SeriesAPreferredStockMember 2026-06-30 0001716166 VVOS:SecuritiesPurchaseAgreementMember VVOS:BiggerCapitalFundLPMember srt:MinimumMember 2026-06-30 0001716166 VVOS:SecuritiesPurchaseAgreementMember VVOS:BiggerCapitalFundLPMember srt:MaximumMember 2026-06-30 0001716166 VVOS:SecuritiesPurchaseAgreementMember 2026-06-30 0001716166 VVOS:January2026WarrantInducementMember 2026-01-15 0001716166 VVOS:January2026WarrantInducementMember 2026-01-15 2026-01-15 0001716166 VVOS:JanuaryTwoThousandAndTwentySixVCoInvestorsThreeLLCNoteMember 2026-01-15 0001716166 VVOS:JanuaryTwoThousandAndTwentySixVCoInvestorsThreeLLCNoteMember 2026-01-15 2026-01-15 0001716166 VVOS:JanuaryTwoThousandAndTwentySixVCoInvestorsThreeLLCNoteMember 2026-03-26 2026-03-26 0001716166 VVOS:MarchTwoThousandAndTwentySixPIPEOfferingMember 2026-03-31 2026-03-31 0001716166 VVOS:MarchTwoThousandAndTwentySixPreFundedWarrantMember 2026-03-31 0001716166 VVOS:MarchTwoThousandAndTwentySixSeriesAWarrantMember 2026-03-31 0001716166 VVOS:MarchTwoThousandAndTwentySixSeriesBWarrantMember 2026-03-31 0001716166 VVOS:VCoInvestorsThreeLLCMember VVOS:MarchTwoThousandAndTwentySixCommonStockPurchaseWarrantMember 2026-03-31 0001716166 VVOS:VCoInvestorsThreeLLCMember VVOS:MarchTwoThousandAndTwentySixPIPEOfferingMember 2026-03-31 2026-03-31 0001716166 VVOS:VCoInvestorsThreeLLCMember 2026-03-31 2026-03-31 0001716166 VVOS:VCoInvestorsThreeLLCMember 2026-03-31 0001716166 VVOS:MarchTwoThousandAndTwentySixCommonStockPurchaseWarrantMember 2026-03-31 0001716166 VVOS:NewSenecaPartnersIncMember 2026-03-31 0001716166 VVOS:StreetervilleCapitalLLCMember VVOS:SeriesBNonConvertiblePreferredStockMember 2026-06-05 0001716166 VVOS:StreetervilleCapitalLLCMember VVOS:SeriesBNonConvertiblePreferredStockMember 2026-06-18 2026-06-18 0001716166 VVOS:StreetervilleCapitalLLCMember us-gaap:CommonStockMember 2026-08-04 0001716166 VVOS:StreetervilleCapitalLLCMember us-gaap:CommonStockMember 2026-08-04 2026-08-04 0001716166 VVOS:StreetervilleCapitalLLCMember VVOS:SeriesBNonConvertiblePreferredStockMember 2026-08-04 2026-08-04 0001716166 VVOS:StreetervilleCapitalLLCMember VVOS:SeriesBNonConvertiblePreferredStockMember 2026-08-04 0001716166 VVOS:StreetervilleCapitalLLCMember 2026-08-31 0001716166 VVOS:StreetervilleCapitalLLCMember 2026-09-02 2026-09-02 0001716166 VVOS:StreetervilleCapitalLLCMember 2026-09-02 0001716166 VVOS:StreetervilleCapitalLLCMember 2026-09-02 0001716166 VVOS:StreetervilleCapitalLLCMember us-gaap:CommonStockMember 2026-09-02 2026-09-02 0001716166 VVOS:StreetervilleCapitalLLCMember 2026-09-30 0001716166 us-gaap:SeriesCPreferredStockMember us-gaap:SubsequentEventMember 2026-10-16 0001716166 VVOS:SodSciencesIncMember us-gaap:SubsequentEventMember 2026-10-16 0001716166 VVOS:ATMSalesAgreementMember us-gaap:CommonStockMember 2025-09-12 2025-09-12 0001716166 VVOS:ATMSalesAgreementMember us-gaap:CommonStockMember 2026-01-01 2026-09-30 0001716166 VVOS:ATMSalesAgreementMember us-gaap:CommonStockMember 2026-09-30 0001716166 VVOS:TwoThousandTwentyFourOmnibusPlanMember 2024-11-26 0001716166 VVOS:TwoThousandNineteenPlanMember 2024-11-26 0001716166 VVOS:TwoThousandTwentyFourOmnibusPlanMember 2025-11-03 0001716166 VVOS:TwoThousandTwentyFourOmnibusPlanMember 2025-11-04 0001716166 VVOS:TwoThousandTwentyFourOmnibusPlanMember 2026-01-01 2026-09-30 0001716166 us-gaap:WarrantMember 2026-01-01 2026-09-30 0001716166 us-gaap:EmployeeStockOptionMember 2025-12-31 0001716166 us-gaap:EmployeeStockOptionMember 2025-01-01 2025-12-31 0001716166 us-gaap:EmployeeStockOptionMember 2026-01-01 2026-09-30 0001716166 us-gaap:EmployeeStockOptionMember 2026-09-30 0001716166 us-gaap:RestrictedStockUnitsRSUMember 2025-12-31 0001716166 us-gaap:RestrictedStockUnitsRSUMember 2025-01-01 2025-12-31 0001716166 us-gaap:RestrictedStockUnitsRSUMember 2026-01-01 2026-09-30 0001716166 us-gaap:RestrictedStockUnitsRSUMember 2026-09-30 0001716166 2025-01-01 2025-12-31 0001716166 us-gaap:PrivatePlacementMember 2026-01-01 2026-09-30 0001716166 VVOS:WarrantInducementMember 2026-01-01 2026-09-30 0001716166 us-gaap:MeasurementInputSharePriceMember us-gaap:WarrantMember 2026-09-30 0001716166 us-gaap:MeasurementInputExpectedTermMember us-gaap:WarrantMember 2026-09-30 0001716166 us-gaap:MeasurementInputRiskFreeInterestRateMember us-gaap:WarrantMember 2026-09-30 0001716166 us-gaap:MeasurementInputPriceVolatilityMember us-gaap:WarrantMember 2026-09-30 0001716166 us-gaap:MeasurementInputExpectedDividendRateMember us-gaap:WarrantMember 2026-09-30 0001716166 VVOS:LeaseOneNovemberTwoThousandTwentyFourMember 2024-11-01 2024-11-30 0001716166 VVOS:LeaseOneNovemberTwoThousandTwentyFourMember 2026-09-30 0001716166 VVOS:LeaseOneNovemberTwoThousandTwentyFourMember 2026-01-01 2026-09-30 0001716166 VVOS:LeaseTwoJanuaryTwoThousandTwentyFourMember 2026-01-01 2026-09-30 0001716166 VVOS:LeaseTwoJanuaryTwoThousandTwentyFourMember 2026-09-30 0001716166 VVOS:LeaseThreeDecemberThousandTwentyFiveMember 2025-12-31 0001716166 VVOS:LeaseThreeDecemberThousandTwentyFiveMember 2026-01-01 2026-09-30 0001716166 VVOS:LeaseThreeDecemberThousandTwentyFiveMember 2026-09-30 0001716166 srt:ChiefExecutiveOfficerMember us-gaap:CommonStockMember 2026-01-01 2026-09-30 0001716166 srt:ChiefExecutiveOfficerMember us-gaap:CommonStockMember 2026-09-30 0001716166 VVOS:MasterServicesAgreementMember 2026-07-31 2026-07-31 0001716166 VVOS:MasterServicesAgreementMember 2026-07-31 0001716166 VVOS:MasterServicesAgreementMember us-gaap:SubsequentEventMember 2026-07-31 2026-10-09 0001716166 us-gaap:WarrantMember 2026-01-01 2026-09-30 0001716166 us-gaap:WarrantMember 2025-01-01 2025-09-30 0001716166 us-gaap:RestrictedStockUnitsRSUMember 2026-01-01 2026-09-30 0001716166 us-gaap:RestrictedStockUnitsRSUMember 2025-01-01 2025-09-30 0001716166 us-gaap:EmployeeStockOptionMember 2026-01-01 2026-09-30 0001716166 us-gaap:EmployeeStockOptionMember 2025-01-01 2025-09-30 0001716166 us-gaap:CustomerConcentrationRiskMember us-gaap:AccountsReceivableMember VVOS:NoSingleCustomerMember 2026-01-01 2026-09-30 0001716166 us-gaap:SupplierConcentrationRiskMember us-gaap:CostOfGoodsTotalMember VVOS:FiveSuppliersMember 2026-01-01 2026-09-30 0001716166 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2026-09-30 0001716166 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2025-12-31 0001716166 srt:MaximumMember 2026-04-30 0001716166 srt:MinimumMember 2026-04-30 0001716166 srt:MinimumMember 2026-04-01 2026-04-30 0001716166 VVOS:StreetervilleCapitalLLCMember us-gaap:SubsequentEventMember us-gaap:SeriesCPreferredStockMember 2026-10-14 2026-10-14 0001716166 VVOS:SodSciencesIncMember us-gaap:SubsequentEventMember 2026-10-16 2026-10-16 0001716166 VVOS:SodSciencesIncMember us-gaap:SubsequentEventMember srt:ScenarioPreviouslyReportedMember 2026-10-16 2026-10-16 0001716166 us-gaap:SubsequentEventMember VVOS:SeriesCConvertiblePreferredStockMember VVOS:SodSciencesIncMember 2026-10-16 2026-10-16 0001716166 us-gaap:SubsequentEventMember us-gaap:SeriesCPreferredStockMember VVOS:SodSciencesIncMember 2026-10-16 0001716166 us-gaap:SubsequentEventMember VVOS:SodSciencesIncMember VVOS:SeriesCConvertiblePreferredStockMember 2026-10-16 0001716166 us-gaap:SubsequentEventMember us-gaap:SeriesCPreferredStockMember 2026-10-16 2026-10-16 0001716166 us-gaap:SeriesAPreferredStockMember us-gaap:SubsequentEventMember 2026-12-02 2026-12-02 0001716166 us-gaap:SeriesCPreferredStockMember us-gaap:SubsequentEventMember 2026-12-02 2026-12-02 0001716166 us-gaap:SubsequentEventMember 2026-12-02 0001716166 us-gaap:SubsequentEventMember srt:MinimumMember 2026-12-02 0001716166 us-gaap:SubsequentEventMember srt:MaximumMember 2026-12-02 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure utr:sqft VVOS:Segment

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

(Mark One)

 

☒ QUARTERLY report pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934
   
For the Quarterly Period Ended September 30, 2026
or
   
☐ Transition report pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934
   
  For the Transition Period from        to  

 

Commission File Number: 001-39796

 

Vivos Therapeutics, Inc.

(Exact Name of Registrant as Specified in its Charter)

 

Delaware   81-3224056

(State or other jurisdiction

of incorporation or organization)

 

(I.R.S. Employer

Identification No.)

     

7921 Southpark Plaza, Suite 210,

Littleton, CO

  80120
(Address of principal executive offices)   (Zip Code)
     
Registrant’s telephone number, including area code:   (866) 908-4867

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading symbol(s)   Name of exchange on which registered
Common stock, par value $0.0001 per share   VVOS   Nasdaq Capital Market

 

Securities registered pursuant to Section 12(g) of the Act:

 

None

 

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. YES ☐ NO ☒

 

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. YES ☐ NO ☒

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. YES ☒ NO ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). YES ☒ NO ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer”, “accelerated filer”, “smaller reporting company”, or “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer ☐ Accelerated filer ☐
Non-accelerated filer ☒ Smaller reporting company ☒
  Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). YES ☐ NO ☒

 

The registrant had 33,820,768 shares of its common stock, $0.0001 par value per share, outstanding as of November 12, 2026.

 

 

 

 

 

 

TABLE OF CONTENTS

 

    Page
     
  Cautionary Note Regarding Forward-Looking Statements ii
     
PART I. FINANCIAL INFORMATION 1
     
Item 1. Condensed Consolidated Financial Statements (Unaudited) 1
  Condensed Consolidated Balance Sheets as of September 30, 2026 and December 31, 2025 1
  Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2026 and 2025 2
  Condensed Consolidated Statements of Stockholders’ Equity (Deficit) for the three and nine months ended September 30, 2026 and 2025 3
  Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2026 and 2025 4
  Notes to the Condensed Consolidated Financial Statements 5
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 26
Item 3. Quantitative and Qualitative Disclosures About Market Risk 36
Item 4. Controls and Procedures 36
     
PART II. OTHER INFORMATION 37
     
Item 1. Legal Proceedings 37
Item 1A. Risk Factors 37
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 44
Item 3. Defaults Upon Senior Securities 44
Item 4. Mine Safety Disclosures 44
Item 5. Other Information 44
Item 6. Exhibits, Financial Statement Schedules 44
     
  Signatures 46

 

i

 

 

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

 

This Quarterly Report on Form 10-Q (this “Report”) contains “forward-looking statements” (as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended) that reflect the Company’s current expectations and views of future events. The forward-looking statements are contained principally in the section entitled “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” Readers are cautioned that known and unknown risks, uncertainties and other factors, including those over which the Company may have no control and others listed in this Report and the Company’s other public filings, may cause the Company’s actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements.

 

You can identify some of these forward-looking statements by words or phrases such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “is/are likely to,” “potential,” “continue,” “goal” or other similar expressions. The Company has based these forward-looking statements largely on its current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. These forward-looking statements include statements relating to:

 

  ● the Company’s ability to continue to refine and execute the Company’s evolving business plan, including establishing and growing the Company’s new medical-provider focused sales, marketing and distribution model where the Company acquires or create contractual alliances with operators of sleep testing and treatment centers as a means of driving sales of the Company’s appliances, including the Company’s June 2025 acquisition of The Sleep Center of Nevada (“SCN”);
     
  ● the Company’s ability to implement, generate material revenues from, and grow the Company’s medical-provider focused sales, marketing distribution model, which is new and unproven and may not produce the benefits the Company anticipates, and to fully wind down the Company’s legacy dentist-focused model;
     
  ● the Company’s ability to successfully integrate SCN business into the Company’s operations, including managing staffing, accounting, insurance reimbursement and other challenges;
     
  ● the Company’s ability to service the substantial indebtedness the Company incurred in connection with financing the SCN acquisition;
     
  ● compliance with laws, rules and regulations relating to the corporate practice of medicine;
     
  ● the acceptance and adoption by sleep specialists, medical doctors and other healthcare professionals of the Company’s proprietary oral appliances as a treatment for dentofacial abnormalities and/or mild to severe obstructive sleep apnea (“OSA”) and snoring in adults and moderate to severe OSA in children ages 6-17 as per the Company’s U.S. Food and Drug Administration (“FDA”) clearances, including the anticipated benefits of insurance coverage for products;
     
  ● The Company’s ability to comply  with the covenants in its financing agreements, including the requirements to keep the Company’s common stock listed om Nasdaq or another stock exchange;
     
  ● the Company’s ability to realize the anticipated benefits of its October 2026 transaction (the “SOD Transaction”) with SOD Sciences, Inc. (“SOD”);
     
  ● the dilution and other effects of the conversion of the 12,000 shares of Series C Convertible Preferred Stock the Company issued in the SOD Transaction (the “Series C Preferred”);
     
  ● the Company’s accounting for the SOD Transaction, which has not been completed and remains subject to adjustment for twelve months after the closing;
     
  ● the Company’s expectations concerning the effectiveness and duration of treatment using the Company’s appliances and protocols (which the Company refers to as The Vivos Method) and the potential for side effects including, but not limited to, patient relapse after completion of treatment;
     
  ● the potential financial benefits to doctors, sleep testing centers, sleep specialists, and other healthcare professionals from treating patients with The Vivos Method;
     
  ● the Company’s revenues, profit margin and cash flows based on sales or leasing of the Company’s appliances and other treatments and services, including the Company’s SleepImage® home sleep testing rings;
     
  ● the Company’s ability to formulate, implement and modify as necessary effective sales, marketing and strategic initiatives to drive revenue growth (including, for example, the Company’s medical provider-focused strategic alliance and/or acquisition model, the Company’s SleepImage® home sleep apnea test and the Company’s other arrangements with sleep clinics and/or durable medical equipment companies (“DMEs”));

 

ii

 

 

  ● the viability of the Company’s current intellectual property and the Company’s ability to create and protect new intellectual property in the future;
     
  ● acceptance of the Company’s products and services by the medical and dental communities, as well as the marketplace of the products and services that the Company markets;
     
  ● government regulations and the Company’s ability to obtain applicable regulatory approvals and comply with both state and federal government regulations including under healthcare laws and the rules and regulations of the FDA and non-U.S. equivalent regulatory bodies;
     
  ● the Company’s ability to hire and retain key employees and other service providers (including dentists, medical doctors or other healthcare providers);
     
  ● the emergence of alternative competing technologies, devices, drugs or other therapies which directly or indirectly impact the marketability of the Company’s products and services;
     
  ● adverse changes in general market conditions for medical devices and the products and services the Company offers;
     
  ● the Company’s ability to generate cash flow and profitability and continue as a going concern;
     
  ● the Company’s ability to satisfy the criteria for maintaining the listing of the Company’s common stock on Nasdaq, including the $1.00 minimum closing bid price requirement, Nasdaq’s rule requiring a delisting determination and suspension of trading if the closing bid price is $0.10 or less for ten consecutive business days, the minimum stockholders’ equity requirement of $2.5 million and, if it takes effect, Nasdaq’s new minimum market value of listed securities requirement, which the Company has faced challenges with;
     
  ● the Company’s immediate and future financing plans, including the Company’s ability to raise capital on acceptable terms or at all; and
     
  ● the Company’s ability to adapt to changes in market conditions (including volatile and difficult to access capital markets) which could impair the Company’s operations and financial performance.

 

These forward-looking statements involve numerous risks and uncertainties. Although the Company believes that its expectations expressed in these forward-looking statements are reasonable, the Company’s expectations may later be found to be incorrect. The Company’s actual results of operations or the results of other matters that the Company anticipates herein could be materially different from its expectations. Important risks and factors that could cause the Company’s actual results to be materially different from the Company’s expectations are generally set forth in “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” “Business” and other sections in this Report as well as the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and the Company’s other public filings. You should thoroughly read this Report and the documents that the Company refers to with the understanding that its actual future results may be materially different from and worse than what the Company expects. The Company qualifies all of its forward-looking statements by these cautionary statements.

 

The forward-looking statements made in this Report relate only to events or information as of the date on which the statements are made in this Report. Except as required by law, the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this Report and the documents that the Company refers to in this Report and have filed as exhibits to this Report, completely and with the understanding that the Company’s actual future results may be materially different from what the Company expects.

 

iii

 

 

PART I – FINANCIAL INFORMATION

 

Item 1. Financial Statements.

 

VIVOS THERAPEUTICS INC.

Unaudited Condensed Consolidated Balance Sheets

(In Thousands, Except Per Share Amounts)

 

   September 30,
2026
   December 31,
2025
 
Current assets          
Cash and cash equivalents  $247   $2,029 
Accounts receivable, net of allowance of $1,250 and $882, respectively   2,370    1,581 
Prepaid expenses and other current assets   891    774 
           
Total current assets   3,508    4,384 
           
Long-term assets          
Goodwill   8,572    8,572 
Property and equipment, net   3,347    3,757 
Operating lease right-of-use asset   3,624    4,166 
Intangible assets, net   3,438    4,045 
Deposits and other   367    228 
           
Total assets  $22,856   $25,152 
           
LIABILITIES AND STOCKHOLDERS’ EQUITY/(DEFICIT)          
Current liabilities          
Accounts payable  $2,739   $1,679 
Accrued expenses   8,819    5,988 
Contract liabilities   72    479 
Current portion of operating lease liability   850    672 
Current portion of financing lease liability   57    55 
Current portion of debt   1,502    8,353 
Other current liabilities   2,124    850 
           
Total current liabilities   16,163    18,076 
           
Long-term liabilities          
Employee retention credit liability   -    2,904 
Operating lease liability, net of current portion   3,198    3,840 
Financing lease liability, net of current portion   69    113 
Debt, net of current portion   313    469 
Other liabilities   950    1,300 
           
Total liabilities   20,693    26,702 
           
Commitments and contingencies (Note 12)   -    - 
           
Stockholders’ equity/(deficit)          
Preferred Stock, $0.0001 par value per share. Authorized 50,000,000 shares; 3,610,995 shares issued and outstanding  $-   $- 
Preferred Stock – additional paid in capital   3,605    - 
Common Stock, $0.0001 par value per share. Authorized 200,000,000 shares; issued and outstanding 33,820,768 shares as of September 30, 2026 and 9,286,609 shares as December 31, 2025   3    1 
Additional paid-in capital   139,217    123,866 
Accumulated deficit   (140,465)   (125,357)
Total stockholders’ equity/(deficit)   2,360    (1,490)
           
Non-controlling interest   (197)   (60)
Total equity/(deficit)   2,163    (1,550)
           
Total liabilities and equity/(deficit)  $22,856   $25,152 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

1

 

 

VIVOS THERAPEUTICS INC.

Unaudited Condensed Consolidated Statements of Operations

(In Thousands, Except Per Share Amounts)

 

   2026   2025   2026   2025 
   Three Months Ended September 30,   Nine Months Ended September 30, 
   2026   2025   2026   2025 
Revenue                    
Product revenue  $1,772   $2,195   $4,567   $5,893 
Service revenue   4,642    4,588    12,141    7,726 
Total revenue   6,414    6,783    16,708    13,619 
                     
Cost of sales (exclusive of depreciation and amortization shown separately below)   3,100    2,846    7,382    6,065 
                     
Gross profit   3,314    3,937    9,326    7,554 
                     
Operating expenses                    
General and administrative   6,450    7,884    22,533    19,181 
Sales and marketing   210    403    614    1,018 
Depreciation and amortization   550    384    1,515    867 
                     
Total operating expenses   7,210    8,671    24,662    21,066 
                     
Operating loss   (3,896)   (4,734)   (15,336)   (13,512)
                     
Non-operating income (expense)                    
Other expense   (981)   (679)   (3,199)   (850)
Other income   2,906    13    3,290    86 
Loss before income taxes   (1,971)   (5,400)   (15,245)   (14,276)
                     
Net loss  $(1,971)  $(5,400)  $(15,245)  $(14,276)
Net loss attributable to non-controlling interest   (26)   -    (137)   - 
Net loss attributable to stockholders  $(1,945)  $(5,400)  $(15,108)  $(14,276)
Net loss per share (basic and diluted)  $(0.07)  $(0.49)  $(0.77)  $(1.49)
Weighted average number of shares of Common Stock outstanding (basic and diluted)   26,528,253    10,963,590    19,658,339    9,557,368 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

2

 

 

VIVOS THERAPEUTICS INC.

Unaudited Condensed Consolidated Statements of Stockholders’ Equity (Deficit)

(In Thousands, Except Common Stock Amounts)

 

   Shares   Amount   Capital   Shares   Amount   Capital   Deficit   (Deficit)   interest   (Deficit)  
   Nine Months Ended September 30, 2026 and 2025  
   Preferred Stock  

Preferred

Additional

Paid-in

   Common Stock  

Additional

Paid-in

   Accumulated  

Total Stockholders’

Equity

   Non-controlling   

Total

Equity

 
   Shares   Amount   Capital   Shares   Amount   Capital   Deficit   (Deficit)   interest   (Deficit)  
                                             
Balances, December 31, 2024   -   $-   $-    5,889,520   $-   $112,141   $(104,187)  $7,954   $-   $ 7,954  
Stock-based compensation expense   -    -    -    -    -    317    -    317    -     317  
Net loss   -    -    -    -    -    -    (3,864)   (3,864)   -     (3,864 )
                                                      
Balances, March 31, 2025   -   $-   $-    5,889,520   $-   $112,458   $(108,051)  $4,407   $-   $ 4,407  
Issuance of common stock and warrants in private placement, net of issuance costs   -    -    -    828,000    -    3,642    -    3,642    -     3,642  
Common stock consideration for acquisition   -    -    -    607,287    -    1,305    -    1,305    -     1,305  
Stock-based compensation expense   -    -    -    -    -    242    -    242    -     242  
Net loss   -    -    -    -    -    -    (5,013)   (5,013)   -     (5,013 )
                                                      
Balances, June 30, 2025  $-   $-   $-    7,324,807   $-   $117,647   $(113,064)  $4,583   $-   $ 4,583  
 Issuance of common stock under At-The-Market program, net of issuance costs  $-   $-   $-    762,070   $1   $2,427   $-   $2,428   $-   $ 2,428  
Issuance of common stock upon exercise of warrants, net of issuance costs   -    -    -    180,000    -    866    -    866    -     866  
Stock-based compensation expense   -    -    -    -    -    55    -    55    -     55  
Net loss   -    -    -    -    -    -    (5,400)   (5,400)   -     (5,400 )
                                                      
Balances, September 30, 2025  $-   $-   $-    8,266,877   $1   $120,995   $(118,464)  $2,532   $-   $ 2,532  
                                                      
Balances, December 31, 2025   -    -    -    9,286,609    1    123,866    (125,357)   (1,490)   (60)    (1,550 )
Issuance of common stock under At-The-Market program, net of issuance costs   -    -    -    57,547    -    302    -    302    -     302  
Issuance of common stock for consultants for services   -    -    -    340,422    -    514    -    514    -     514  
Issuance of warrants in private placement, net of issuance costs   -    -    -    -    -    567    -    567    -     567  
Issuance of pre-funded warrants in private placement, net of issuance cost   -    -    -    -    -    68    -    68    -     68  
Issuance of common stock upon exercise of warrants, net of issuance costs   -    -    -    1,982,356    -    4,191    -    4,191    -     4,191  
Conversion of debt to equity   -         -    1,819,072         2,240    -    2,240    -     2,240  
Stock-based compensation expense   -    -    -    -    -    151    -    151    -     151  
Net loss   -    -    -    -    -    -    (7,682)   (7,682)   (69)    (7,751 )
                                                      
Balances, March 31, 2026   -   $-   $-    13,486,006   $1   $131,900   $(133,039)  $(1,138)  $(129)  $ (1,267 )
Issuance of common stock under At-The-Market program, net of issuance costs        -    -    637,017    -    332    -    332    -     332  
Issuance of preferred stock, net of issuance costs   3,608,495    -    1,105    -    -    -    -    1,105    -     1,105  
Issuance of warrants in private placement, net of issuance costs   -    -         -    -    995    -    995    -     995  
Issuance of common stock for consultants for services        -    -    100,000    -    72    -    72    -     72  
Conversion of debt to equity        -         308,594    -    250    -    250    -     250  
Stock-based compensation expense        -    -         -    50    -    50    -     50  
Net loss   -    -    -    -    -    -    (5,481)   (5,481)   (42)    (5,523 )
                                                      
Balances, June 30, 2026   3,608,495   $-   $1,105    14,531,617   $1   $133,599   $(138,520)  $(3,815)  $(171)  $ (3,986 )
                                                      
Issuance of preferred stock, net of issuance costs   2,500    -    2,500    -    -    -    -    2,500    -     2,500  
Issuance of common stock in accordance with Exchange Agreement                  13,257,111    1    3,610    -    3,611    -     3,611  
Issuance of common stock under At-The-Market program, net of issuance costs                  5,719,540    1    1,932    -    1,933          1,933  
Issuance of common stock for consultants for services                  312,500    -    -    -                   
Stock-based compensation expense                            76         76          76  
Net loss                                 (1,945)   

(1,945

)   (26)    (1,971 )
Balances, September 30, 2026   3,610,995   $-   $3,605    33,820,768   $3   $139,217   $(140,465)  $2,360  $(197)  $ 2,163

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

3

 

 

VIVOS THERAPEUTICS INC.

Unaudited Condensed Consolidated Statements of Cash Flows

(In Thousands)

 

   2026   2025 
   Nine Months Ended September 30, 
   2026   2025 
         
CASH FLOWS FROM OPERATING ACTIVITIES:          
Net loss  $(15,245)  $(14,276)
Adjustments to reconcile net loss to net cash used in operating activities:          
Stock-based compensation expense   277    614 
Employee retention credit liability   (2,904)   - 
Non-cash interest expense on promissory note   -    100 
Depreciation and amortization   1,515    867 
Fair value of common stock issued for services   585    - 
Changes in operating assets and liabilities:          
Accounts receivable   (789)   (770)
Operating lease liabilities, net   71    (74)
Prepaid expenses and other current assets   (117)   228 
Deposits and other   (139)   48 
Accounts payable   1,060    948 
Accrued expenses   2,835    315 
Other liabilities   924    1,004 
Contract liability   (407)   (455)
           
Net cash used in operating activities   (12,334)   (11,451)
           
CASH FLOWS FROM INVESTING ACTIVITIES:          
Payment for acquisition, net of cash acquired of $0 and $865   -    (5,135)
Acquisitions of property and equipment   (495)   (810)
           
Net cash used in investing activities   (495)   (5,945)
           
CASH FLOWS FROM FINANCING ACTIVITIES:          
Proceeds from issuance of debt   2,200    9,225 
Proceeds from issuance of common stock   935    2,775 
Proceeds from issuance of preferred stock   3,605    - 
Proceeds from issuance of warrants   1,562    1,699 
Proceeds from issuance of pre-funded warrants   68    609 
Proceeds from exercise of warrants   4,192    866 
Payments for issuance costs   -    (837)
Reduction of debt liability   (1,473)   (97)
Payments for finance lease liability   (42)   (17)
           
Net cash provided by financing activities   11,047    14,223 
           
Net (decrease) increase in cash and cash equivalents   (1,782)   (3,173)
Cash and cash equivalents at beginning of year   2,029    6,260 
           
Cash and cash equivalents at end of period  $247   $3,087 
           
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:          
Cash paid for interest  $568   $- 
SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:          
Conversion of promissory note  $2,400   $1,100 
Conversion of debt to common stock  $950   $- 

Exchange of debt for common stock

  $3,611   $- 

Exchange of debt for Series B non-convertible preferred stock

  $2,500   $- 
Common stock issued as consideration for acquisition  $-   $1,305 
Contingent consideration as consideration for acquisition  $-   $1,400 
Acquisitions of property, plant and equipment by issuing debt  $-   $928 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

4

 

 

VIVOS THERAPEUTICS INC.

Notes to Unaudited Condensed Consolidated Financial Statements

For the Three and Nine Months Ended September 30, 2026 and 2025

 

NOTE 1 - ORGANIZATION, DESCRIPTION AND SIGNIFICANT ACCOUNTING POLICIES

 

Organization

 

BioModeling Solutions, Inc. (“BioModeling”) was organized on March 20, 2007 as an Oregon limited liability company, and subsequently incorporated in 2013. On August 16, 2016, BioModeling entered into a share exchange agreement (the “SEA”) with First Vivos, Inc. (“First Vivos”), and Vivos Therapeutics, Inc. (“Vivos”), a Wyoming corporation established on July 7, 2016 to facilitate the SEA transaction. Vivos was formerly named Corrective BioTechnologies, Inc. until its name changed on September 6, 2016 to Vivos Biotechnologies and on March 2, 2018 to Vivos Therapeutics, Inc. and had no substantial pre-combination business activities. First Vivos was incorporated in Texas on November 10, 2015. Pursuant to the SEA, all of the outstanding shares of common stock and warrants of BioModeling and all of the shares of common stock of First Vivos were exchanged for newly issued shares of common stock and warrants of Vivos, the legal acquirer.

 

The transaction was accounted for as a reverse acquisition and recapitalization, with BioModeling as the acquirer for financial reporting and accounting purposes. Upon the consummation of the merger, the historical financial statements of BioModeling became the Company’s historical financial statements and recorded at their historical carrying amounts.

 

On August 12, 2020, Vivos reincorporated from Wyoming to become a domestic Delaware corporation under Delaware General Corporate Law. Accordingly, as used herein, the term “the Company” refers to Vivos Therapeutics, Inc., a Delaware corporation and its consolidated subsidiaries. As used herein, the term “Common Stock” refers to the common stock, $0.0001 par value per share, of Vivos Therapeutics, Inc., a Delaware corporation.

 

On June 10, 2025, the Company acquired all of the operating assets (the “Acquisition”) of R.D. Prabhu-Lata K. Shete MDs, LTD., a Nevada professional corporation d/b/a The Sleep Center of Nevada (“SCN”) in consideration for a (i) cash payment equal to $6.0 million, (ii) 607,287 shares of restricted Common Stock, equal to $1.3 million based on the volume-weighted average price (“VWAP”) of the Common Stock for the 30 days immediately preceding the Acquisition and (iii) the assumption of certain specific trade accounts payable and liabilities related to specific SCN contracts assigned to the Company in connection with the Acquisition.

 

On July 14, 2025, the Company entered into a management agreement with MISleep Solution LLC to provide full suite of Vivos treatments and services to OSA patients at a joint location in Auburn Hills, Michigan. As a result, the Company formed AIM Detroit, LLC, a Colorado limited liability company (“AIM Detroit”) to serve as a management services organization to medical and dental clinical sleep practices located in the Detroit Tri-County metropolitan area, to wit: Wayne County, Oakland County and Macomb County. The Company holds an 80% ownership interest in AIM Detroit. See Note 17 for further information.

 

On June 10, 2026, the Company entered into a collaboration agreement with South Palm Cardiovascular Associates, LLC (SPCVA) to establish and operate a Sleep and Airway Medicine Center (SAMC) in a location (to be determined) near one of the firm’s four locations in Del Ray Beach, Boynton Beach, Boca Raton, and West Palm Beach, Florida. The intent of the agreement is to bring much needed sleep testing and treatment to SPCVA’s estimated patient population of over 31,000 patients. The business model will be patterned after the Company’s successful SAMC model pioneered in Las Vegas, Nevada in connection with the Sleep Center of Nevada acquisition. Operations are expected to begin in early 2027. The collaboration agreement contemplates a fair market value financial investment by SPCVA into the management services operating entity (the MSO) that will run the SAMC operation with a proportionate participation in net income (if any) earned by the MSO.

 

Description of Business

 

The Company is a medical technology and healthcare services company that features a comprehensive suite of proprietary oral appliances and therapeutic treatments for a variety of sleep disorders. The Company’s products non-surgically treat certain maxillofacial and developmental abnormalities of the mouth and jaws that are closely associated with breathing and sleep disorders such as, mild to severe obstructive sleep apnea (“OSA”) and snoring in adults. The Company currently operates seven sleep testing centers (Sleep Center of Nevada or SCN) that it acquired in June of 2025 from Dr. Prabhu Rachakonda, MD. That acquisition was part of a strategic pivot away from a reliance on dentists and independent dental practices and toward a focus on affiliations with sleep specialty practices and other medical practices where large numbers of patients with sleep disorders and related conditions may be found.

 

In connection with that acquisition, Vivos established two treatment centers it calls Sleep and Airway Medicine Centers (SAMC). SAMC centers take in patients who have tested positive for OSA, insomnia, or other sleep disorders and offer them a full spectrum of treatment options, including CPAP, advanced laser therapy, Vivos mandibular advancement devices, Vivos CARE devices, and other adjunctive treatments such as myofunctional therapy. The SAMC offices operate under a management services organization model that manages and supports both medical and dental professionals in their respective and independent professional entities. The Company has taken several precautions to ensure that the business entity and legal structure is compliant with both state and federal laws and regulations that govern such relationships. Under such regulations, licensed healthcare providers may participate in ownership of the management services company as long as they are not compensated for referrals or in any manner that is tied to referrals or other volume based incentives.

 

5

 

 

In addition to the SCN and SAMC offices in Nevada, the Company intends to pursue similar affiliations with medical practices in other areas, and has already executed affiliation agreements in Detroit, Michigan and South Florida. Concurrently, Vivos continues to offer separate training and clinical pathways or programs to independent dental providers who wish to learn more about Vivos products and services. Such training programs include: (i) Lifeline (focused on basic dental airway management and principles of mandibular advancement devices and other adjunctive services, and (ii) Complete Airway Repositioning and Expansion (“C.A.R.E.”). Each program features certain oral appliances coupled with specific therapeutic treatments, and each clinical pathway is intended to address the specific needs of a diverse patient population with different patient journeys. For example, the Lifeline program features training in the use of CO2 laser treatments and other adjunctive and a selection of mandibular advancement devices (“MADs”) such as the Versa and Vida Sleep which are U.S. Food and Drug Administration (“FDA”) 510(k) cleared for mild-to-moderate OSA in adults, along with the patented Vida appliance, which is FDA 510(k) cleared as unspecified classification for the alleviation of Temporomandibular Joint Dysfunction (“TMD”) symptoms, bruxism, migraine headaches, and nasal dilation.

 

The Company’s flagship C.A.R.E. program, which is part of The Vivos Method, features the Company’s patented DNA, mRNA and mmRNA appliances, which are also FDA 510(k) cleared for mild-to-severe OSA and snoring in adults. The Vivos Method may also include adjunctive myofunctional, chiropractic/physical therapy, and laser treatments that, when properly used with the C.A.R.E. appliances, constitute a powerful non-invasive and cost-effective means of reducing or eliminating OSA symptoms. In a small subset of a study, the data has actually shown that The Vivos Method can reverse OSA symptoms in a large portion (up to 80%) of patients. The primary competitive advantage of The Vivos Method over other OSA therapies is that The Vivos Method’s typical course of treatment is limited in most cases to 12 to 15 months, and it is possible not to need lifetime intervention, unlike CPAP and neuro-stimulation implants. Additionally, out of approximately 75,000 patients treated to date worldwide with the Company’s entire current suite of products, there have been very few known instances of relapse.

 

Although not the Company’s current focus due to the pivot in the business model, the Company has historically offered a suite of diagnostic and support products and services to dental and medical providers and distributors who service patients with OSA or related conditions. Such products and services include (i) VivoScore home sleep screenings and tests (powered by SleepImage® technology), (ii) Treatment Navigator (a concierge service to assist a provider in educating and supporting the doctors as they navigate insurance coverage, diagnostic indications and treatment options), (iii) Billing Intelligence Services (which optimizes medical and dental reimbursement), (iv) advanced training and continuing education courses at the Company’s Vivos Institute in Denver, Colorado, and (v) MyoSync (formerly MyoCorrect), a service through which Vivos-trained providers can provide orofacial myofunctional therapy (“OMT”) to patients via a telemedicine platform. Some of these services including home sleep screenings, treatment navigator services and MyoSync are being provided to patients directly under the new sales, marketing and distribution model described below. With this pivot, the Company shifted its Medical Integration Division (“MID”) to pursue strategic alliances and acquisitions of sleep centers to provide better options using Vivos products for patients who have been diagnosed with OSA.

 

Legacy Business Model

 

Prior to 2024, the Company’s business model was to teach, train, and support dentists, medical doctors, and distributors in the use of the Company’s products and services. Dentists who use the Company’s products and services typically enrolled in a variety of live or online training and educational programs offered through the Company’s Vivos Institute; an 18,000 sq. ft. facility located near the Denver International Airport. Dentists were able to select the specific program or clinical pathway that they want to focus on, such as Guided Growth and Development or Lifeline or both. They could also enroll in the Company’s Vivos Integrated Provider (“VIP”) program for the complete set training, educational, and support services available in all three clinical pathway programs. Since 2024, Vivos has phased out and discontinued offering the VIP program, although it continues to offer training and continuing education courses on a more limited basis for Lifeline and CARE product lines. The Company refers to the former VIP-focused business model as the Company’s “legacy” or “historic” business model.

 

New Sales, Marketing and Distribution Model

 

Over the course of 2024 and during 2025, the Company worked to pivot its business strategy and began to steadily decrease the Company’s prior dependence on dentists to sell the Company’s products and the Company’s dependence on VIP enrollment revenue. This new business strategy is focused on contractual alliances with and outright acquisitions of medical sleep specialty providers, sleep centers and other medical specialty practices and is based on a profit-sharing model between the Company and the provider which aligns the Company’s revenue generation more directly to sales of the Company’s novel appliances.

 

6

 

 

In June 2025, the Company acquired all assets, including operating assets such as sleep testing, diagnostics, and treatment centers of SCN. The Acquisition marked a milestone in the pivot to the Company’s sales, marketing and distribution model for the Company’s innovative OSA appliances. Under the new model, SCN will provide sleep disorder patients with the opportunity to be candidates for the Company’s advanced, proprietary and FDA-cleared CARE oral medical devices, oral appliances and additional adjunctive therapies and methods. Under customary agreements designed to comply with applicable corporate practice of medicine law, the Company’s operation of SCN allows the Company to manage and capture both diagnostic and consulting revenues, representing new higher margin revenue streams for the Company, as well as potential Vivos appliance and related product and service revenue from SCN.

 

On July 14, 2025, the Company entered into a management agreement under this revised approach with MISleep Solution LLC to provide full suite of Vivos treatments and services to OSA patients at a joint location in Auburn Hills, Michigan. Consistent with the Company’s new model, the Company owns a supermajority equity stake in the management services company, with the sleep doctors having minority ownership interests. AIM Detroit entered into Practice Administration Agreements and Management and Succession Agreements with affiliated Practices (defined as the professional medical and dental practice entities, including Sleep Dentistry of Detroit, P.C. and Sleep Medicine of Detroit, P.C., each owned and controlled by their respective licensed professionals) under which AIM Detroit provides business, administrative, and other non-clinical management services, while all clinical and professional services remain exclusively under the authority and control of the Practices and their licensed professionals.

 

On June 10, 2026, Vivos entered into a collaboration and services agreement with South Palm Cardiovascular Associates (SPCVA) in order to establish and operate a SAMC center near any of four separate SPCVA office locations in South Florida. Under the collaboration and services agreement, SPCVA will invest directly in the management services entity that will manage the licensed professional entities for both medical and dental practitioners at the SAMC location. The model being employed in South Florda with SPCVA is expected to become the primary operating model as the Company scales up and into multiple additional markets going forward.

 

The Company is exploring and seeking to implement additional acquisitions of, or collaborations with, medical sleep and similar healthcare practices to expand the Company’s business model in an effort to grow the Company’s revenues.

 

The Company refers to this new model herein alternatively as its new sales, marketing and distribution model or the Company’s strategic alliance and/or acquisition model.

 

Basis of Presentation and Consolidation

 

The Company’s unaudited condensed consolidated financial statements have been prepared in accordance with current United States generally accepted accounting principles (“GAAP”). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Updates (“ASU”) of the Financial Accounting Standards Board (“FASB”).

 

In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring adjustments, which are necessary to present fairly the Company’s financial position, results of operations, and cash flows. The condensed consolidated balance sheet at December 31, 2025 has been derived from audited financial statements at that date. The interim results of operations are not necessarily indicative of the results that may occur for the full fiscal year. Certain information and footnote disclosure normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to instructions, rules, and regulations prescribed by the United States Securities and Exchange Commission (“SEC”).

 

The Company believes that the disclosures provided herein are adequate to make the information presented not misleading when these unaudited condensed consolidated financial statements are read in conjunction with the December 31, 2025 audited consolidated financial statements contained in the Company’s 2025 Annual Report on Form 10-K, which was filed with the Securities and Exchange Commission on April 15, 2026.

 

The Company evaluates its interests in legal entities to determine whether such entities should be consolidated under the voting interest entity model or the variable interest entity (“VIE”) model. When the Company determines that it is the primary beneficiary of a VIE, the Company consolidates the entity and includes its assets, liabilities, revenues, and expenses in the consolidated financial statements. Ownership interests not held by Vivos are reflected as noncontrolling interests within equity. All significant intercompany balances and transactions have been eliminated in consolidation. See Note 17 for additional information regarding Vivos’ involvement with AIM Detroit.

 

7

 

 

Purchase Price Allocation

 

The Company accounts for business combinations in accordance with ASC Topic 805, Business Combinations, which requires the assets acquired and liabilities assumed in business combinations based on their estimated fair values at the date of acquisition, which involves a number of assumptions, estimates, and judgments, which are inherently uncertain and subject to refinement. The Company determines the estimated fair values with the assistance of valuations performed by third party specialists, discounted cash flow analysis, and estimates made by management derived from comparable market data and cash flow projections used to value the acquired business. The Company’s ability to realize the future cash flows used in the Company’s fair value estimates may be affected by changes in the Company’s financial condition, financial performance, or business strategies. The Company’s assumptions and estimates are also used to allocate goodwill to the Company’s reporting units that are expected to benefit from the business combination.

 

Emerging Growth Company Status

 

Effective December 31, 2025, the Company was no longer an “emerging growth company” (an “EGC”), as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”). As a result, the Company has lost some of the benefits of being an EGC, although the Company remains a “smaller reporting company” and therefore can avoid the auditor attestation requirements of Section 404(b) of the Sarbanes-Oxley Act of 2002 (the “Sarbanes-Oxley Act”).

 

Use of Estimates

 

The preparation of financial statements and related disclosures in conformity with GAAP requires the Company to make judgments, assumptions, and estimates that affect the amounts reported in its consolidated financial statements and accompanying notes. The Company bases its estimates and assumptions on existing facts, historical experience, and various other factors that the Company believes are reasonable under the circumstances, to determine the carrying values of assets and liabilities that are not readily apparent from other sources. The Company’s significant accounting estimates include, but are not necessarily limited to, assessing collectability on accounts receivable, determining customer life and breakage related to recognizing revenue for VIP contracts, impairment of goodwill and long-lived assets; valuation assumptions for assets acquired in asset acquisitions and business combinations; valuation assumptions for stock options, warrants, warrant liabilities and equity instruments issued for goods or services; deferred income taxes and the related valuation allowances; the evaluation and measurement of contingencies; and the derecognition of the Company’s employee retention credit liability. The Company believes the Company has made appropriate accounting estimates based on the facts and circumstances available as of the reporting date. To the extent there are material differences between the Company’s estimates and the actual results, the Company’s future consolidated results of operations will be affected.

 

Accounting Pronouncements

 

Presented below is a discussion of new accounting standards including deadlines for adoption.

 

Recent Accounting Pronouncements Yet to be Adopted

 

In November 2024, the FASB issued ASU No. 2024-03, Disaggregation of Income Statement Expenses (“ASU 2024-03”). The standard’s purpose is “to improve the disclosures about a public business entity’s expenses and address requests from investors for more detailed information about the types of expenses (including purchases of inventory, employee compensation, depreciation, amortization, and depletion) in commonly presented expense captions (such as cost of sales, SG&A, and research and development).” Public companies will be required to disclose in the notes to financial statements specified information about certain costs and expenses at each interim and annual reporting period. Specifically, they will be required to:

 

  1. Disclose the amounts of (a) purchases of inventory; (b) employee compensation; (c) depreciation; (d) intangible asset amortization; and (e) depreciation, depletion, and amortization recognized as part of oil- and gas-producing activities (or other amounts of depletion expense) included in each relevant expense caption.

 

8

 

 

  2. Include certain amounts that are already required to be disclosed under current GAAP in the same disclosure as the other disaggregation requirements.

 

  3. Disclose a qualitative description of the amounts remaining in relevant expense captions that are not separately disaggregated quantitatively.
     
  4. Disclose the total amount of selling expenses and, in annual reporting periods, an entity’s definition of selling expenses.

 

The amendments in the ASU are effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Early adoption is permitted. The Company is currently evaluating the effect of this new guidance on its consolidated financial statements and disclosures.

 

In September 2025, the FASB issued ASU 2025-06, Intangibles-Goodwill and Other-Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software (“ASU 2025-06”), which updates the accounting for internal-use software by removing project stage references and introduces a new capitalization threshold based on management authorization and project completion probability. The guidance requires evaluation of significant development uncertainty, including novel functionality and unresolved performance requirements. ASU 2025-06 also requires website-specific development costs to be evaluated under the same framework as other internal-use software and clarifies that capitalized internal-use software costs are subject to the property, plant and equipment disclosure requirements under ASC 360-10. The amendments in the ASU are effective for fiscal years beginning after December 15, 2027, and interim periods within those fiscal years. Early adoption permitted. The Company is currently evaluating the impact of ASU 2025-06 on the Company’s consolidated financial statements and disclosures.

 

The Company has reviewed and considered all other recent accounting pronouncements that have not yet been adopted and believe there are none that could potentially have a material impact on the Company’s business practices, financial condition, results of operations, or disclosures.

 

NOTE 2 - LIQUIDITY AND ABILITY TO CONTINUE AS A GOING CONCERN

 

The financial statements have been prepared in conformity with generally accepted accounting principles, which contemplate continuation of the Company as a going concern. The Company has incurred losses since inception, including $1.9 and $5.4 million for the three months ended September 30, 2026 and 2025, respectively, and $15.1 and $14.3 million for the nine months ended September 30, 2026 and 2025, respectively, resulting in an accumulated deficit of approximately $140.5 million as of September 30, 2026.

 

Net cash used in operating activities amounted to approximately $12.3 and $11.5 million for the nine months ended September 30, 2026 and 2025, respectively. As of September 30, 2026, the Company had total liabilities of approximately $20.7 million.

 

As of September 30, 2026, the Company had approximately $0.2 million in cash and cash equivalents, which will not be sufficient to fund operations and strategic objectives over the next twelve months from the date of the issuance of these financial statements. Without additional financing, these factors raise substantial doubt regarding the Company’s ability to continue as a going concern.

 

As of September 30, 2026, the Company had approximately $2.3 million of outstanding principal under its senior secured note with Streeterville Capital, LLC, which is due on June 10, 2027. The Company expects to satisfy this obligation through available cash, additional financing, or other sources of liquidity.

 

The Company has implemented cost savings measures that lead to reduced impact to cash used in operations. Sales grew in the financial year ended December 31, 2025 and the first nine months of 2026 as anticipated as the Company continued to refine its product offerings and strategies. As such, notwithstanding that the Company has raised equity capital throughout the fiscal year ended December 31, 2025 and through the first three quarters of 2026, the Company will be required to obtain additional financing through the first quarter of 2027 to satisfy the cash needs for the Company’s business and bolster the Company’s stockholders’ equity for Nasdaq compliance purposes, as management continues to work towards increasing revenue to achieve cash flow positive operations in the foreseeable future

 

9

 

 

The Company does not have any off-balance sheet arrangements, as defined by applicable regulations of the SEC, that are reasonably likely to have a current or future material effect on the Company’s financial condition, results of operations, liquidity, capital expenditures or capital resources.

 

NOTE 3 - REVENUE, CONTRACT ASSETS AND CONTRACT LIABILITIES

 

Net Revenue

 

For the three and nine months ended September 30, 2026 and 2025, the components of revenue from contracts with customers and the related timing of revenue recognition is set forth in the table below (in thousands):

 

   2026    2025   2026   2025 
   Three Months Ended September 30,   Nine Months Ended September 30, 
   2026    2025   2026   2025 
                  
Product revenue                     
Appliances  $1,126    $1,405   $2,189   $3,805 
Tooth Positioners   646     790    2,378    2,088 
Total product revenue   1,772 (1)    2,195(1)    4,567(1)    5,893(1) 
                      
Service revenue                     
Sleep testing services  $2,485 (3)   $2,560(3)   $7,172(3)   $3,727(3) 
Treatment centers   1,172 (2)    1,321(2)    2,832(2)    1,563(2) 
VIP   - (2)    82(2)    49(2)    435(2) 
Billing intelligence services   345 (3)    184(3)    620(3)    556(3) 
Myofunctional therapy services   461 (2)    205(2)    923(2)    516(2) 
Sponsorship/seminar/other   179 (3)    236(3)    545(3)    929(3) 
Total service revenue   4,642     4,588    12,141    7,726 
                      
Total revenue  $6,414    $6,783   $16,708   $13,619 

 

(1) Product revenue from the sale of appliances and preformed appliances is typically fixed at the inception of the contract and is recognized at the point in time when shipment of the related products occurs.
   
(2) Service revenue from the sale of VIP enrollments, billing services and therapy is typically fixed at the inception of the contract and is recognized ratably over time as the services are performed and the performance obligations completed.
   
(3) Sleep testing, treatment center, and other revenue is recognized at a point in time.

 

10

 

 

Changes in Contract Liabilities

 

The key components of changes in contract liabilities related to the Company’s legacy model for the nine months ended September 30, 2026 and 2025 are as follows (in thousands):

 

   2026   2025 
         
Beginning balance, January 1  $479   $993 
New contracts, net of cancellations   615    539 
Revenue recognized   (1,022)   (994)
Ending balance, September 30  $72   $538 

 

The current portion of deferred revenue is approximately $0.1 million, which is expected to be recognized over the next 12 months from the date of the period presented.

 

Changes in Accounts Receivable

 

The Company’s customers are billed based on fees agreed upon in each customer contract. Receivables from customers, which are stated at the net amount expected to be collected, were $2.4 million at September 30, 2026 and $1.6 million at December 31, 2025. Adjustments to the allowance are recorded in bad debt expense under general and administrative expenses in the consolidated statement of operations. An allowance of $1.3 and $0.9 million existed as of September 30, 2026 and December 31, 2025, respectively.

 

NOTE 4 - PROPERTY AND EQUIPMENT, NET

 

As of September 30, 2026 and December 31, 2025, property and equipment consist of the following (in thousands):

 

  

September 30,

2026

  

December 31,

2025

 
         
Furniture and equipment  $3,241   $3,090 
Leasehold improvements   3,526    3,197 
Molds and other   406    406 
Gross property and equipment   7,173    6,693 
Less accumulated depreciation   (3,826)   (2,936)
           
Net Property and equipment  $3,347   $3,757 

 

Leasehold improvements relate to the Vivos Institute (a 18,000 square foot facility where the Company provides advanced post-graduate education and certification to dentists, dental teams, and other healthcare professionals in a live and hands-on setting), two Company-owned dental centers in Colorado, seven diagnostic centers, two treatment centers in Nevada and one treatment center in Detroit. Total depreciation and amortization expense was $0.4 million and $0.4 million for the three months ended September 30, 2026 and 2025, respectively, and $1.0 million and $0.9 million for the nine months ended September 30, 2026 and 2025, respectively.

 

NOTE 5 - GOODWILL AND INTANGIBLE ASSETS

 

Goodwill

 

Goodwill of $8.6 million as of September 30, 2026 and December 31, 2025, consisting of the following acquisitions (in thousands):

 

Acquisitions  September 30,
2026
   December 31,
2025
 
 
The Sleep Center of Nevada  $5,729   $5,729 
BioModeling   2,619    2,619 
Empowered Dental   52    52 
Lyon Dental   172    172 
           
Total goodwill  $8,572   $8,572 

 

11

 

 

Intangible Assets

 

Intangible assets consist of assets acquired from First Vivos and costs paid to (i) MyoSync, from whom the Company acquired certain assets related to its OMT service in March 2021, (ii) Lyon Dental, from whom the Company acquired certain medical billing and practice management software, licenses and contracts in April 2021 (including the software underlying AireO2) for work related the Company’s acquired patents, intellectual property and customer contracts and (iii) AFD, from whom the Company acquired certain U.S. and international patents, trademarks, product rights, and other miscellaneous intellectual property in March 2023, and (iv) SCN, from whom the Company acquired tradenames and referral relationships. Internal-use software of $2.4 million represents capitalized software development costs for cloud-based ordering platform placed in service early 2025.

 

The identifiable intangible assets acquired from First Vivos and Lyon Dental for customer contracts are amortized using the straight-line method over the estimated life of the assets, which approximates five years. The costs paid to MyoSync, Lyon Dental and AFD for patents and intellectual property are amortized over the life of the underlying patents, which approximates 15 years. The identifiable intangible assets acquired from SCN for tradenames are to be amortized over four years, and the referral relationships are to be amortized over eight years.

 

As of September 30, 2026, and December 31, 2025, identifiable intangible assets were as follows (in thousands):

 

  

September 30,

2026

  

December 31,

2025

 
 
Patents and developed technology  $3,802   $3,802 
Internal-use software   2,377    2,377 
Trade name   730    730 
Other   27    27 
           
Total intangible assets   6,936    6,936 
Less accumulated amortization   (3,498)   (2,891)
           
Net intangible assets  $3,438   $4,045 

 

Amortization expense of identifiable intangible assets was $0.2 and less than $0.1 million for the three months ended September 30, 2026 and 2025, respectively. For the nine months ended September 30, 2026 and 2025, amortization expense was $0.6 and less than $0.1 million, respectively. The estimated future amortization of identifiable intangible assets is as follows (in thousands):

   

Years Ending December 31,    
     
2026 (remaining three months)   206 
2027   823 
2028   823 
2029   673 
2030   206 
Thereafter   707 
      
Total  $3,438 

 

12

 

 

NOTE 6 – OTHER FINANCIAL INFORMATION

 

Accrued Expenses

 

As of September 30, 2026 and December 31, 2025, accrued expenses consist of the following (in thousands):

 

    September 30,
2026
    December 31,
2025
 
             
Accrued payroll   $ 1,815     $ 1,843  
Accrued interest expense     2,662       1,952  
Accrued royalties     150       175  
Accrued sales tax     1,023       799  
Accrued legal and other     3,169       1,219  
Total accrued liabilities   $ 8,819     $ 5,988  

 

NOTE 7 – DEBT AND OTHER LIABILITIES

 

Debt

 

The Company had the following outstanding Note Payable balance as of September 30, 2026 and December 31, 2025, excluding equipment financing:

 

   September 30,
2026
   December 31,
2025
 
Principal amount  $2,256   $10,109 
Less: Unamortized debt issuance costs and original issue discount   (441)   (2,014)
Total notes payable  $1,815   $8,095 

 

On June 9, 2025, the Company entered into a note purchase agreement with Streeterville Capital, LLC (“Streeterville” or the “Lender”) secured by the assets of Airway Integrated Management Company, LLC, a Colorado limited liability company and a wholly-owned subsidiary of the Company (“AIM”), pursuant to which the Company agreed to issue and sell to the Lender a secured promissory note (the “Note”) in an aggregate initial principal amount of $8.2 million, which is payable on or before June 10, 2027. The initial principal amount includes an original issue discount of $0.7 million and $50 thousand that the Company agreed to pay to the Lender to cover the Lender’s legal fees, accounting costs, due diligence, monitoring and other transaction costs. The net proceeds of the Note were $7.5 million.

 

Interest on the Note accrues at a rate of 9% per annum and is payable on the maturity date. The Company may prepay all or a portion of the Note at any time.

 

A monitoring fee equal to the outstanding balance divided by 0.85, less the outstanding balance (about 17.6% of the outstanding balance, under Section 2 of the Note) was charged starting on the 120-day anniversary of the issuance of the Note (October 7, 2025) to cover Lender’s accounting, legal and other costs incurred in monitoring. The foregoing fee was automatically added to the outstanding balance on the applicable date without any further action by either party.

 

Beginning on the sixth month anniversary of the issuance, which was December 9, 2025, the Lender shall have the right to redeem up to $0.6 million (reduced to a maximum of $225,000 a month by the amendment described below) of the Note plus any interest accrued thereunder each month by providing written notice delivered to the Company; provided, however, that if the Lender does not exercise any monthly redemption amount in its corresponding month then such monthly redemption amount shall be available for the Lender to redeem in any further month in addition to such future month’s monthly redemption amount. Upon receipt of any monthly redemption notice, the Company shall pay the applicable monthly redemption amount in cash to the Lender within three (3) trading days of the Company’s receipt of such monthly redemption notice. As of September 30, 2026 and December 31, 2025, the lender redeemed $5.0 million and less than $0.1 million, respectively.

 

In connection with the Exchange Agreement described in Note 9, the Note was amended by an Amendment to Secured Promissory Note dated June 5, 2026, as modified by a letter agreement dated June 18, 2026. Because the Company completed the qualifying equity financing in August 2026, the maturity date of the Note was extended to June 10, 2027, the Lender’s monthly redemption requests were suspended until September 15, 2026, and the maximum monthly redemption amount was reduced from $550,000 to $225,000. As of September 2, 2026, after the exchanges described in Note 9, the outstanding principal balance of the Note was approximately $3.7 million. The principal balance at September 30, 2026 is $2.3 million.

 

13

 

 

The Note includes customary event of default provisions, some of which are subject to cure periods; however, a failure to comply with the covenants in Section 4 of the Note Purchase Agreement, which include keeping the Company’s common stock listed on The Nasdaq Stock Market and filing its SEC reports on time, is an event of default with no cure period, and provides for a default interest rate equal to the lesser of twenty-two percent (22%) or the maximum rate permitted under applicable law. Upon the occurrence of an event of default, interest would accrue on the outstanding balance of the Note beginning on the date the applicable event of default occurred.

 

On December 5, 2025, the Company entered into a Note Purchase Agreement with Avondale Capital, LLC, a Utah limited liability company (“Avondale”), pursuant to which the Company issued and sold to Avondale a Promissory Note in the original principal amount of $2.1 million. The principal amount of the Avondale Note includes an original issue discount of $0.6 million. The Company also agreed to pay $6,000 to Avondale to cover its legal fees, accounting costs, due diligence, monitoring, and other transaction costs, each of which was added to the principal amount of the Avondale Note, resulting in gross proceeds to the Company of approximately $1.5 million. The Avondale Note is not convertible into shares of Common Stock or otherwise. Avondale is an affiliate of Streeterville.

 

The Avondale Note does not bear interest and no interest will accrue on the Avondale Note unless an event of default occurs as further described below. The Company has made weekly payments of approximately $70 thousand beginning on December 12, 2025. The Company may prepay the outstanding amount due under the Avondale Note at any time without penalty. The Company used the net proceeds from the Avondale Note Financing for working capital and other general corporate purposes. No placement agent was used in connection with the Avondale Note Financing. As of September 30, 2026, the Company has paid approximately $1.7 million to Avondale.

 

The Avondale Note is unsecured. In connection with the Avondale Note Financing, the Company has caused Company’s wholly-owned subsidiary, AIM to enter into the Guaranty Agreement, dated December 5, 2025, in favor of Avondale to provide a guarantee of the Company’s obligations to Avondale under the Avondale Note and the other transaction documents.

 

During the third quarter 2026, the Company entered into several short-term agreements, collateralized by a portion of its accounts receivable, for approximately $3.7 million (gross of issue discount). Maturity dates range from approximately 3 months to 8 months and are payable in weekly installments of principal and interest totaling and aggregate of $230,800. The effective combined interest rate on the two loans is approximately 38%.

 

Equipment Financing

 

At September 30, 2026 and December 31, 2025, the Company had the following outstanding notes payable for equipment financing as follows (in thousands):

  

   September 30,
2026
   December 31,
2025
 
Principal amount  $533   $727 
Total  $533   $727 

 

The maturity of notes payable for equipment financing is as follows (in thousands):

 

Years Ending December 31,    
     
2026 (remaining three months)  $64 
2027   211 
2028   162 
2029   49 
2030   31 
Thereafter   16 
      
Total  $533 

 

Interest expense recognized on the condensed consolidated statement of operations was $0.6 million and $2.8 million for the three and nine months ended September 30, 2026, respectively, and is reported as part of Other Expense in the Statement of Operations.

 

14

 

 

Other Liabilities

 

As of September 30, 2026 and December 31, 2025, other liabilities consist of the following (in thousands):

 

    September 30,
2026
    December 31,
2025
 
             
Contingent consideration on acquisition of SCN   $ 950     $ 1,300  
                 
Total   $ 950     $ 1,300  

 

The fair value of the contingent consideration was determined using a Monte Carlo simulation of potential outcomes. The contingent consideration is payable in the form of restricted Common Stock equal to $1.5 million based on the volume-weighted average price of the Common Stock for the 30 days immediately preceding the date on which such financial milestone is achieved. If the financial milestone is not achieved, the contingent consideration will not be paid. The fair value of the contingent consideration was based on the valuation of their fair values on the Acquisition closing date.

 

This contingent consideration liability is recognized as a liability due to the variability of the potential share settlement and will be remeasured at fair value each reporting period until the contingency is resolved, with changes in fair value recognized in operating expenses. During the three and nine months ended September 30, 2026, the Company recognized a gain in other income for the change in fair value of contingent consideration of approximately $0.3 and $0.4 million, respectively. Significant assumptions included a discount rate of 9% as well as projected revenue derived from internal forecasts with a three-month volatility rate of 20%.

 

Employee Retention Credit

 

During the period, management reassessed the Company’s potential obligation to repay amounts previously received under the Employee Retention Credit (“ERC”) program established by the Coronavirus Aid, Relief, and Economic Security Act. Based on its evaluation of the Company’s eligibility for the credits, applicable guidance, and other relevant facts and circumstances, management concluded that repayment of the credits is no longer deemed probable. Accordingly, the Company reversed its previously recorded ERC liability of approximately $2.9 million, recognizing the corresponding benefit in other income during the period.

 

The Company acknowledges that ERC claims remain subject to potential examination by the Internal Revenue Service.

 

NOTE 8 – PREFERRED STOCK

 

As of September 30, 2026, the Company’s Board of Directors continues to have the authority to designate up to 50,000,000 shares of Preferred Stock in various series that provide for liquidation preferences, and voting, dividend, conversion, and redemption rights as determined at the discretion of the Board of Directors.

 

June 2026 PIPE Offering and Conversion of V-CO 4 Bridge Note

 

On June 30, 2026, the Company entered into a Securities Purchase Agreement (the “PIPE SPA”) with V-Co 4 and Bigger Capital Fund, LP (“Bigger” and collectively, the “Investors”).

 

Pursuant to the PIPE SPA, the Company sold an aggregate of 3,608,495 units (the “Units”), at a purchase price of $0.582 per Unit, with each Unit consisting of (i) one share of Series A Convertible Preferred Stock, par value $0.0001 per share and with a stated value of $0.456 per share (the “Preferred Stock”), convertible into one share of Common Stock on a one-for-one basis, and (ii) Common Stock purchase warrants with a five year term (collectively, the “Warrants”) to purchase a number of shares of Common Stock equal to 100% of the number of shares of Common Stock issuable upon conversion of the Preferred Stock included in such Unit.

 

The $0.582 per Unit purchase price comprises $0.457 attributable to the share of Preferred Stock included in such Unit and $0.125 attributable to the Warrant included in such Unit. Such $0.125 per Warrant Share was included for purposes of satisfying the “Minimum Price” requirement of Nasdaq Listing Rule 5635(d), but not in determining the exercise price of the Warrants. The $0.456 Market Price was calculated as the lower of (i) the Nasdaq official closing price of the Common Stock on the trading day immediately preceding the date of the PIPE SPA and (ii) the average Nasdaq official closing price of the Common Stock for the five trading days immediately preceding the date of the PIPE SPA. The $0.582 per Unit purchase price accordingly exceeds the sum of the $0.456 Market Price and the $0.125 per Warrant Share attribution. The PIPE Offering closed on June 30, 2026. The aggregate purchase price for the securities sold in the PIPE Offering was $2.1 million. The Company received $1,000,000 in cash proceeds upon the closing of the PIPE Offering. Additionally, $1,000,000 previously funded by V-Co 4 under a previously reported bridge promissory note entered into by the Company and V-Co 4 on May 7, 2026 (the “Bridge Note”) automatically converted into the PIPE Offering. The gross proceeds of funded under the Bridge Note of $1.0 million exclude an original issue discount of $100,000 paid by the Company in connection with previous funding under the Bridge Note.

 

15

 

 

NOTE 9 – COMMON STOCK

 

The Company is authorized to issue 200,000,000 shares of Common Stock. Holders of Common Stock are entitled to one vote for each share held. The Company’s Board of Directors may declare dividends payable to the holders of Common Stock.

 

The following is a description of Common Stock transactions since December 31, 2025:

 

January 2026 Warrant Inducement Transaction

 

On January 15, 2026, the Company entered into a warrant inducement letter agreement (the “January 2026 Inducement Agreement”) with an institutional investor (the “Holder”), pursuant to which the Holder agreed to exercise for cash the entirety of its January 2023 Warrants, November 2023 Series A Warrants and February 2024 Inducement Warrants at a reduced exercise price of $2.34 per share (with such exercise price being established for purposes of compliance with the listing rules of the Nasdaq Stock Market), resulting in gross proceeds to the Company of approximately $4.6 million. The January 2023 Warrant, the November 2023 Warrant and the February 2024 Inducement Warrant are referred to collectively as the “January 2026 Exercised Warrants.” The resale of the shares of Common Stock underlying the January 2026 Exercised Warrants have been registered pursuant to a Post-Effective Amendment to Form S-1 on a Registration Statement on Form S-3 (File No. 333-278564), which became effective with the SEC on January 7, 2026.

 

January 2026 V-CO Investors 3 LLC Note

 

On January 15, 2026, the Company entered into an unsecured convertible promissory note in favor of V-CO Investors 3 LLC (“V-CO 3”) in the maximum principal amount of up to $5,500,000 (the “V-CO 3 Note” and the maximum principal amount, inclusive of the original issuance discount described below, the “Maximum Principal”). V-CO 3 is an affiliate of Seneca.

 

The purpose of the V-CO 3 Note is to provide advanced funding and support to the Company in connection with a proposed equity financing of the Company in the aggregate amount of up to $5,500,000 (the “Subsequent Financing”).

 

On January 15, 2026 and March 26, 2026, V-CO funded an initial $900,000 and $500,000, respectively, to the Company under the V-CO 3 Note. The Maximum Principal shall include a ten percent (10%) original issuance discount of the aggregate Maximum Principal as a financing fee to V-CO 3.

 

The V-CO 3 Note does not bear any interest, except in the case of an event of default, which is defined as (i) the Company fails to pay the principal or any accrued interest under the V-CO 3 Note on demand, (ii) the Company fails to observe or perform any other material covenant, obligation, condition or agreement in any material respect contained in the V-CO 3 Note, (iii) the Company’s voluntary bankruptcy or (iv) an involuntary bankruptcy is commenced against the Company. Upon the occurrence of any event of default, interest shall accrue on the V-CO 3 Note at a rate equal to fifteen percent (15%) per annum and shall be computed on the basis of a 365-day year.

 

In the event of a Subsequent Financing prior to the Outside Date, all principal under the V-CO 3 Note shall automatically convert dollar-to-dollar, without any further action required on the part of V-CO or the Company, into such equity instruments of the Company as are issued in the Subsequent Financing. The Subsequent Financing may, but is not required to be, led by V-CO. Following the Outside Date, the Company may repay all or any portion of the outstanding principal amount and any accrued interest of the V-CO 3 Note in whole or in part without penalty.

 

On March 31, 2026, the Company entered into an equity financing with V-CO 3 and accordingly, $1,400,000 of the V-CO 3 automatically converted into such equity financing. For more information, please refer to “March 2026 PIPE Offering” below.

 

16

 

 

March 2026 PIPE Offering

 

On March 31, 2026, the Company entered into a Securities Purchase Agreement (the “March 2026 PIPE SPA”) with V-CO 3.

 

Pursuant to the March 2026 PIPE SPA, the Company sold to V-CO 3 in a private placement offering (the “March 2026 PIPE Offering”): (i) 1,353,625 shares (the “March 2026 PIPE Shares”) of Common Stock, (ii) a pre-funded warrant to purchase 429,957 shares of Common Stock (the “March 2026 Pre-Funded Warrant”, with the shares of Common Stock underlying the Pre-Funded Warrant being referred to as the “March 2026 PFW Shares”), (iii) a Series A Common Stock Purchase Warrant (the “March 2026 Series A Warrant”) to purchase up to 1,783,582 shares of Common Stock and (iv) a Series B Common Stock Purchase Warrant to purchase up to 1,783,582 shares of Common Stock (the “March 2026 Series B Warrant”, and together with the Series A Warrant, the “March 2026 Common Stock Purchase Warrants”, and together with the Pre-Funded Warrant, the “March 2026 Warrants”, and with the shares of Common Stock underlying the Common Stock Purchase Warrants being referred to as the “March 2026 Warrant Shares”).

 

V-CO 3 paid a purchase price of $1.34 for each March 2026 PIPE Share and March 2026 Pre-Funded Warrant Share and associated March 2026 Common Stock Purchase Warrants, with such price being established for purposes of compliance with the listing rules of the Nasdaq Stock Market LLC. The March 2026 PIPE Offering closed on March 31, 2026. The Company received $850,000 in cash proceeds upon the closing of the March 2026 PIPE Offering. Additionally, $1,400,000 previously funded by V-CO 3 under the V-CO 3 Note automatically converted into the PIPE Offering. The gross proceeds funded under the V-CO 3 Note exclude an original issue discount of $140,000 paid by the Company in connection with previous funding under the V-CO 3 Note. The Company expected to use the net proceeds from the March 2026 PIPE Offering for general working capital purposes. No placement agent was used in connection with the March 2026 PIPE Offering.

 

Both March 2026 Common Stock Purchase Warrants have an exercise price of $1.09 per share and became exercisable immediately as of the date of issuance. The March 2026 Common Stock Purchase Warrants are identical to each other, other than their dates of expiration (the March 2026 Series A Warrant has a term of two years and the March 2026 Series B Warrant has a term of five years). The March 2026 Pre-Funded Warrant has a term ending on the complete exercise of the March 2026 Pre-Funded Warrant, an exercise price of $0.0001 per share and became exercisable immediately as of the date of issuance. The March 2026 Warrants also contain customary stock-based (but not price-based) anti-dilution protection as well as beneficial ownership limitations preventing Seneca or its affiliates from exercising March 2026 Warrants if such exercise would result in Seneca or its affiliates from owning in excess of 19.99% of the then outstanding Common Stock.

 

The terms of the March 2026 PIPE SPA require the Company to file a registration statement on Form S-3 or other appropriate form registering the March 2026 PIPE Shares, the March 2026 PFW Shares and the March 2026 Warrant Shares (collectively, the “March 2026 Registrable Securities”) for resale no later than 45 days of the closing of the March 2026 PIPE Offering and to use commercially reasonable best efforts to cause such resale registration statement to be effective within 90 days of the closing of the March 2026 PIPE Offering. The Company must also use its commercially reasonable efforts to keep such resale registration statement continuously effective (including by filing a post-effective amendment to such resale registration statement or a new registration statement if such resale registration statement expires) for a period of three (3) years after the date of effectiveness of such resale registration statement or for such shorter period as such securities no longer constitute March 2026 Registrable Securities, subject to certain limitations specified in the March 2026 PIPE SPA.

 

The March 2026 PIPE SPA further provides that the Company shall pay V-CO 3 in the amount equal to $50,000 for the fees and expenses of V-CO 3’s counsel incurred in connection with the March 2026 PIPE Offering. The March 2026 PIPE SPA also includes standard representations, warranties, indemnifications, and covenants of the Company and V-CO 3.

 

17

 

 

Streeterville Exchange Agreement

 

On June 5, 2026, the Company entered into an Exchange Agreement (the “Exchange Agreement”) with Streeterville Capital, LLC pursuant to which Streeterville agreed to exchange up to approximately $4.5 million of outstanding senior secured debt for a combination of perpetual non-convertible preferred stock of a new series (“Series B Non-Convertible Preferred Stock”) and shares of common stock, contingent upon the Company completing certain qualifying equity financings. On June 18, 2026, the parties entered into a letter agreement extending the outside date for completion of the initial qualifying financing of at least $2.6 million from June 15, 2026 to August 31, 2026.

 

On August 4, 2026, the Company exceeded the financing requirement, which triggered the exchange of a total of $3,250,000 of debt for the Company’s common stock and Series B Non-Convertible Preferred Stock ($750,000 to common stock at a price of $0.4139 per share for a total of 1,812,031 shares of the Company’s common stock and $2,500,000 to Series B Non-Convertible Preferred Stock at $1,000 per share for a total of 2,500 shares of Series B Non-Convertible Preferred Stock). Series B Non-Convertible Preferred Stock is (i) non-convertible, (ii) non-voting (except in certain limited circumstances), (iii) non-transferable, and (iv) required to pay a 9% annual dividend, compounding daily and payable quarterly. The Series B Non-Convertible Preferred Stock provides for a liquidation preference over the Company’s common stock, and the certificate of designation with respect thereto contains certain affirmative and negative covenants in favor of Streeterville, including a requirement that the Company obtains Streeterville’s consent for future debt and equity financings over $2.5 million in the aggregate (in addition to the $2.6 million raised in the aforementioned qualifying financing). The Company completed the exchange on August 4, 2026.

 

Additionally, effective August 31, 2026, the Company entered into twelve separate exchange agreements with Streeterville, pursuant to which an aggregate of $2,861,270 of outstanding principal under the Streeterville note was partitioned into twelve separate secured promissory notes. On September 2, 2026, Streeterville surrendered the partitioned notes in exchange for an aggregate of 11,445,080 shares of the Company’s common stock at an average exchange price of $0.25 per share. Under the exchange agreements, Streeterville’s beneficial ownership of the common stock is limited to 4.9%, and Streeterville will surrender each partitioned note for cancellation when the related shares become freely tradable. The exchanges were completed in reliance on the exemption from registration provided by Section 3(a)(9) of the Securities Act of 1933, and no proceeds were received by the Company. Immediately prior to the exchanges, the Company had 22,164,313 shares of common stock outstanding. Following the exchanges, the Company had 33,820,768 shares outstanding, with the shares issued to Streeterville representing approximately 34% of the post-exchange outstanding common stock. As of September 2, 2026, after these exchanges, the outstanding principal balance of the Streeterville note was approximately $3.7 million. The principal balance at September 30, 2026 is $2.3 million.

 

On October 16, 2026, Streeterville provided its consent, pursuant to the Company’s existing financing arrangements, to the issuance of 12,000 shares of Series C Convertible Preferred Stock to SOD Sciences, Inc. in connection with the Company’s acquisition of an equity interest in SOD Sciences and a 50% co-ownership interest in certain intellectual property. The transaction was completed on October 16, 2026.

 

“At-the-Market” Equity Offering

 

As previously reported on a Current Report on Form 8-K filed on February 14, 2025 (the “February 8-K”), on February 14, 2025, pursuant to a prospectus supplement to the Company’s previously filed shelf registration statement on Form S-3 (File No. 333-262554) (the “Prior Shelf Registration”), the Company entered into an At The Market Offering Agreement (the “ATM Sales Agreement”) with HCW, pursuant to which the Company may offer and sell shares of Common Stock from time to time through HCW. The Company did not sell any shares of Common Stock under the Prior Shelf Registration pursuant to the ATM Sales Agreement.

 

On September 12, 2025, the Company filed a prospectus supplement (the “ATM Pro Supp”) with the SEC pursuant to which the Company may continue, under the ATM Sales Agreement, to sell, from time to time, up to an aggregate sales price of $5,830,572 of its Common Stock (the “ATM Shares”), through HCW as sales agent. HCW will be entitled to compensation at a fixed commission rate of 3.0% of the gross proceeds of each sale of Shares. In connection with the sale of the Company’s ATM Shares on the Company’s behalf, HCW will be deemed to be an “underwriter” within the meaning of the Securities Act and the compensation of HCW will be deemed to be underwriting commissions or discounts. The Company has also agreed to provide indemnification and contribution to HCW with respect to certain liabilities, including liabilities under the Securities Act.

 

The offer and sale of the ATM Shares have been made pursuant to a shelf registration statement on Form S-3 (File No. 333-284834), as amended (the “New Shelf Registration”), initially filed by the Company with the SEC on February 11, 2025 and declared effective by the SEC on September 10, 2025, as supplemented by the ATM Pro Supp filed with the SEC pursuant to Rule 424(b) under the Securities Act.

 

During the nine months ended September 30, 2026, the Company sold an aggregate of 6,414,104 ATM Shares at an average price of $0.45 per share through the ATM Sales Agreement, resulting in proceeds of approximately $2.4 million net of commissions. Under the ATM Offering, $0.4 million remain available for future sales as of September 30, 2026; however, the Company is not obligated to make any sales under this program.

 

As of September 30, 2026 and December 31, 2025, all warrants outstanding have been classified as equity and recorded at fair values of the date of issuance on the Company’s consolidated balance sheets and there have been no further adjustments to their issuance date valuation. To better ascertain the nature of the equity, ASC 815, Derivatives and Hedging and ASC 480, Distinguishing Liabilities from Equity were referenced.

 

NOTE 10 – STOCK OPTIONS AND WARRANTS

 

Stock Options

 

On November 26, 2024, the Company’s shareholders approved and adopted the Vivos Therapeutics, Inc. 2024 Omnibus Equity Incentive Plan (or the “2024 Omnibus Plan”). The 2024 Omnibus Plan automatically replaced and superseded the 2019 Plan. Under the 2024 Omnibus Plan, a total of 1,600,000 shares are available for future use. No awards are to be granted under the 2019 Plan or any other prior plan on or after the effective date of the 2024 Omnibus Plan and after the 2024 Omnibus Plan became effective any unused shares left in the 2019 Plan are to be retired. On November 4, 2025, the Company conducted its 2025 annual meeting of stockholders (the “Annual Meeting”). At the Annual Meeting, the Company’s stockholders approved and adopted an amendment to the 2024 Omnibus Plan to increase the number of shares of the Company’s Common Stock authorized to be issued pursuant to the 2024 Omnibus Plan from 1,600,000 shares to 4,100,000 shares in the aggregate.

 

18

 

 

The purpose of the 2024 Omnibus Plan is to promote the success and enhance the value of the Company by linking the personal interest of the participants to those of the Company’s stockholders by providing the participants with an incentive for outstanding performance. Any non-employee director, officer, employee or consultant of the Company or its subsidiaries or affiliates will be eligible to participate in the 2024 Omnibus Plan. As of September 30, 2026, the Company had six non-employee directors, two officers, 242 employees and four consultants, although the Company expects that, based on the Company’s current usage, award will be generally limited to approximately six non-employee directors, two officers, twelve employees, and three consultants. The 2024 Omnibus Plan provides for the grant of options to purchase shares of the Company’s Common Stock, including stock options intended to qualify as incentive stock options (“ISOs”) under Section 422 of the Code and nonqualified stock options that are not intended to so qualify (“NQSOs”), stock appreciation rights (“SARs”), restricted stock awards, and other equity-based or equity-related awards including restricted stock units and performance units (each, an “Award”). As of September 30, 2026, awards (in the form of options, stock grants, performance stock units (“PSUs”) and restricted stock units (“RSU”) for an aggregate of 3,269,487 shares of Common Stock have been issued under the Company’s 2024 Omnibus Plan.

 

The following table summarizes all stock options as of September 30, 2026 (shares in thousands):

 

   2026 
   Shares   Price (1)   Term (2) 
             
Outstanding, at December 31, 2025   1,223   $6.83    7.6 
Granted   774         
Forfeited   (25)         
Exercised   -          
                
Outstanding, at September 30 2026   1,972(3)   $2.68    8.1 
                
Exercisable, at September 30 2026   395(4)   $12.80    5.7 

 

(1) Represents the weighted average exercise price.
   
(2) Represents the weighted average remaining contractual term until the stock options expire.
   
(3) As of September 30, 2026, the aggregate intrinsic value of stock options outstanding was $0.
   
(4) As of September 30, 2026, the aggregate intrinsic value of exercisable stock options was $0.

 

There were 774,000 stock options granted for the three and nine months ended September 30, 2026 and no stock options granted for the three and nine months ended September 30, 2025. For the three and nine months ended September 30, 2026, the Company recognized approximately $0.1 million and $0.3 million of share-based compensation expense, respectively, compared with $0.1 million and $0.6 million for the three and nine months ended September 30, 2025, respectively.

 

Unrecognized expense relating to these awards as of September 30, 2026 and 2025 was approximately $2.7 million and $2.8 million, which will be recognized over the weighted average remaining term of 8.1 years and 7.8 years, respectively.

 

19

 

 

Restricted Stock Units

 

The following table summarizes all RSUs as of September 30, 2026 (shares in thousands):

 

   2026 
   Shares   Price (1)   Term (2) 
             
Outstanding, at December 31, 2025   90   $5.57    10 
Granted   115    0.18      
Forfeited   -    -      
Exercised   -    -      
                
Outstanding, at September 30 2026   205(3)   $2.55    9.5 
                
Exercisable, at September 30 2026   45(4)   $5.57    9.0 

 

(1) Represents the weighted average exercise price.
   
(2) Represents the weighted average remaining contractual term until the RSUs expire.
   
(3) As of September 30, 2026, the aggregate intrinsic value of stock options outstanding was $0.
   
(4) As of September 30, 2026, the aggregate intrinsic value of exercisable stock options was $0.

 

Warrants

 

The following table sets forth activity with respect to the Company’s warrants to purchase Common Stock for the nine months ended September 30, 2026 (shares in thousands):

 

   2026 
   Shares   Price (1)   Term (2) 
             
Outstanding, at December 31, 2025   11,782   $2.44    3.40 
Granted               
Private placement   7,605           
Warrant Inducement   4,103           
Forfeited   (11)   -      
Exercised   (1,982)   -      
                
Outstanding, at September 30,   21,497(3)   $2.04    3.15 
                
Exercisable, at September 30,   21,497(4)    2.04    3.15 

 

(1) Represents the weighted average exercise price.
   
(2) Represents the weighted average remaining contractual term until the warrants expire.
   
(3) As of September 30, 2026, the aggregate intrinsic value of warrants outstanding was $0 million.
   
(4) As of September 30, 2026, the aggregate intrinsic value of warrants exercisable was $0 million.

 

For the nine months ended September 30, 2026, the valuation assumptions for warrants issued were estimated on the measurement date using the BSM option-pricing model with the following weighted-average assumptions:

 

   2026 
     
Measurement date closing price of Common Stock (1)  $0.456 
Contractual term (years) (2)   5.0 
Risk-free interest rate   4.1%
Volatility   140%
Dividend yield   0%

 

(1) Weighted average grant price.
   
(2) The valuation of warrants is based on the expected term.

 

20

 

 

NOTE 11 - INCOME TAXES

 

The Company calculates its income tax expense during interim periods based upon applying an estimated annual effective income tax rate to its year-to-date income, considering, any significant, unusual or infrequently occurring items which have been recorded for the interim period. The provision for income taxes for the three and nine months ended September 30, 2026, and 2025 differs from the amount that would be provided by applying the statutory U.S. federal income tax rate of 21% to pre-tax income primarily due to permanent differences, state taxes and change in the Company’s income tax valuation allowance.

 

For the periods ended three and nine months ended September 30, 2026, and 2025, a full income tax valuation allowance was in effect, which resulted in the Company having no income tax expense for these periods. Management assesses the available positive and negative evidence to estimate if sufficient future taxable income will be generated in the future to allow the Company to use its existing deferred tax assets. Currently, significant objective negative evidence was evaluated by the Company’ management including the existing net operating loss carryforward composed of the cumulative loss incurred since the Company’s inception, and such objective evidence limits management’s ability to consider other subjective evidence such as the Company’s projections for future growth. Based on this evaluation, a full income tax valuation allowance has been recorded at September 30, 2026 and December 31, 2025, and therefore no deferred income tax asset was recorded since it is not likely to be realized.

 

The computation of the annual estimated effective tax rate at each interim period requires certain estimates and significant judgement including, but not limited to, the expected operating income for the year, projections of the proportion of income earned and taxed in various jurisdictions, permanent and temporary differences, and the likelihood of recovering deferred tax assets generated in the current year. The accounting estimates used to compute the provision for income taxes may change as new events occur, more experience is obtained, additional information becomes known or as the tax environment changes.

 

NOTE 12 - COMMITMENTS AND CONTINGENCIES

 

On March 13, 2026, the Company entered into a confidential joint settlement and release agreement (the “Settlement Agreement”) with Ortho-Tain for the full release, waiver and dismissal of all claims asserted by the parties against each other in the lawsuit the Company filed in federal district court in Colorado, Case No. 20 cv 1634 and the lawsuit Ortho-Tain, Inc. filed in the United States District Court for the Northern District of Illinois on July 22, 2020.

 

In June of 2020, the Company filed a lawsuit in federal district court in Colorado, Case No. 20 cv 1634. The Company’s Complaint alleged that the Company had suffered economic injuries, including lost profits/sales and an injury to its business reputation, as a result of allegedly false, misleading, and defamatory statements made by Ortho-Tain, Inc.’s CEO and legal counsel. In July of 2020, Ortho-Tain, Inc. filed a lawsuit in federal district court in Illinois, Case No. 20 cv 4301. Ortho-Tain’s Complaint alleged that it had suffered economic injuries, including lost profits/sales and an injury to its business reputation, as a result of allegedly unlawful marketing conduct by agents of Vivos.

 

The Settlement Agreement resolves any claim for relief that was, or could have been alleged, in the foregoing litigation matters. Pursuant to the Settlement Agreement, the Company agreed to pay Ortho-Tain a confidential sum and, among other considerations, not make use of the phrase “Guide” or “Guides” in the formal product name of any of the Company’s oral appliance products and cease direct solicitation and training of independent dental professionals in the use of any Vivos pre-formed tooth positioner products that are competitive with Ortho-Tain. The settlement was paid late March 2026.

 

There were no new other material commitments or contingencies entered into as of the nine months ended September 30, 2026.

 

21

 

 

NOTE 13 – RELATED PARTY TRANSACTIONS

 

The Company has certain office space leases whereby the entity leasing the office space as the lessor is controlled or owned by Dr. Prabhu Rachakonda, the founder of SCN and an employee of the Company. The details of these leases are as follows:

 

Lease #1 – In November 2024, SCN entered into an amended office lease agreement for $22,186 per month with an annual 3% increase to the monthly rent effective each succeeding November. The remaining lease term is for approximately 8.0 years as of September 30, 2026. The Company paid approximately $200 thousand in fixed rent amounts for the nine months ended September 30, 2026.

 

Lease #2 – In January 2024, SCN entered into an office lease agreement when the previous agreement expired. The monthly amount for the lease is $11,452 and has a remaining lease term of 2.3 years as of September 30, 2026. The Company paid approximately $103 thousand in fixed rent amounts for the nine months ended September 30, 2026.

 

Lease #3 – As of December 31, 2025, the Company has an office lease with five years remaining on its lease term. The monthly lease amount is $12,320 and increases each April by 3% and has a remaining lease term of 4.3 years as of September 30, 2026. The Company paid approximately $117 thousand in fixed rent amounts for the nine months ended September 30, 2026.

 

On June 30, 2026, the Company’s Chairman and Chief Executive Officer, R. Kirk Huntsman purchased $50,000 of Units in the PIPE SPA at $0.582 per Unit with each Unit consisting of (i) one share of Preferred Stock with a stated value of $0.456 per share, convertible into one share of Common Stock on a one-for-one basis, and (ii) Common Stock purchase Warrants to purchase a number of shares of Common Stock equal to 100% of the number of shares of Common Stock issuable upon conversion of the Preferred Stock included in such Unit.

 

On July 31, 2026, the Company entered into a Master Services Agreement (the “MSA”) with The CFO Portal, LLC (“CFO Portal”), under which CFO Portal provides managed chief financial officer and finance-and-accounting leadership services to the Company, including the services of Roman Franklin as the Company’s Chief Financial Officer and principal financial officer. Mr. Franklin has been Chief Executive Officer of CFO Portal since September 2025. Under the MSA, the Company pays CFO Portal a fixed monthly retainer of $27,000 (an annual retainer of $324,000), together with event-based fees for certain extraordinary, non-recurring work and reimbursement of pre-approved expenses. The MSA has an initial term of twelve months and renews automatically for successive twelve-month terms unless either party gives sixty days’ notice of non-renewal. The Audit Committee of the Board of Directors reviewed and approved the arrangement. On July 31, 2026, the Company granted Mr. Franklin an option to purchase 552,000 shares of common stock with an approximate grant-date value of $226,320. From July 31, 2026 through October 9, 2026, the Company paid CFO Portal $144,121 under the MSA, covering the services of Mr. Franklin and other accounting personnel.

 

NOTE 14 - NET LOSS PER SHARE OF COMMON STOCK

 

Basic and diluted net loss per share of Common Stock (“EPS”) is computed by dividing (i) net loss (the “Numerator”), by (ii) the weighted average number of shares of Common Stock outstanding during the period (the “Denominator”).

 

The calculation of diluted EPS is also required to include the dilutive effect, if any, of stock options, unvested restricted stock awards, convertible debt and Preferred Stock, and other Common Stock equivalents such as pre-funded warrants computed using the treasury stock method, in order to compute the weighted average number of shares outstanding. As of September 30, 2026 and 2025, all Common Stock equivalents were antidilutive.

 

Presented below are the calculations of the Numerators and the Denominators for basic and diluted EPS (dollars in thousands, except per share amounts):

 

   2026   2025   2026   2025 
   For the Three Months Ended
September 30,
   For The Nine Months Ended
September 30,
 
   2026   2025   2026   2025 
Calculation of Numerator:                    
Net loss  $(1,971)   (5,400)  $(15,245)   (14,276)
                     
Loss applicable to common stockholders  $(1,945)  $(5,400)  $(15,108)  $(14,276)
                     
Calculation of Denominator:                    
Weighted average number of shares of Common Stock outstanding   26,528,253    10,963,590    19,658,339    9,557,368 
                     
Net loss per share of Common Stock (basic and diluted)  $(0.07)  $(0.49)  $(0.77)  $(1.49)

 

22

 

 

As of September 30, 2026 and 2025, the following potential Common Stock equivalents were excluded from the computation of diluted net loss per share of Common Stock since the impact of inclusion was antidilutive (in thousands):

 

   September 30,
2026
   September 30,
2025
 
 
Common stock warrants   21,497    11,798 
Restricted stock units   205    - 
Common stock options   1,972    1,225 
Total   23,674    13,023 

 

NOTE 15 - FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS

 

Fair Value Measurements

 

Fair value is defined as the price that would be received upon sale of an asset or paid to transfer a liability in an orderly transaction between market participants on the measurement date. When determining fair value, the Company considers the principal or most advantageous market in which it transacts and considers assumptions that market participants would use when pricing the asset or liability. The Company applies the following fair value hierarchy, which prioritizes the inputs used to measure fair value into three levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the measurement of fair value:

 

Level 1 - Quoted prices in active markets for identical assets or liabilities accessible to the reporting entity at the measurement date

 

Level 2 - Other than quoted prices included in Level 1 that are observable for the asset and liability, either directly or indirectly through market collaboration, for substantially the full term of the asset or liability

 

Level 3 - Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any market activity for the asset or liability at measurement date

 

As of September 30, 2026 and 2025, the fair value of the Company’s cash and cash equivalents, accounts receivable, accounts payable, and other accrued liabilities approximated their carrying values due to the short-term nature of these instruments.

 

Recurring Fair Value Measurements

 

For the three months ended September 30, 2026 and 2025, only the contingent consideration liability discussed in Note 7 was identified as Level 1, Level 2 or Level 3. Level 3 techniques were used in the non-recurring measurement of assets and liabilities acquired in the SCN acquisition.

 

The Company’s policy is to recognize asset or liability transfers among Level 1, Level 2 and Level 3 as of the actual date of the events or change in circumstances that caused the transfer. During the three months ended September 30, 2026 and 2025 the Company had no transfers of assets or liabilities between levels of the fair value hierarchy.

 

23

 

 

Significant Concentrations

 

Credit Risk

 

The Company maintains its cash and cash equivalents primarily in depository and money market accounts within three large financial institutions in the United States. Cash balances deposited at these major financial banking institutions exceed the insured limits. The Company has not experienced any losses on its bank deposits and believe these deposits do not expose the Company to any significant credit risk. If the Company was unable to access cash and cash equivalents as needed, the financial position and ability to operate the business could be adversely affected. As of September 30, 2026, the Company had cash and cash equivalents with five financial institutions in the United States with an aggregate balance of $0.2 million.

 

Generally, credit risk with respect to accounts receivable is diversified due to the number of entities comprising the Company’s customer base and their dispersion across different geographies and industries. The Company performs ongoing credit evaluations on certain customers and generally do not require collateral on accounts receivable. No single customer represented more than 10% of the Company’s sales or accounts receivable as of September 30, 2026. The Company maintains reserves for potential bad debts.

 

Supplier Concentration

 

As previously disclosed, the Company relies on third-party suppliers and contract manufacturers for the raw materials and components used in the Company’s appliances and to manufacture and assemble the Company’s products. As of September 30, 2026, the Company had five suppliers that accounted for approximately 63% of its total purchases during the year. The Company expects to maintain existing relationships with these vendors.

 

NOTE 16 – SEGMENT INFORMATION

 

The Company operates its business as one operating segment. An operating segment is defined as a component of an enterprise for which separate discrete financial information is available and evaluated regularly by a CODM in deciding how to allocate resources and in assessing performance. The Company’s CODM is the Company’s Chief Executive Officer and Chair of the Board of Directors. Reportable segment information is consistent with how management reviews the business, makes investing and resource allocation decisions and assesses operating performance. The Company’s segment revenues are derived from the sales of the Company’s products, service revenue, the Vivos Method, to sleep centers and VIP providers in the U.S., Canada, Australia and in select countries in Europe and Asia.

 

The Company’s CODM uses consolidated revenue, gross profit, gross margin and operating loss as the measure of profit or loss. The Company’s CODM assesses performance for the segment and allocates resources and monitors budget versus actual results using consolidated revenue, gross profit, gross margin and operating loss, as disclosed in the statement of operations. The monitoring of budget versus actual results are used in establishing management’s compensation. The measure of segment assets is reported on the balance sheet as total consolidated assets. Revenue and long-lived tangible assets are all located in the U.S.

 

NOTE 17 – Variable Interest Entities

Variable Interest Entities

 

The Company evaluates its involvement with variable interest entities (“VIEs”) to determine whether it is required to consolidate such entities and to provide related disclosures.

 

Consolidated Variable Interest Entity

 

AIM Detroit, LLC (“AIM Detroit”) is a limited liability company formed to provide management and administrative services to affiliated clinical practices. The Company holds an 80% ownership interest in AIM Detroit.

 

The Company has determined that AIM Detroit is a variable interest entity because, by design, AIM Detroit’s equity at risk is not sufficient to permit it to finance its activities without additional subordinated financial support. Such support includes, among other things, as-needed member funding during the start-up period and credit support arrangements related to equipment financing.

 

The Company is the primary beneficiary of AIM Detroit because the Company has substantive decision-making authority over the activities that most significantly affect AIM Detroit’s economic performance and have the obligation to absorb losses or the right to receive benefits that could potentially be significant. Accordingly, AIM Detroit is consolidated in the Vivos’ consolidated financial statements.

 

24

 

   September 30,
2026
   December 31,
2025
 
Current assets          
Cash and cash equivalents  $5   $20 
Accounts receivable, net of allowance   7    3 
           
Total current assets   12    23 
           
Long-term assets          
Property and equipment, net   362    318 
Operating lease right-of-use asset   66    80 
Deposits and other   9    9 
           
Total assets  $449   $430 
           
LIABILITIES AND STOCKHOLDERS’ EQUITY/(DEFICIT)          
Current liabilities          
Accounts payable  $236   $126 
Accrued expenses   220    78 
Current portion of operating lease liability   20    19 
Current portion of debt   38    39 
Other current liabilities   14    2 
           
Total current liabilities   528    264 
           
Long-term liabilities          
Operating lease liability, net of current portion   143    167 
Debt, net of current portion   54    87 
           
Total liabilities  $725   $518 

 

NOTE 18 – SUBSEQUENT EVENTS

 

As previously disclosed, in April 2026 Vivos Therapeutics, Inc. (the “Company”) received a deficiency notice from the Listing Qualifications staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company did not comply with the continued listing requirements of Nasdaq Listing Rules 5550(b)(1), 5550(b)(2), or 5550(b)(3), which require a listed company to maintain a minimum of $2.5 million in stockholders’ equity, a minimum $35 million market value of listed securities, or a minimum of $500,000 of net income from continuing operations, respectively.

 

On October 20, 2026, the Company received a letter from the Staff stating that, based on the Company’s Current Report on Form 8-K filed October 19, 2026, the Staff has determined that the Company complies with the minimum stockholders’ equity requirement of Nasdaq Listing Rule 5550(b)(1). The letter further stated that if the Company fails to evidence compliance upon the filing of its next periodic report, the Company may be subject to delisting, in which case the Staff would provide written notification to the Company, which may then appeal the Staff’s determination to a Nasdaq Hearings Panel.

 

On October 14, 2026 the Company entered into a Mutual Stock Purchase and Asset Exchange Agreement (the “Agreement”) with SOD Sciences, Inc., a Nevada corporation (“SOD”), providing for the Company’s acquisition of a minority equity interest in SOD and an undivided fifty percent (50%) co-ownership interest in SOD’s pseudohypoxia early-warning test and related intellectual property, in exchange for the issuance to SOD of 12,000 shares of the Company’s Series C Convertible Preferred Stock.

 

On October 15, 2026, the Company and SOD entered into a First Amendment to the Agreement (the “First Amendment”), which extended the outside date under the Agreement from October 15, 2026 to October 16, 2026 and established October 16, 2026 as the closing date. On October 16, 2026, the Company and SOD entered into Amendment No. 2 to the Agreement (“Second Amendment”), which corrected a scrivener’s error in the Agreement and the related transaction documents that had described SOD as a Florida corporation. Neither the First Amendment nor the Second Amendment otherwise modified the Agreement.

 

On October 16, 2026 (the “Closing Date”), at the closing under the Agreement (the “Closing”), the Company and SOD entered into an Assignment and Co-Ownership Agreement (the “Assignment Agreement”), pursuant to which SOD assigned to the Company an undivided fifty percent (50%) co-ownership interest in the pseudohypoxia early-warning test (the “Test Interest”) and related intellectual property (the “Test IP”), free and clear of liens. The Company and SOD hold the Test IP as tenants in common, share equally all revenue and consideration derived from its exploitation and the costs of patent prosecution, maintenance and enforcement, and have mutual consent rights over licenses and settlements. The Assignment Agreement contains customary representations and warranties of SOD regarding title, authority, the absence of liens and conflicting licenses, inventor assignments and non-infringement, which survive for twelve (12) months after the Closing (and, as to title, liens and the completeness of the scheduled patent rights, until sixty (60) days after expiration of the applicable statute of limitations), and provides for a right of first refusal in favor of the Company on any transfer of SOD’s retained interest and a buy-sell exit mechanism at independently appraised fair market value.

 

On the Closing Date, the Company completed the acquisition of (i) 3,057,879 shares of common stock of SOD (the “SOD Shares”), representing at least eleven percent (11%) of SOD’s fully diluted capital stock immediately after the Closing (as adjusted in accordance with the Agreement from the 2,907,338 shares previously reported by the Company), and (ii) the Test Interest, in exchange for the issuance to SOD of 12,000 shares of the Company’s Series C Convertible Preferred Stock, par value $0.0001 per share (the “Series C Preferred”), with a stated value of $1,000 per share and an aggregate stated value of $12,000,000. No cash consideration was paid by either party. Under the Assignment Agreement, SOD is required to record the assignment of the Test Interest with the United States Patent and Trademark Office, and with applicable foreign patent authorities with respect to the pending international application, within thirty (30) days after the Closing Date. The consideration was determined by arm’s-length negotiation between the Company and SOD. No placement agent, broker or finder was used in connection with the transaction, and, other than in respect of the Agreement and the related transaction documents, there is no material relationship between the Company or any of its affiliates, directors or officers, on the one hand, and SOD, on the other hand. The material terms of the Agreement are described in the Company’s Current Report on Form 8-K filed with the SEC on October 19, 2026. The Company is evaluating the accounting for this transaction, including the fair value of the SOD Shares and the Test Interest and the classification and measurement of the Series C Preferred. The Company has stated that it expects to classify the Series C Preferred in permanent stockholders’ equity and to record the SOD Shares and the Test Interest at fair value, and that its initial purchase price allocation remains subject to adjustment for twelve months after the Closing Date. The transaction is not reflected in the accompanying condensed consolidated financial statements as of September 30, 2026.

 

Each share of the Series C Preferred is convertible at the option of the holder into the number of shares of common stock determined by dividing the $1,000 stated value by a conversion price of $0.15 per share, subject to proportional adjustment for stock splits, reverse stock splits, combinations, stock dividends and similar events. At that conversion price, the Series C Preferred is convertible into up to 80,000,000 shares of common stock in the aggregate. Until the Company’s stockholders approve the issuance of shares in excess of that cap for purposes of Nasdaq Listing Rule 5635(a), no more than 6,718,517 shares of common stock (19.99% of the shares outstanding before the Agreement was signed) may be issued upon conversion, and that cap cannot be waived by the Company or any holder. The Series C Preferred may not be converted to the extent the holder, together with its affiliates, would beneficially own more than 4.99% of the outstanding common stock, which the holder may increase to not more than 9.99% upon 61 days’ prior written notice. The Series C Preferred ranks pari passu with the Series A Convertible Preferred Stock and the Series B Non-Convertible Preferred Stock and senior to the common stock with respect to dividends and liquidation, participates on an as-converted basis in any dividends declared on the common stock, and votes with the common stock on an as-converted basis, subject to the lesser of the beneficial ownership limitation and the exchange cap. Streeterville Capital, LLC consented to the issuance of the Series C Preferred.

 

The Company has called its 2026 annual meeting of stockholders for December 2, 2026 (record date October 9, 2026). In addition to the election of directors and other customary matters, stockholders are being asked to approve: (i) an amendment to the Company’s Certificate of Incorporation to effect a reverse stock split of the common stock at a ratio in the range of 1-for-20 to 1-for-40, with the exact ratio and timing to be determined by the Board of Directors, which may abandon the amendment; (ii) for purposes of Nasdaq Listing Rules 5635(b) and 5635(d), the issuance of up to 18,476,959 shares of common stock upon conversion of the Series A Convertible Preferred Stock and exercise of the warrants and pre-funded warrants held by New Seneca Partners Inc. and its affiliates; (iii) for purposes of Nasdaq Listing Rules 5635(a) and 5635(b), the issuance of up to 80,000,000 shares of common stock (subject to proportional adjustment for the reverse stock split) upon conversion of the Series C Preferred in excess of the 19.99% exchange cap; (iv) an amendment to the 2024 Omnibus Equity Incentive Plan increasing the number of shares authorized for issuance by 4,900,000 shares, from 4,100,000 to 9,000,000; and (v) the conversion of the Company from a Delaware corporation to a Nevada corporation. The Company has stated that holders of its Series A, Series B and Series C preferred stock may be entitled to appraisal rights under Section 262 of the Delaware General Corporation Law in connection with the conversion. There can be no assurance that any of these proposals will be approved.

 

25

 

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

 

The following discussion and analysis of the Company’s financial condition and results of operations should be read in conjunction with the Company’s financial statements and the related notes to those statements included elsewhere in this Quarterly Report on Form 10-Q. In addition to historical financial information, the following discussion and analysis contains forward-looking statements that involve risks, uncertainties, and assumptions. Some of the numbers included herein have been rounded for the convenience of presentation. The Company’s actual results may differ materially from those anticipated in these forward-looking statements as a result of many factors. See “Cautionary Note Regarding Forward-Looking Statements.” See also Part II, Item A, “Risk Factors.”

 

Overview

 

The Company is a revenue stage medical technology and healthcare services company focused on the development and commercialization of innovative treatment alternatives for patients with dentofacial abnormalities and/or patients diagnosed with mild to severe obstructive sleep apnea (“OSA”) and snoring in adults. The Company believes its technologies and conventions represent a significant improvement in the treatment of mild to severe OSA versus other treatments such as CPAP or palliative oral appliance therapies. The Company’s alternative treatments are part of The Vivos Method.

 

The Vivos Method is an advanced therapeutic protocol, which often combines the use of customized oral appliance specifications and proprietary clinical treatments developed by the Company and prescribed by specially trained dentists in cooperation with their medical colleagues. Published studies have shown that using the Company’s customized appliances and clinical treatments led to significantly lower Apnea Hypopnea Index scores and have improved other conditions associated with OSA. Nearly 75,000 patients have been treated to date.

 

In June 2025, the Company acquired all assets, including operating assets such as sleep testing, diagnostics, and treatment centers of SCN. The Acquisition marked a milestone in the pivot to the Company’s medical provider-focused sales, marketing and distribution model for the Company’s innovative OSA appliances. Under the new model, SCN will provide sleep disorder patients with the opportunity to be candidates for the Company’s advanced, proprietary and FDA-cleared CARE oral medical devices, oral appliances and additional adjunctive therapies and methods. Under customary agreements designed to comply with applicable corporate practice of medicine law, the Company’s operation of SCN allows the Company to manage and capture both diagnostic and diagnostic consulting revenues, representing new higher margin revenue streams for the Company, as well as potential Vivos appliance and related product and service revenue.

 

See Note 1 to the accompanying financial statements for additional background information on the Company and current product and service offerings.

 

Third Quarter 2026 Highlights

 

 ●Operating loss improved by $0.8 million, or 18%, to $3.9 million, compared to $4.7 million for the third quarter of 2025.
 ●Net loss improved by $3.4 million, or 64%, to $2.0 million, compared to $5.4 million for the third quarter of 2025 due to an increase in Other Income related to Employee Retention Credits.
 ●General and administrative expenses decreased by $1.4 million, or 18%, to $6.5 million, reflecting the Company’s cost reduction initiatives.
 ●Sales and marketing expenses decreased by $0.2 million, or 48%, to $0.2 million.
 ●Total revenue was $6.4 million, a decrease of 5% from the prior-year quarter which was the first full quarter after the acquisition of SCN, as lower product revenue offset a 1% increase in service revenue to $4.6 million. Gross margin was 52%, compared to 58% for the third quarter of 2025.

 

26

 

 

Nine Months Ended September 30, 2026

 

 ●Total revenue increased by $3.1 million, or 23%, to $16.7 million, driven by a $4.4 million, or 57%, increase in service revenue.
 ●Gross profit increased by $1.8 million, or 23%, to $9.3 million, and gross margin improved to 56% from 55%.

 

Recent Developments

 

Nasdaq Stockholders’ Equity Compliance. On October 20, 2026, the Company received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC confirming that, based on the Company’s Current Report on Form 8-K filed October 19, 2026, the Company complies with the minimum stockholders’ equity requirement of Nasdaq Listing Rule 5550(b)(1). Nasdaq will continue to monitor the Company’s ongoing compliance and, if the Company fails to evidence compliance upon the filing of its next periodic report, the Company may be subject to delisting.

 

Strategic Transaction with SOD Sciences, Inc. On October 16, 2026, the Company acquired 3,057,879 shares of common stock of SOD Sciences, Inc. (“SOD”), representing at least 11% of SOD’s fully diluted capital stock, and an undivided 50% co-ownership interest in SOD’s pseudohypoxia early-warning test and related intellectual property, in exchange for 12,000 shares of the Company’s Series C Convertible Preferred Stock with an aggregate stated value of $12.0 million. No cash consideration was paid by either party. The Company and SOD share equally in all revenue derived from the test and related intellectual property and in the related patent costs. Under the Agreement, the Company and SOD are to negotiate a joint marketing agreement under which SOD would market the Company’s testing and device products through the American Health Associates and Cleveland Clinic Weston channels, with the Company retaining 80% of the contribution margin on sales of its products through those channels, and a separate agreement addressing the marketing of SOD’s ReBalU Protocol to U.S. sleep-testing centers. The Company is entitled to 50% of the contribution margin on all sales of the test through any channel. If the joint marketing agreement is not signed within 90 days after the closing, either party may submit the unresolved terms to binding determination by an independent expert. There can be no assurance that definitive agreements with American Health Associates or Cleveland Clinic Weston will be signed or that any commercial activity will result. The Company is evaluating the accounting for this transaction, including the fair value of the assets acquired and the classification of the Series C Convertible Preferred Stock. The transaction is not reflected in the accompanying financial statements as of September 30, 2026. See Note 18 to the accompanying financial statements.

 

Reduction of Senior Secured Debt. In August 2026, the Company completed a qualifying equity financing in excess of the $2.6 million threshold under its Exchange Agreement with Streeterville Capital, LLC, which triggered the exchange of approximately $3.25 million of senior secured debt for 1,812,031 shares of common stock and 2,500 shares of Series B Non-Convertible Preferred Stock. The exchange was completed on August 4, 2026. In addition, on September 2, 2026, the Company exchanged $2,861,270 of principal of the Streeterville note for up to 11,445,080 shares of common stock at an average exchange price of approximately $0.25 per share. These exchanges reduced the Company’s outstanding senior secured indebtedness. As of September 2, 2026, after these exchanges, the outstanding principal balance of the Streeterville note was approximately $3.7 million, as reported in the Company’s Current Report on Form 8-K/A filed September 8, 2026. The Series B Non-Convertible Preferred Stock carries a 9% annual dividend and certain covenants in favor of Streeterville, including consent rights over future financings exceeding $2.5 million in the aggregate.

 

CFO Transition. Effective July 31, 2026, Bradford Amman voluntarily resigned as Chief Financial Officer and Secretary of the Company. Mr. Amman’s resignation was not the result of any disagreement with the Company on any matter relating to its operations, accounting policies or practices, financial reporting, internal controls, or disclosures. Concurrently, the Board of Directors appointed Roman Franklin as Chief Financial Officer and principal financial officer pursuant to a managed services agreement with The CFO Portal, LLC, a related-party arrangement. Mr. Amman agreed to remain with the Company as a non-executive transition employee for 90 days after July 31, 2026, serving as principal accounting officer, receiving his base salary and benefits and being paid previously deferred compensation during that period, and then to serve as an independent contractor advisor for an additional 180 days at a monthly fee of $13,333, under a Separation, Resignation and Executive Transition Agreement dated July 31, 2026. The Company also agreed to pay his COBRA premiums for up to six months and, subject to approval by the Board of Directors and the effectiveness of a release, to grant him a fully vested award of 250,000 shares of common stock and an option to purchase 150,000 shares of common stock that vests monthly during the advisory period. Any amounts still payable under the agreement will become due, and the option will vest in full, if the Company completes an equity financing of $5 million or more. These payments and benefits are provided in place of severance under his employment agreement.

 

Material Items, Trends and Risks Impacting the Company’s Business

 

The Company believes that the following items and trends may be useful in better understanding the Company’s results of operations.

 

VIP Enrollments (Service Revenue). Enrolling dental practices as VIPs has historically been the first step in the Company’s ability to generate new revenue. As part of the Company’s strategic pivot previously described herein, the Company has phased out the VIP program and no longer offers it to independent dentists.

 

In addition to enrollment service revenue, the Company offers additional services, such as the Company’s Billing Intelligence Services offering, and MyoSync (formerly MyoCorrect) orofacial myofunctional therapy services, which was introduced in April 2021. Revenue for these services is recognized as the Company’s performance obligations are satisfied in accordance with ASC 606.

 

27

 

 

Because of the Company’s 2024 marketing and distribution business model pivot, which was accelerated by the Company’s June 2025 acquisition of SCN, the Company has become primarily focused on engaging in strategic collaborations or acquisitions to market the benefits of the Vivos treatment modalities to dentists and other medical providers, including the Company’s cooperative relationships with various medical providers to deliver diagnostic and medical consultation services to people across North America who suffer from OSA. As such, while the Company will continue to recognize minimal VIP enrollment revenue through 2026, the Company believes such revenue will become immaterial. Going forward, the Company no longer expects to recognize revenue on VIP enrollment as the Company’s performance obligations are believed to have been satisfied in accordance with ASC 606.

 

Product Sales Revenue. Vivos treatment “case starts” are paramount to the Company’s business, as case starts lead to appliance orders and related revenue. Once a provider is fully trained, the Company encourages them to start cases. However, the Company’s historic experience had been that VIPs typically start slowly as they introduce The Vivos Method into their practices. The slow acceptance rate of Vivos appliances with providers led the Company to consider other business models, most notably the medical provider-focused alliance marketing and distribution model announced in 2024 and the 2025 acquisition of SCN, to provide services and sell appliance product. In the Company’s new model, the Company’s biggest challenge to date has been hiring, equipping and training personnel at SCN locations in the Vivos Method, as well as insurance reimbursement. Navigating these challenges has led to increases in service revenue (including sleep testing) and the Company’s goal is to increase case starts and appliance sales as well. Since the Company’s SCN acquisition, the Company has been unable to generate sufficient revenues to pay for all of the Company’s expenses, including debt service, so the Company’s primary business goal is to increase revenues through SCN and also consider other acquisitions or alliances as a means of increasing revenue from services and appliance sales.

 

In addition, an important aspect of the Company’s strategy to increase product revenues relates to the products and related intellectual property the Company acquired in March 2023 from Advanced Facialdontics, LLC (“AFD”), including a custom single arch device with an FDA 510(k) clearance for treating TMD and/or Bruxism (teeth grinding or clenching). The Company has rebranded the AFD products as Vivos Versa, Vivos Vida and Vivos Vida Sleep.

 

Clinical Trial Work. The Company’s efforts to engage in research to demonstrate the clinical efficacy of the Company’s products and obtain additional regulatory clearances for the use of the Company’s products is an important aspect of the Company’s overall strategy. In this regard, on May 29, 2023, the Company and Stanford University executed an agreement to commence a sponsored clinical research study to evaluate the efficacy of the Company’s FDA-cleared DNA appliance compared to the standard of care, CPAP for treatment of sleep apnea. The Company’s DNA device is currently indicated for the treatment of mild to severe sleep apnea and jaw repositioning in adults (and in the case of severe OSA, along with positive airway pressure and/or myofunctional therapy, as needed) and has an FDA clearance intended to reduce nighttime snoring and to treat moderate and severe obstructive sleep apnea in children, 6 - 17 years of age who are diagnosed with snoring and/or moderate or severe obstructive sleep apnea and need orthodontic treatment. Enrollment of 150 patients with moderate to severe sleep apnea (apnea-hypopnea index score of 15 or greater) will be randomly assigned to either treatment with the Company’s FDA-cleared DNA appliance or CPAP. The protocol has been finalized, and enrollment began in 2024. In late 2024, the Company’s clinical study conducted in collaboration with Stanford University and evaluating the DNA and CPAP for the treatment of OSA, was placed on hold by Stanford University. The decision to pause the study was made due to low recruitment into the study. The study remained on hold as of the date of this Report.

 

The Company is working with Stanford University to address the concerns that led to the hold and has continued to engage in discussions with the university. While the Company believes these efforts will facilitate the resumption of the study, there can be no assurance that the hold will be lifted in a timely manner, or at all. Any delay or failure to resolve the issues could impact the development timeline and future prospects for the study. The Company remains committed to the highest standards of patient safety, scientific integrity, and regulatory compliance and will provide updates as material developments occur. This trial may not meet its designated endpoints, and therefore additional FDA clearances for the DNA device may not be obtained.

 

28

 

 

Inflation. The U.S. has been experiencing a period of inflation which has increased (and may continue to increase) the Company’s and its suppliers’ costs as well as the end cost of the Company’s products to consumers. To date, the Company has been able to manage inflation risk without a material adverse impact on the Company’s business or results of operations. However, inflationary pressures (including increases in the price of raw material components of the Company’s appliances) made it necessary for the Company to adjust the Company’s standard pricing for the Company’s appliance products in 2022 and will be revisited in 2027. The full impact of such price adjustments on sales or demand for the Company’s products is not fully known at this time and may require the Company to adjust other aspects of the Company’s business as the Company seeks to grow revenue and, ultimately, achieve profitability and positive cash flow from operations.

 

Supply Chain. From time to time, the Company may experience supply chain challenges due to forces beyond the Company’s control. For example, the Suez Canal blockage in 2021 caused some delay in shipments of SleepImage® rings from China. Changes in U.S. or foreign trade policy, including the imposition of new tariffs, increases in existing tariffs or changes in customs classifications, could increase the Company’s costs. Overall, however, as the Company’s appliances are made in the U.S., the Company has not experienced significant supply chain issues as a result of COVID-19 or otherwise, although this may change in future periods.

 

Middle East Hostilities. In addition, geopolitical instability in the Middle East continues to create uncertainty in global economic conditions and commercial activity. Hostilities in the region, including the attacks by Hamas on Israel in October 2023, Israel’s subsequent military responses, and more recent U.S. and Israeli military actions involving Iran, have contributed to heightened regional and global tensions. These developments, combined with the ongoing effects of Russia’s invasion of Ukraine that began in February 2022, have intensified supply chain constraints, increased commodity price volatility and disrupted international trade flows. If an economic recession or depression commences and is sustained, it could have a material adverse effect on the Company’s business as demand for the Company’s products could decrease. Capital markets uncertainty, with public stock price decreases and volatility, could make it more difficult for the Company to raise capital when needed.

 

Nasdaq Listing Requirements. The Company is subject to the continued listing requirements of The Nasdaq Stock Market LLC (“Nasdaq”), including the minimum stockholders’ equity requirement (the “Equity Requirement”). During 2026, the Company received notices from Nasdaq regarding its compliance with the Equity Requirement and the $1.00 minimum bid price requirement, as described below. On October 20, 2026, Nasdaq confirmed that the Company complies with the Equity Requirement, subject to ongoing monitoring. The Company intends to hold an annual stockholder’s meeting on December 2, 2026. At this meeting shareholders will vote on a proposed reverse split at a ratio that management believes will resolve Nasdaq’s $1.00 minimum bid price requirement (the “Minimum Bid Requirement”).

 

The Company has a history of challenges of maintaining compliance with the Nasdaq’s continuing listing requirements. The Company has been subject to multiple Nasdaq listing deficiencies relating to the Minimum Bid Requirement and the Equity Requirement. Nasdaq confirmed on October 20, 2026 that the Company complies with the Equity Requirement. The Company has not regained compliance with the Minimum Bid Requirement as of the date of this Report.

 

On September 21, 2023, the Company received a written notice from the Nasdaq staff confirming that since, as of that date, the Company failed to meet the Minimum Bid Requirement, and because as of the period ended June 30, 2023 the Company also failed the Equity Requirement, Nasdaq would commence delisting proceedings against the Company. As permitted under Nasdaq rules, the Company appealed the Nasdaq staff’s determination and requested a hearing (the “Hearing”) before a Nasdaq Hearing Panel (the “Hearing Panel”). The Hearing request stayed any delisting or suspension action by the Nasdaq staff pending the issuance of the Hearing’s Panel decision. The Hearing took place on November 9, 2023.

 

Prior to the date of the Hearing, the Company effectuated a reverse stock split of its issued and outstanding shares of common stock at a ratio of 1-for-25 (the “Reverse Stock Split”). The Reverse Stock Split became effective on October 25, 2023, and the Company’s common stock began trading on a post-Reverse Stock Split basis on the Nasdaq on October 27, 2023. To satisfy the Minimum Bid Requirement, the Company’s common stock was required to trade at above $1.00 per share for at least 10 trading days, and this was achieved on November 9, 2023. The Company therefore regained compliance with the Minimum Bid Requirement in November 2023.

 

29

 

 

At the Hearing on November 9, 2023, the Company presented its plan to regain compliance with the Equity Requirement, which included raising additional equity capital. On November 30, 2023, the Company received a letter from the Hearings Panel that, subject to certain conditions, the Hearings Panel granted the Company’s request to continue to be listed on Nasdaq. On February 23, 2024 the Company presented its plan of compliance to the Hearings Committee. On May 6, 2024, the Company received written notice from the Nasdaq staff indicating that the Company had regained compliance with the Equity Requirement.

 

On May 16, 2024, the Company received a further written notice from Nasdaq indicating that, as of March 31, 2024, the Company failed to comply with the Equity Requirement. On June 25, 2024, the Company reported in a Current Report on Form 8-K that the Company believed the Company had stockholders’ equity of at least $2.5 million as of the date of the filing of such report as a result of the Company’s closing of a $7.5 million equity private placement on June 10, 2024.

 

On June 27, 2024, the Company met with the Panel to discuss the Company’s past, current, and anticipated future compliance with the Equity Requirement, and requested the continued listing of its securities on Nasdaq.

 

On July 5, 2024, the Company was notified that the Panel granted the Company’s request for continued listing on Nasdaq, subject to the Company’s filing of the Form 10-Q for the quarter ended June 30, 2024, with the Securities and Exchange Commission, evidencing the Company’s compliance with the Equity Requirement. The Company made such filing in a timely manner.

 

On April 17, 2026, the Company received a letter (“Letter”) from the Listing Qualifications Staff (the “Staff”) of Nasdaq indicating that the Company’s stockholders’ equity as reported in its Annual Report on Form 10-K for the year ended December 31, 2025 (the “Form 10-K”), did not satisfy the continued listing requirement under the Equity Requirement. As reported in its Form 10-K, as of December 31, 2025 the Company had a negative stockholders’ equity of approximately $1.55 million. The Staff’s notice has no immediate impact on the listing of the Company’s common stock on Nasdaq.

 

On June 5, 2026, the Company received a notice from the Listing Qualifications Staff of Nasdaq indicating that, based on the closing bid price of the Company’s common stock from April 23, 2026 through June 4, 2026, the Company was no longer in compliance with the Minimum Bid Requirement. The Company has a compliance period of 180 calendar days, through December 2, 2026, to regain compliance, and as of the date of this report it has not regained compliance. The Company is seeking stockholder approval at its December 2, 2026 annual meeting of a reverse stock split of the common stock at a ratio in the range of 1-for-20 to 1-for-40, to be determined by the Board of Directors, to raise the bid price and regain compliance. If the Company does not regain compliance by December 2, 2026, it may be eligible for a second 180-day compliance period if it meets the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, other than the minimum bid price requirement, and notifies Nasdaq of its intent to cure the deficiency. There can be no assurance that the Company will regain compliance or that Nasdaq will grant a second compliance period.

 

The Company has taken affirmative steps since December 31, 2025 to remedy the Minimum Stockholders’ Equity Requirement. Specifically, as previously reported, the Company engaged in two equity financing transactions during the first quarter ended March 31, 2026 for aggregate gross proceeds of $6.8 million: a $4.6 million warrant exercise inducement transaction and $2.25 million private placement with an existing investor. The Company also engaged in an approximately $2.1 million private placement in the second quarter ended June 30, 2026 with one new and one existing investor. During the third quarter ended September 30, 2026, the Company exchanged $3,250,000 of principal of its senior secured note held by Streeterville Capital, LLC for 1,812,031 shares of common stock and 2,500 shares of Series B Non-Convertible Preferred Stock on August 4, 2026, and exchanged a further $2,861,270 of principal for up to 11,445,080 shares of common stock on September 2, 2026. The Company also sold shares of common stock under its at-the-market offering program in the third quarter, with net proceeds of approximately $1.9 million. These transactions improved stockholders’ equity but did not by themselves restore compliance, as the Company’s total stockholders’ equity at September 30, 2026 was approximately $2.4 million ($2.2 million including non-controlling interest), below the $2.5 million minimum. On October 16, 2026, the Company issued 12,000 shares of Series C Convertible Preferred Stock, with an aggregate stated value of $12.0 million, to SOD in exchange for 3,057,879 shares of SOD common stock and an undivided 50% co-ownership interest in SOD’s pseudohypoxia early-warning test and related intellectual property, as described under “Recent Developments” above. In its Current Report on Form 8-K filed October 19, 2026, the Company reported unaudited pro forma stockholders’ equity of approximately $6.6 million as of June 30, 2026, giving effect to the closing, and stated that it expects the closing to increase its stockholders’ equity by more than $10 million, subject to completion of the purchase price allocation and review by its independent registered public accounting firm. On October 20, 2026, Nasdaq notified the Company that it had regained compliance with the Minimum Stockholders’ Equity Requirement, subject to Nasdaq’s continued monitoring.

 

In accordance with the Nasdaq Listing Rules, the Company timely submitted a plan to regain compliance with the Stockholders’ Equity Requirement for the Staff’s consideration. Following the Company’s qualifying equity financing in August 2026, the related exchange of senior secured debt for equity, and the October 16, 2026 issuance of Series C Convertible Preferred Stock in the SOD transaction described under “Recent Developments” above, the Company filed a Current Report on Form 8-K on October 19, 2026, and on October 20, 2026, Nasdaq notified the Company that it complies with the Equity Requirement. Nasdaq will continue to monitor the Company’s ongoing compliance and, if the Company fails to evidence compliance upon the filing of its next periodic report, the Company may be subject to delisting.

 

The Company intends to seek shareholder approval at its annual meeting scheduled for December 2, 2026, to effect a reverse stock split at a ratio management believes will enable the Company to regain compliance with the Minimum Bid Requirement. However, because the shareholder vote is scheduled for the same date as the expiration of the compliance period, the timing of the proposed reverse stock split may not allow the Company sufficient time to regain compliance before the deadline. There can be no assurance that shareholders will approve the proposed reverse stock split, that the Company will be able to implement the reverse stock split in time to regain compliance, or that the Company will otherwise regain compliance with the Minimum Bid Requirement. If the Company fails to regain compliance within the applicable compliance period, its common stock may be subject to delisting from Nasdaq.

 

30

 

 

The Company anticipates that its new medical provider-focused strategic marketing and distribution alliance model will also positively impact the Company’s revenue growth and stockholders’ equity in upcoming fiscal quarters. However, there is a risk that the Company will be unable to raise sufficient capital, reduce costs sufficiently or generate sufficient revenue or operating results to maintain compliance with the Equity Requirement. If the Company fails to achieve ongoing compliance and its common stock is delisted by Nasdaq, such delisting would likely have a material adverse effect on the Company’s stock price, the ability of the Company’s stockholders to buy or sell their common stock, the Company’s ability to raise capital and on the Company’s reputation, all of which could make it significantly more difficult to operate.

 

Key Components of Consolidated Statements of Operations

 

Net revenue. The Company recognizes revenue when the Company satisfies its performance obligations over time as its customers receive the benefit of the promised goods and services, which generally occurs over a short period of time. Performance obligations with respect to appliance sales are typically satisfied at a point in time by shipping or delivering products to the Company’s VIPs or to the sleep clinic, through the Company’s new strategic alliance model. In the case of enrollment or service revenue, upon the Company’s satisfaction of performance obligations associated with VIP enrollments. Revenue consists of the gross sales price, net of estimated allowances, discounts, and personal rebates that are accounted for as a reduction from the gross sale price.

 

In the case of product purchased by clinics managed by the Company’s subsidiary for inclusion in a treatment protocol, the sales price of the Vivos device is recognized by the Company and becomes a component of cost of sales of the treatment center service provided to the patient. For the treatment centers, the intercompany account is used to fulfil the account payable obligation and recognize the expense of the goods and services in cost of sales.

 

Cost of sales. Cost of goods sold primarily consists of direct costs attributable to the purchase from third party suppliers and related products. It also includes freight costs, fulfillment, distribution, and warehousing costs related to products sold.

 

Sales and marketing. Sales and marketing costs primarily consist of personnel costs for employees engaged in sales and marketing activities, commissions, advertising and marketing costs, website enhancements, and conferences for the Company’s sales and marketing staff.

 

General and administrative expenses. General and administrative (“G&A”) expenses consist primarily of personnel costs for the Company’s administrative, human resources, finance and accounting employees, and executives. General and administrative expenses also include contract labor and consulting costs, travel-related expenses, legal, auditing and other professional fees, rent and facilities costs, repairs and maintenance, and general corporate expenses.

 

Depreciation and amortization expense. Depreciation and amortization expense is comprised of depreciation expense related to property and equipment, amortization expense related to leasehold improvements, and amortization expense related to identifiable intangible assets.

 

Other income. Other income relates to the excess warrant fair value and change in fair value of warrant liability and contingent consideration for the purchase of SCN.

 

31

 

 

Results of Operations

 

Comparison of the three and nine months ended September 30, 2026 and 2025

 

The Company’s consolidated statements of operations for the three and nine months ended September 30, 2026 and 2025 (which includes incremental revenue recognized from the operations of SCN since June 10, 2025) are presented below (dollars in thousands):

 

   Three Months Ended
September 30,
   Nine Months Ended
September 30,
 
   2026   2025   Change   2026   2025   Change 
                         
Revenue                              
Product revenue  $1,772   $2,195   $(423)  $4,567   $5,893   $(1,326)
Service revenue   4,642    4,588    54    12,141    7,726    4,415 
Total revenue   6,414    6,783    (369)   16,708    13,619    3,089 
                               
Cost of sales (exclusive of depreciation and amortization shown separately below)   3,100    2,846    254    7,382    6,065    1,317 
Gross profit   3,314    3,937    (623)   9,326    7,554    1,772 
Gross profit %   52%   58%        56%   55%     
                               
Operating expenses                              
General and administrative   6,450    7,884    (1,434)   22,533    19,181    3,352 
Sales and marketing   210    403    (193)   614    1,018    (404)
Depreciation and amortization   550    384    166    1,515    867    648 
                               
Operating loss   (3,896)   (4,734)   838    (15,336)   (13,512)   (1,824)
                               
Non-operating income (expense)                              
Other expense   (981)   (679)   (302)   (3,199)   (850)   (2,349)
Other income   2,906    13    2,893   3,290    86    3,204 
                               
Net loss  $(1,971)  $(5,400)  $3,429   $(15,245)  $(14,276)  $(969)

 

Comparison of the three months ended September 30, 2026 and 2025

 

Revenue

 

Revenue decreased by approximately $0.4 million, or 5%, to approximately $6.4 million for the three months ended September 30, 2026 compared to $6.8 million for the three months ended September 30, 2025. The decrease in total revenue during the third quarter of 2026 was impacted by a decrease of approximately $0.4 million in product revenue offset by a slight increase in service revenue. The decrease in product revenue is attributable to a decrease in appliance sales to VIPs of approximately $1.1 million related to the Company’s previously stated change in business strategy, offset by a decrease of approximately $0.5 million in discounts offered and an increase in diagnostic reports of $0.1 million. The increase in service revenue is attributable to approximately $1.5 million in sleep testing services primarily generated from SCN and an increase of approximately $0.6 million of revenue generated from Vivos treatment to patients launched at two SCN locations, offset by a decrease of approximately $0.1 million in VIP enrollment revenue and approximately $0.1 million from sponsorship, seminar and other service revenue.

 

Cost of Sales and Gross Profit

 

Cost of sales increased $0.3 million or 9% to approximately $3.1 million for the three months ended September 30, 2026, compared to $2.8 million for the three months ended September 30, 2025. This was primarily attributable to higher costs associated with diagnostic services and patient therapy, including the addition of staff at the Vivos treatment centers.

 

For the three months ended September 30, 2026, gross profit decreased by approximately $0.6 million to $3.3 million. This decrease was attributable to the decrease in revenue of approximately $0.4 million and increase in cost of sales of $0.3 million. Gross margin decreased to 52% for the three months ended September 30, 2026, compared to 58% for the three months ended September 30, 2025 due to the decrease in Product Revenue.

 

32

 

 

General and Administrative Expenses

 

General and administrative expenses decreased $1.4 million, or 18%, to approximately $6.5 million for the three months ended September 30, 2026, as compared to $7.9 million for the three months ended September 30, 2025. The decrease was primarily attributable to a $0.8 million reduction in professional fees; a $0.3 million reduction in equipment maintenance; a $0.2 million decrease in office expenses and supplies and a decrease in infrastructure expenses, of $0.1 million. The decrease reflects the Company’s continued focus on cost reduction and the absence of certain integration costs incurred in the prior-year period following the acquisition of SCN.

 

Sales and Marketing

 

Sales and marketing expenses decreased $0.2 million, or 48%, to approximately $0.2 million for the three months ended September 30, 2026, as compared to $0.4 million for the three months ended September 30, 2025, which is attributable in significant part to the Company’s focus on reducing costs.

 

Depreciation and Amortization

 

Depreciation and amortization expense increased $0.2 million for the three months ended September 30, 2026 due to assets being placed into service.

 

Other Income/(Expense)

 

Other (Expense) increased $0.3 million during the three months ended September 30, 2026. The increase is primarily attributable to interest expense from the short-term financing agreements entered into in the third quarter. Other Income was $2,906,000 and $13,000 for the three months ended September 30, 2026 and 2025, respectively. The increase in Other Income is primarily attributable to the reversal of the Company’s previously recorded Employee Retention Credit liability of approximately $2.9 million, because management concluded that repayment of the credits is no longer deemed probable. See Note 7 to the accompanying unaudited condensed consolidated financial statements.

 

Comparison of the nine months ended September 30, 2026 and 2025

 

Revenue

 

Revenue increased by approximately $3.1 million, or 23%, to approximately $16.7 million for the nine months ended September 30, 2026 compared to $13.6 million for the nine months ended September 30, 2025. The increase in total revenue during the period was impacted by an increase of approximately $4.4 million in service revenue offset by a decrease of approximately $1.3 million in product revenue. The $ 1.3 million decrease in product revenue was attributable to a decrease in the sales volume of the Company’s On Demand Orthodontic (ODO) devices to VIP members.  During 2026 the Company has shifted its marketing focus to concentrate on providing services to patients who will potentially utilize the Company products, and accordingly the Company experienced a $4.4 million increase for this period in its service revenues due to new patients being treated in its Sleep and Airway facilities in Las Vegas and Henderson, Nevada.

 

Cost of Sales and Gross Profit

 

Cost of sales increased $1.3 million or 22% to approximately $7.4 million for the nine months ended September 30, 2026, compared to $6.1 million for the nine months ended September 30, 2025. This was primarily related to higher costs associated with diagnostic services and patient therapy, including the addition of staff at the Vivos treatment centers.

 

For the nine months ended September 30, 2026, gross profit increased by approximately $1.8 million to $9.3 million compared to approximately $7.6 million for the nine months ended September 30, 2025. This increase was attributable to the increase in revenue of approximately $3.1 million partially offset by the increase in cost of sales of $1.3 million. Gross margin for the nine months ended September 30, 2026 and 2025 was 56% and 55%, respectively.

 

33

 

 

General and Administrative Expenses

 

General and administrative expenses increased by approximately $3.4 million, or approximately 17%, to approximately $22.5 million for the nine months ended September 30, 2026, as compared to $19.2 million for the nine months ended September 30, 2025. The primary driver of this increase related to the costs associated with establishing the two Sleep and Airway treatment facilities in Las Vegas and Henderson, Nevada, including an increase in salaries and related compensation of approximately $1.7 million; an increase in professional fees of approximately $ 0.9 million; an increase in occupancy expenses of approximately $ 0.6 million and an increase in other costs of approximately $0.3 million.

 

Sales and Marketing

 

Sales and marketing expenses decreased by $0.4 million to $0.6 million for the nine months ended September 30, 2026, compared to $1.0 million for the nine months ended September 30, 2025. This decrease was primarily driven by the Company’s decrease in sales and marketing campaigns, lower commissions paid to the Company’s employees for digital media services and reduction in use of marketing supplies.

 

Depreciation and Amortization

 

Depreciation and amortization expense increased $0.6 million to approximately $1.5 million for the nine months ended September 30, 2026 from $0.9 million for the nine months ended September 30, 2025. Depreciation and amortization increased during the period due to assets being placed into service during the period.

 

Other Income/(Expense)

 

Other (Expense) increased $2.3 million due primarily to interest expense, including interest expense from the short-term financing agreements entered into in the third quarter, offset by an increase in Other Income of $3.2 million, which includes the reversal of the Company’s previously recorded Employee Retention Credit liability of approximately $2.9 million and $0.3 million related to the valuation change in the contingent earnout related to the acquisition of SCN.

 

Liquidity and Capital Resources

 

The financial statements have been prepared in conformity with generally accepted accounting principles, which contemplate continuation of the Company as a going concern. The Company has incurred losses since inception, including $1.9 and $5.4 million for the three months ended September 30, 2026 and 2025, respectively, and $15.1 million and $14.3 million for the nine months ended September 30, 2026 and 2025, respectively, resulting in an accumulated deficit of approximately $140.5 million as of September 30, 2026.

 

Net cash used in operating activities amounted to approximately $12.3 million and $11.5 million for the nine months ended September 30, 2026 and 2025, respectively. As of September 30, 2026, the Company had total liabilities of approximately $20.7 million.

 

On June 5, 2026, the Company entered into an Exchange Agreement with Streeterville Capital, LLC pursuant to which Streeterville agreed to exchange up to approximately $4.5 million of outstanding senior secured debt for a combination of perpetual non-convertible preferred stock and shares of common stock, contingent upon the Company completing certain qualifying equity financings. On June 18, 2026, the parties entered into a letter agreement extending the outside date for completion of the initial qualifying financing of at least $2.6 million from June 15, 2026 to August 31, 2026. In August 2026, the Company completed a qualifying financing in excess of the $2.6 million threshold, triggering the exchange of approximately $3.25 million of senior secured debt for 1,812,031 shares of common stock and 2,500 shares of Series B Non-Convertible Preferred Stock, which was completed on August 4, 2026. On September 2, 2026, the Company exchanged an additional $2,861,270 of principal of the Streeterville note for 11,445,080 shares of common stock at an average exchange price of approximately $0.25 per share. See Note 9 to the accompanying financial statements for additional information.

 

On June 30, 2026, the Company closed a private placement with V-Co Investors 4 LLC and Bigger Capital Fund, LP for aggregate proceeds of approximately $2.1 million through the sale of units consisting of Series A Convertible Preferred Stock and warrants at a purchase price of $0.582 per unit. In connection with the transaction, the Company filed a Certificate of Designation creating the Series A Convertible Preferred Stock and entered into a registration rights agreement. A portion of the proceeds reflected the conversion of previously outstanding bridge financing.

 

34

 

 

During 2026, the Company has taken steps to strengthen its balance sheet and reduce costs, including raising equity capital in each of the first three quarters of 2026, exchanging approximately $6.1 million of senior secured debt for equity, and reducing general and administrative and sales and marketing expenses for the third quarter by a combined $1.6 million compared to the prior-year period. Notwithstanding these actions, the Company continues to face significant liquidity challenges, as described below.

 

As of September 30, 2026, the Company had approximately $0.2 million in cash and cash equivalents, which will not be sufficient to fund operations and strategic objectives over the next twelve months from the date of the issuance of these financial statements. Without additional financing, these factors raise substantial doubt regarding the Company’s ability to continue as a going concern.

 

As of September 30, 2026, the Company had approximately $2.3 million of outstanding principal under its senior secured note with Streeterville Capital, LLC, which is due on June 10, 2027. The Company expects to satisfy this obligation through available cash, additional financing, or other sources of liquidity.

 

The Company has implemented cost savings measures in its legacy business that have reduced cash used in operations. In the latter part of the third quarter of 2026 and through the present date, management has continued to reduce its operating costs and streamline operations. The Company estimates it has eliminated over $5 million in annual operating costs, with further cuts and efficiencies still being worked on. During the first nine months of 2025, many one-time costs related to the acquisition of SCN were recognized and were not recurring in 2026.

 

In addition to the Company’s material cost reduction initiatives, the Company has also embarked on a number of important clinical initiatives aimed at raising the level of services offered to patients at both SCN and SAMC centers. Such clinical programs are expected to yield significant revenue enhancements at high gross margins. These initiatives include, but are not limited to, EEG testing and treatment for insomnia and other non-OSA forms of sleep disorders, the distribution and set up of PAP and CPAP treatments, and Remote Patient Monitoring (RPM) of CPAP users from both existing CPAP populations as well as new CPAP enrollments from new testing being conducted each month. In addition, payer contracts that have not been renegotiated in some time are actively being renegotiated with payers. The Company has retained professional third-party experts to assist and guide the negotiation process. All told, these collective clinical and payer contract initiatives are expected to contribute materially to the Company’s revenue and overall profit margins in the fourth quarter of 2026 and increasingly throughout 2027.

 

As such, the Company has funded its operations through equity raises and debt financings during the nine months ended September 30, 2026 and the fiscal year ended December 31, 2025. The Company was required to obtain additional financing to satisfy its cash needs, including funding the SCN acquisition, and increasing the Company’s stockholders’ equity for Nasdaq compliance purposes as the Company seeks to increase revenue with a view towards ultimately achieving positive cash flow operations in 2027. On October 16, 2026, the Company issued 12,000 shares of Series C Convertible Preferred Stock to acquire interests in SOD. The SOD transaction provided no cash to the Company.

 

Until the Company has attained positive cash flow, the Company’s management is reviewing all options to obtain additional financing to fund the Company’s operations. The Company financed the SCN acquisition from the issuance of senior secured debt and equity securities. The Company expects the SCN acquisition will ultimately allow the Company to achieve positive cash flows; however, there is a risk this may not occur. The Company originally expected the Strategic Alliance Agreement (“SAA”) with Rebis Health entered into in June 2024 to increase patient volume, drive top line revenue and lower customer acquisition costs and overhead. However, due to ongoing delays at Rebis Health that are beyond the Company’s control, the Company is currently re-evaluating and lowering its revenue expectations under the SAA. As such, the Company seeks to acquire other sleep centers in transactions similar to the SCN acquisition or enter into other strategic alliances. There can be no assurances that adequate additional funding will be available on favorable terms, or at all. If such funds are not available in the future, or the SAA or similar alliances or acquisitions do not result in the patient volume, appliance sales and financial results within the timeframes the Company expects, the Company may be required to delay, significantly modify or terminate some or all of the Company’s operations, all of which could have a material adverse effect on the Company and the Company’s stockholders.

 

The Company does not have any off-balance sheet arrangements, as defined by applicable regulations of the SEC, that are reasonably likely to have a current or future material effect on the Company’s financial condition, results of operations, liquidity, capital expenditures or capital resources.

 

Cash Flows

 

The following table presents a summary of the Company’s cash flow for the nine months ended September 30, 2026 and 2025 (in thousands):

 

   2026   2025 
         
Net cash (used in) provided by:          
Operating activities  $(12,334)  $(11,451)
Investing activities   (495)   (5,945)
Financing activities   11,047    14,223 

 

35

 

 

Net cash used in operating activities increased by approximately $0.9 million to $12.3 million for the nine months ended September 30, 2026, compared to $11.5 million for the same period in 2025. The increase was primarily attributable to a higher net loss, partially offset by changes in operating assets and liabilities, including increases in accounts payable and accrued expenses and a decrease in the employee retention credit liability.

 

For the nine months ended September 30, 2026, net cash used in investing activities consisted of approximately $0.5 million related to the acquisition of property, plant and equipment. This compares to net cash used in investing activities for the nine months ended September 30, 2025 of approximately $5.1 million for payment of a business acquisition and capital expenditures of approximately $0.8 million related to internally developed software.

 

Net cash provided by financing activities of $11.0 million for the nine months ended September 30, 2026, is attributable to proceeds of approximately $6.2 million from the issuance of common stock, proceeds of approximately $4.2 million from the exercise of warrants, proceeds of approximately $2.2 million from the issuance of debt, proceeds of approximately $3.6 million for the issuance of preferred stock and proceeds of approximately $1.6 million from the issuance of warrants, offset by $6.7 million of debt payments.

 

Critical Accounting Policies Involving Management Estimates and Assumptions

 

The Company’s critical accounting policies and estimates are described in “Management’s Discussion and Analysis of Financial Condition and Results of Operations—Critical Accounting Policies and Estimates” in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025. The Company has reviewed and determined that those critical accounting policies and estimates remain the Company’s critical accounting policies and estimates as of and for the three and nine months ended September 30, 2026.

 

Recent Accounting Pronouncements

 

From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board or other standard setting bodies that are adopted by the Company as of the specified effective date. Unless otherwise discussed in Note 1 to the accompanying condensed consolidated financial statements included in this Report, the Company believes that the impact of recently issued standards that are not yet effective is not expected to have a material impact on the Company’s financial position or results of operations upon adoption. For additional information on recently issued accounting standards and the Company’s plans for adoption of those standards, please refer to the section titled Recent Accounting Pronouncements under Note 1 to the accompanying condensed consolidated financial statements included in this Report.

 

Item 3. Quantitative and Qualitative Disclosures About Market Risk

 

Not applicable to smaller reporting companies.

 

Item 4. Controls and Procedures.

 

Evaluation of Disclosure Controls and Procedures

 

The Company’s disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e)) are designed to ensure that information required to be disclosed by the Company in reports the Company files or submits under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the appropriate time periods, and that such information is accumulated and communicated to the Company’s Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely discussions regarding required disclosure. The Company, under the supervision of and with the participation of the Company’s management, including the Company’s Chief Executive Officer and Chief Financial Officer, have evaluated the effectiveness of the Company’s disclosure controls and procedures. Based on that evaluation, the Company’s Chief Executive Officer and Chief Financial Officer concluded that the design and operation of the Company’s disclosure controls and procedures were effective, at the reasonable assurance level, as of the end of the period covered by this Report.

 

Changes in Internal Control over Financial Reporting

 

During the quarter ended September 30, 2026, the Company’s former Chief Financial Officer resigned. In connection with this departure, the Company engaged The CFO Portal, LLC to provide outsourced CFO services, with Roman Franklin serving as the Company’s Chief Financial Officer and principal financial officer. Management evaluated the impact of these changes on the Company’s internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) and determined that these changes did not materially affect, and are not reasonably likely to materially affect, the Company’s internal control over financial reporting.

 

36

 

 

PART II – OTHER INFORMATION

 

Item 1. Legal Proceedings.

 

From time to time, the Company may become involved in various lawsuits and legal proceedings which arise in the ordinary course of business. Below is a description of the Company’s outstanding pending litigation matters. Litigation is subject to inherent uncertainties and an adverse result in the below described or other matters may arise from time to time that may harm the Company’s business.

 

Item 1A. Risk Factors

 

The Company is voluntarily providing in this Item 1A. updated risk factors associated with SCN, the Acquisition, the Company’s October 2026 transaction with SOD Sciences, Inc. and the Series C Convertible Preferred Stock issued in it, the accounting for that transaction, the listing of the Company’s common stock on Nasdaq and the Company’s debt and related matters.

 

The Company may not realize the anticipated benefits of its October 2026 transaction with SOD Sciences, Inc., and the value of what the Company acquired could decline or be impaired.

 

On October 16, 2026, the Company acquired 3,057,879 shares of common stock of SOD Sciences, Inc., a privately held Nevada corporation (“SOD”), and an undivided 50% co-ownership interest in SOD’s pseudohypoxia early-warning test and related intellectual property (the “Test IP”), in exchange for 12,000 shares of the Company’s Series C Convertible Preferred Stock (the “SOD Transaction”). The SOD shares represent at least 11% of SOD’s fully diluted capital stock, so the Company is a minority stockholder and does not control SOD. There is no public market for the SOD shares, and the Company may not be able to sell them at a price it considers acceptable, or at all. The value of the SOD shares depends on SOD’s results of operations and financial condition, which the Company does not control.

 

The Company owns the Test IP jointly with SOD as a tenant in common. Under the Assignment and Co-Ownership Agreement, the Company and SOD share equally all revenue from the test and the costs of patent prosecution, maintenance and enforcement, and each party has consent rights over licenses and settlements. As a result, the Company may be unable to license, enforce or commercialize the Test IP without SOD’s agreement, and the Company will bear half of the costs of patent prosecution, maintenance and enforcement.

 

The Company’s ability to benefit from the SOD Transaction depends on commercial arrangements that have not been finalized. Following the closing, the Company and SOD are to negotiate a joint marketing agreement, under which SOD would market the Company’s sleep testing and oral appliance products through SOD’s relationships with American Health Associates (“AHA”) and Cleveland Clinic Weston, and a separate agreement for marketing SOD’s ReBalU Protocol to sleep testing centers. As of October 19, 2026, none of these agreements, including the definitive agreements SOD is to seek with AHA and Cleveland Clinic Weston, had been signed. Any arrangement with AHA is also subject to approval by the bankruptcy court in AHA’s pending bankruptcy proceeding. Even if the agreements are signed, they may be on terms less favorable than the Company expects, and the AHA and Cleveland Clinic Weston channels may not produce meaningful revenue.

 

The pseudohypoxia test is also unproven. It may not achieve clinical validation, regulatory clearance or market acceptance, and the Company’s existing FDA clearances for its oral appliances do not cover the test. Any revenue or contribution margin from the test will depend on clinical validation, regulatory status, testing volume, pricing and the costs allocated under definitive agreements, and may be lower than the Company expects or may never materialize.

 

Most of SOD’s representations and warranties to the Company survive for only twelve months after the closing, which may limit the Company’s remedies if problems with SOD or the Test IP are discovered later. If the SOD Transaction does not produce the benefits the Company expects, the Company may be required to record a non-cash impairment charge on the SOD shares or the Test IP, which would reduce the Company’s results of operations and stockholders’ equity. The Company also issued Series C Convertible Preferred Stock, which is convertible into a substantial number of shares of common stock, to complete the transaction. See the next risk factor.

 

37

 

 

The conversion of the Series C Convertible Preferred Stock issued in the SOD Transaction could result in substantial dilution to the Company’s existing stockholders, and sales of the shares issued on conversion could reduce the market price of the common stock.

 

The 12,000 shares of Series C Convertible Preferred Stock issued to SOD (the “Series C Preferred”) have a stated value of $1,000 per share, or $12.0 million in total, and are convertible at SOD’s option into common stock at a fixed conversion price of $0.15 per share. At that price, the Series C Preferred is convertible into up to 80,000,000 shares of common stock, compared with 33,820,768 shares of common stock outstanding at September 30, 2026, and the Company has issued additional shares since then. Based on the $0.098 closing price of the common stock on November 13, 2026, 80,000,000 shares would have a market value of approximately $7.8 million, compared with the $12.0 million stated value of the Series C Preferred. The conversion price does not reset if the market price of the common stock falls. Issuing those shares would substantially reduce the percentage ownership and voting power of the Company’s existing stockholders.

 

Until the Company’s stockholders approve the issuance of shares above the exchange cap for purposes of Nasdaq Listing Rule 5635(a), no more than 6,718,517 shares of common stock, which is 19.99% of the shares outstanding before the SOD agreement was signed, may be issued on conversion, and neither the Company nor SOD can waive that cap. The Company has asked its stockholders to approve the issuance of the remaining shares at its annual meeting on December 2, 2026, but there is no assurance that stockholders will approve the proposal. If they do, up to 80,000,000 shares could be issued on conversion, which is approximately 238% of the 33,820,768 shares outstanding on the October 9, 2026 record date. If they do not, the balance of the Series C Preferred will remain outstanding as preferred stock that ranks equally with the Company’s Series A and Series B preferred stock and ahead of the common stock on liquidation.

 

SOD may not convert to the extent that it and its affiliates would then beneficially own more than 4.99% of the outstanding common stock (a limit that SOD may increase to 9.99% on 61 days’ notice), but SOD could convert and sell shares in stages over time. The Series C Preferred also participates in any dividends declared on the common stock on an as-converted basis and votes with the common stock on an as-converted basis, subject to the limits described above. Sales of a substantial number of shares of common stock issued on conversion, or the perception that those sales could occur, could reduce the market price of the common stock. If the Company effects the reverse stock split described below, the conversion price and the share amounts in the exchange cap will be adjusted proportionally, so that the percentage of the Company’s outstanding common stock issuable on conversion is not changed by the reverse stock split.

 

The accounting for the SOD Transaction has not been completed, and the final accounting could differ from the Company’s expectations in a way that affects its stockholders’ equity and its compliance with Nasdaq’s stockholders’ equity requirement.

 

The Company is still evaluating the accounting for the SOD Transaction, including the fair value of the SOD shares and the Test IP and the classification and measurement of the Series C Preferred. The transaction closed after September 30, 2026 and is not reflected in the Company’s condensed consolidated financial statements as of that date, when the Company’s total stockholders’ equity was approximately $2.4 million ($2.2 million including non-controlling interest), which is below the $2.5 million Nasdaq requirement. In its Current Report on Form 8-K filed on October 19, 2026, the Company stated that it expected the transaction to increase its stockholders’ equity by more than $10 million, based on its initial purchase price allocation, which remains subject to adjustment for twelve months after the closing, to completion of the allocation and to review by the Company’s independent registered public accounting firm. In that report, the Company also stated that its unaudited pro forma stockholders’ equity as of June 30, 2026, giving effect to the closing, was approximately $6.6 million. The final accounting could result in a lower value for the assets the Company acquired, or in classifying the Series C Preferred other than as permanent stockholders’ equity, either of which would reduce or eliminate the expected increase. On September 29, 2026, the Company engaged Haynie and Company as its independent registered public accounting firm, replacing Baker Tilly US, LLP. Haynie and Company has not previously audited the Company’s financial statements, and its review of the Company’s financial statements, including the accounting for the SOD Transaction, could lead to changes from the Company’s expectations.

 

Nasdaq Listing Rule 5550(b)(1) requires the Company to maintain stockholders’ equity of at least $2.5 million (the “Minimum Stockholders’ Equity Requirement”). The Company’s total stockholders’ equity at September 30, 2026 was approximately $2.4 million ($2.2 million including non-controlling interest), which is below $2.5 million. On October 20, 2026, based on the Company’s Current Report on Form 8-K filed October 19, 2026, Nasdaq notified the Company that it had regained compliance with the Minimum Stockholders’ Equity Requirement, subject to Nasdaq’s continued monitoring, and that if the Company fails to evidence compliance upon the filing of its next periodic report, it may be subject to delisting. The Company’s continued compliance depends on the SOD Transaction and its accounting. If Nasdaq or the Company’s independent registered public accounting firm reaches conclusions about the accounting for the SOD Transaction that differ from the Company’s expectations, or if the Company’s stockholders’ equity later falls below $2.5 million, Nasdaq could issue a delisting determination. See the next risk factor regarding the listing of the Company’s common stock on Nasdaq.

 

38

 

 

The Company’s common stock may be delisted from The Nasdaq Capital Market, including on short notice if its closing bid price remains at or below $0.10 per share for ten consecutive business days, which would reduce the liquidity and market price of the common stock and make it harder for the Company to raise capital.

 

The Company’s common stock is listed on The Nasdaq Capital Market. Nasdaq Listing Rule 5550(a)(2) requires a minimum closing bid price of $1.00 per share (the “Minimum Bid Requirement”). On June 5, 2026, Nasdaq notified the Company that, based on the closing bid price of the common stock from April 23, 2026 through June 4, 2026, the Company was no longer in compliance with the Minimum Bid Requirement. The Company has a compliance period of 180 calendar days, through December 2, 2026, to regain compliance, and as of the date of this Report it has not regained compliance. Regaining compliance requires a closing bid price of at least $1.00 for a minimum of ten consecutive business days (and Nasdaq may require a longer period). If the Company does not regain compliance by December 2, 2026, it may be eligible for a second 180-day compliance period if it meets the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, other than the minimum bid price requirement, and notifies Nasdaq of its intent to cure the deficiency. Some of those initial listing standards are more demanding than the continued listing standards that apply to the Company today. There can be no assurance that the Company will regain compliance or that Nasdaq will grant a second compliance period.

 

In addition, Nasdaq Listing Rule 5810(c)(3)(A)(iii) provides that a failure to meet the Minimum Bid Requirement exists if a company’s security has a closing bid price of $0.10 or less for ten consecutive business days. When that occurs, Nasdaq’s Listing Qualifications Department must issue a Staff Delisting Determination, the security is suspended from trading on Nasdaq, and the company is not eligible for any compliance period, including the compliance period the Company currently has through December 2, 2026. Under Nasdaq Listing Rule 5815(a)(1)(B)(ii)e., a timely request for a hearing before a Nasdaq Hearings Panel does not stay that suspension, so the common stock would generally be expected to trade in the over-the-counter market while the Hearings Panel considers the matter. The Hearings Panel may, but is not required to, allow up to 180 days from the date of the Staff Delisting Determination for the Company to regain compliance.

 

The closing sale price of the common stock on Nasdaq was below $0.10 per share on each of the six trading days from November 6, 2026 through November 13, 2026, and was $0.098 on November 13, 2026. Nasdaq applies this rule using the closing bid price, which can differ from the closing sale price. If the closing bid price remains at or below $0.10 for ten consecutive business days, Nasdaq will issue a Staff Delisting Determination and suspend trading in the common stock, which could occur before the Company’s annual meeting on December 2, 2026 and before the Company could effect a reverse stock split. If the closing bid price was also at or below $0.10 on each of those days, the tenth consecutive business day would be November 19, 2026. The Company cannot predict whether the price of the common stock will rise above $0.10 or whether it will remain above that level.

 

The Company has asked its stockholders to approve, at the December 2, 2026 annual meeting, an amendment to its certificate of incorporation to permit a reverse stock split of the common stock at a ratio in the range of 1-for-20 to 1-for-40, with the ratio and timing to be set by the Board of Directors, which may abandon the amendment. Stockholders may not approve the proposal, and the Board may not complete a reverse stock split in time to prevent a delisting determination. Even if a reverse stock split is completed, the market price of the common stock may not rise in proportion to the split ratio, may not stay at or above $1.00 for the ten consecutive business days Nasdaq requires, and may decline afterward. A reverse stock split would also reduce the number of shares outstanding (a 1-for-40 split would leave approximately 840,235 shares outstanding, based on the shares outstanding on the October 9, 2026 record date), and under Nasdaq Listing Rule 5810(c)(3)(A) a company is not considered to have regained compliance with the Minimum Bid Requirement if the action it takes to do so causes its security to fall below the numeric threshold for another listing requirement, such as the minimum number of publicly held shares or public holders.

 

Nasdaq’s rules also limit the time available after a reverse stock split. Under Nasdaq Listing Rule 5810(c)(3)(A)(iv), if a company’s security fails to meet the minimum bid price requirement and the company has effected a reverse stock split over the prior one-year period, or one or more reverse stock splits over the prior two-year period with a cumulative ratio of 250 shares or more to one, the company is not eligible for any compliance period and Nasdaq must issue a Staff Delisting Determination. The Company’s most recent reverse stock split was a 1-for-25 split effective October 25, 2023. If the Company effects a reverse stock split and its common stock again falls below $1.00 within the following year, Nasdaq would not provide a compliance period and would issue a Staff Delisting Determination, although the Company could request review by a Hearings Panel. Additional reverse stock splits within a two-year period could also cause the cumulative ratio to reach 250-to-1 or more, which would have the same result.

 

The Company must also meet Nasdaq’s other continued listing requirements, including the Minimum Stockholders’ Equity Requirement discussed in the preceding risk factor. In addition, Nasdaq has adopted a new continued listing requirement that a company’s market value of listed securities be at least $5 million (Nasdaq Listing Rule 5550(a)(6)). The approval of that rule by the Securities and Exchange Commission’s staff on July 22, 2026 has been stayed pending Commission review (on September 11, 2026, the Commission granted petitions for review and continued the stay), and Nasdaq has stated that the rule will become operative only when the stay is terminated. If the rule takes effect, a company whose market value of listed securities stays below $5 million for 30 consecutive business days will receive a Staff Delisting Determination, and a hearing request will not stay the suspension of its securities from trading. Based on the closing sale price on November 13, 2026 and the 33,820,768 shares outstanding at September 30, 2026, the market value of the Company’s common stock was approximately $3.3 million (the Company has issued additional shares since September 30, 2026).

 

39

 

 

If the common stock is delisted from Nasdaq, it would likely trade on the over-the-counter market, where it would likely be less liquid and more volatile. Delisting would likely reduce the market price of the common stock, make it more difficult for stockholders to buy or sell shares, reduce the Company’s ability to raise capital, limit analyst and institutional investor interest in the common stock, and harm the Company’s reputation. The common stock could also become subject to the SEC’s “penny stock” rules, which require broker-dealers to follow additional disclosure and sales practices before selling the common stock and could further reduce trading in it. Under the Note Purchase Agreement with Streeterville (Section 4), the Company must keep its common stock listed or quoted on Nasdaq, the NYSE or NYSE American, must not allow trading in the common stock to be suspended for more than three full trading days, and must file its SEC reports on time. Under Section 5.1(g) of the Note, a failure to meet these covenants is an Event of Default with no cure period. Streeterville could then accelerate the Note and charge default interest of 22% per year. There can be no assurance that the Company will regain or maintain compliance with Nasdaq’s listing requirements.

 

In 2025 and 2026, the Company worked to pivot its sales, marketing distribution model, including via the acquisition of the Sleep Center of Nevada (the “Acquisition”). However, this new model is unproven and may not produce the benefits the Company anticipates. This makes it difficult to evaluate the Company’s future prospects and may increase the risk of your investment.

 

In June 2025, the Company acquired all assets, including operating assets such as sleep testing, diagnostics, and treatment centers, of SCN. The Acquisition marked the completion in a pivot to the Company’s sales, marketing and distribution model for the Company’s innovative OSA appliances. Under the new model, SCN will provide sleep disorder patients with the opportunity to be candidates for the Company’s advanced, proprietary and FDA-cleared CARE oral medical devices, oral appliances and additional adjunctive therapies and methods. Under customary agreements designed to comply with applicable corporate practice of medicine law, the Company’s operation of SCN allows the Company to manage and capture both diagnostic and consulting revenues, representing new higher margin revenue streams for the Company, as well as potential Vivos appliance sales revenue from SCN. The Company is exploring and seeking to implement additional acquisitions of, or collaborations with, medical sleep and similar healthcare practices to expand the Company’s business model in an effort to grow the Company’s revenues.

 

The Company is placing significant emphasis on establishing and growing this new model as means of increasing the Company’s revenue. However, this new model is unproven, and the Company has limited operating history associated with this new model. The Company’s prior collaboration with Rebis Health in Colorado entered into in 2024 has not met the Company’s expectations and differed materially from the SCN acquisition in that the Company did not have adequate control over patient processing, systems and protocols, dentist hiring and management, staff hiring and management, patient education, hours of operation, or medical provider training and education. As a result, the Rebis Health collaboration has not benefited the Company as the Company had anticipated. There is therefore a lack of information for you to evaluate the Company’s future prospects utilizing this new model. Moreover, there is a material risk that this new model will not increase the Company’s revenues or gross margins in the manner the Company anticipates. In addition, the Company may be unable to find additional sleep medical providers to incorporate into the Company’s business, and even if the Company does, there is a risk the Company may not derive the benefits from additional acquisitions that the Company intends to. The Company’s inability to implement and scale this marketing and distribution model would materially harm the Company’s business and operating results and likely cause the Company’s stock price to suffer.

 

Additionally, if the benefits of the Acquisition or similar acquisitions or collaborations the Company may undertake do not meet the expectations of its shareholders, the market price of the Company’s securities may decline. Fluctuations, including declines, in the price of the Company’s common stock could contribute to the loss of all or part of your investment. Certain factors, including, but not limited to, the factors listed below could have a material adverse effect on the price of the Company’s common stock:

 

  ● actual or anticipated fluctuations in financial results post-Acquisition or following the execution of similar transactions;
     
  ● changes in the market’s expectations about the Company’s operating results post-Acquisition or following the execution of similar transactions;
     
  ● announcements of technological innovation, or new products, by the Company’s competition; and
     
  ● the success of the Company’s competitors.

 

40

 

 

As such, no assurances can be given that the Acquisition or similar transactions will benefit the Company’s operating results or stock price.

 

The Company has incurred substantial indebtedness in connection with financing the SCN acquisition, and the cost of servicing that debt could adversely affect the Company’s business, financial condition, and results of operation, and the Company may not be able to service that debt in the future.

 

Concurrently with the SCN Acquisition, the Company entered into a Note Purchase Agreement with Streeterville Capital, LLC, a Utah limited liability company (“Streeterville” or “Lender”), pursuant to which the Company issued and sold to Lender a Secured Promissory Note in the original principal amount of $8,225,000 (the “Note”). The Note is secured by the Company’s wholly-owned subsidiary AIM, which manages SCN in accordance with the corporate practice of medicine. The Company has also pledged the entirety of AIM’s membership interests to the Lender as collateral for the Note and caused AIM to provide a guarantee of the Company’s obligations to the Lender under the Note and the other transaction documents.

 

In June 2026, the Company entered into an Exchange Agreement with Streeterville under which Streeterville agreed to exchange a portion of the outstanding indebtedness under the Note for shares of the Company’s preferred stock and common stock, contingent on the Company’s completion of a qualifying financing of at least $2.6 million. In August 2026, the financing condition was satisfied. On August 4, 2026, Streeterville exchanged $3,250,000 of principal of the Note for 1,812,031 shares of common stock and 2,500 shares of Series B Non-Convertible Preferred Stock, and on September 2, 2026 it exchanged a further $2,861,270 of principal for up to 11,445,080 shares of common stock. In connection with the Exchange Agreement, the Note was amended on June 5, 2026 (as modified by a letter agreement dated June 18, 2026) to extend the maturity date to June 10, 2027, suspend Streeterville’s monthly redemption requests until September 15, 2026, and reduce the maximum monthly redemption amount from $550,000 to $225,000. Interest on the Note accrues at 9% per year, and a monitoring fee of about 17.6% of the outstanding balance has been added to the balance since October 7, 2025. See Note 9 to the accompanying financial statements for additional information. Notwithstanding the exchange, a portion of the original Note remains outstanding and continues to be secured by the collateral and guarantees described above. As of September 2, 2026, the outstanding principal balance of the Note was approximately $3.7 million, as reported in the Company’s Current Report on Form 8-K/A filed September 8, 2026. The principal balance at September 30, 2026 is $2.3 million. In addition, Series B Non-Convertible Preferred Stock issued in the exchange carries preferential rights (including with respect to dividends, liquidation, and other terms) that rank senior to the Company’s common stock, resulted in dilution to existing common stockholders, and makes the Company subject to certain affirmative and negative covenants in favor of Streeterville, including a requirement that the Company obtains Streeterville’s consent for future debt and equity financings over $2.5 million in the aggregate, which may restrict the Company’s ability to access capital or require the Company to access capital on terms that are not as favorable as would otherwise have been available. The Note Purchase Agreement also requires the Company to keep its common stock listed on a national securities exchange, and a failure to do so is an Event of Default with no cure period. See the risk factor below regarding the listing of the Company’s common stock on Nasdaq.

 

The Company’s ability to make scheduled payments under the Note or any alternative debt financing arrangements the Company may enter into in connection with its growth strategy to acquire additional medical sleep practices will depend on the Company’s financial and operating performance, which will be affected by economic, financial, competitive, business, and other factors, some or all of which are beyond the Company’s control. The indebtedness the Company incurred in connection with the Acquisition will require the Company to dedicate a portion of the Company’s cash flow to servicing this debt, thereby reducing the availability of cash to fund other business initiatives. There can be no assurance that the Company’s business, inclusive of SCN, will generate sufficient cash flow from operations to service the Company’s indebtedness or to fund the Company’s other liquidity needs. If the Company is unable to meet its debt obligations or fund its other liquidity needs, the Company may need to restructure or refinance all or a portion of its indebtedness on or before maturity, which is June 10, 2027, or sell certain of the Company’s assets. As described in Note 2 to the accompanying condensed consolidated financial statements, there is substantial doubt about the Company’s ability to continue as a going concern. There can be no assurance that the Company will be able to restructure or refinance any of its indebtedness on commercially reasonable terms, if at all, which could cause the Company to default on the Company’s debt obligations and impair the Company’s liquidity. Any refinancing of the Company’s indebtedness could be at higher interest rates and may require the Company to comply with more onerous covenants, which could further restrict the Company’s business operations. If the Company is unable to generate or borrow sufficient cash to make payments on the Company’s indebtedness, the Company’s business, financial condition, and results of operations could be adversely affected.

 

Integrating SCN’s operations may be more difficult, costly, or time-consuming than expected.

 

The ongoing integration of Vivos and SCN could result in the disruption of the Company’s ongoing business, and inconsistencies in standards, controls, procedures and policies that adversely affect the Company’s ability to maintain relationships with patients and employees or achieve the anticipated benefits of the Acquisition. As with any acquisition, there also may be disruptions that cause the Company to lose patients or cause patients to elect alternative form of sleep treatment. The Company may also face other unintended consequences from the Acquisition (including adverse effects on the Company’s business reputation, supply chain issues, and similar matters) that could have a material adverse effect on the Company’s results of operations, financial condition and stock price.

 

41

 

 

If the Company’s contractual arrangements between AIM and the Company’s physicians at SCN are found to constitute the improper rendering of medical services or fee splitting under applicable state laws, the Company’s business, financial condition and the Company’s ability to operate in those states could be adversely impacted.

 

The Company’s contractual relationships between AIM and the Company’s physicians at SCN (and similar arrangements the Company may enter into in the future in connection with other sleep provider acquisitions) may implicate certain state laws that generally prohibit non-professional entities from providing licensed medical services or exercising control over medical practitioners or other healthcare professionals (such activities generally referred to as the “corporate practice of medicine”, and laws, rules and regulations relating to the corporate practice of medicine, the “CPM Laws”) or engaging in certain practices such as fee-splitting with such licensed professionals. The interpretation and enforcement of CPM Laws vary significantly from state to state. There can be no assurance that CPM Laws will be interpreted in a manner consistent with the Company’s practices or that other laws or regulations will not be enacted in the future that could have a material and adverse effect on the Company’s business, financial condition and results of operations. Regulatory authorities, state boards of medicine, state attorneys general and other parties may assert that, despite the agreements through which the Company operates, the Company is engaged in the provision of medical services and/or that its arrangements with the Company’s medical practitioners constitute unlawful fee-splitting. If a jurisdiction’s prohibition on the corporate practice of medicine or fee-splitting is interpreted in a manner that is inconsistent with the Company’s practices, the Company would be required to restructure or terminate its arrangements with the Company’s medical practitioner at SCN to bring the Company’s activities into compliance with such CPM Laws. A determination of non-compliance, or the termination of or failure to successfully restructure these relationships could result in disciplinary action, penalties, damages, fines, and/or a loss of revenue, any of which could have a material and adverse effect on the Company’s business, financial condition and results of operations. State corporate practice and fee-splitting prohibitions also often impose penalties on the Company’s medical practitioners for aiding in the improper rendering of professional services, which could discourage medical practitioners and other healthcare professionals from providing clinical services at SCN or other sleep centers the Company may operate in the future.

 

As a result of the Company’s business model pivot which includes the acquisition of sleep centers like SCN, the Company may become a party to lawsuits, demands, claims, qui tam suits, governmental investigations and audits and other legal matters, any of which could result in, among other things, substantial financial and other penalties, damage to the Company’s reputation or adverse effects on the Company’s ability to conduct business.

 

As a result of the Company’s 2025 business model pivot, which includes acquisitions of sleep medical providers like SCN as a means of driving sales of the Company’s OSA treatments, the Company’s business has (subject to compliance with CPM laws as described above) become more associated with diagnosing and treating OSA patients. Given the nature of this business, the Company may in the future be subject to investigations and audits by governmental agencies, private civil qui tam complaints and other lawsuits, demands, claims, legal proceedings and/or other actions alleging the Company’s, or the medical practices the Company manages, failure to comply with applicable rules, regulations, laws or the practice of medicine.

 

For example, the Company and sleep medical providers the Company manages (like SCN) could become subject to audits from the government concerning the billing of patients. If, following the conclusion of any audit, the government were to require refunds and/or modifications to the Company’s business practices, and such amounts or changes are significant, it could have a material adverse effect on the Company’s business, results of operations, financial condition and cash flows. In addition, any allegation against the Company, the Company’s medical providers the Company manages or related personnel, representatives, third party vendors, or operations in such matters or matters that involve patients suffering adverse health outcomes, may, among other things harm the Company’s reputation, stock price, and adversely affect the Company’s relationships and/or contracts related to the Company’s business, among other things.

 

Responding to subpoenas, investigations and other lawsuits, claims and legal proceedings, as well as defending itself in such matters, would require management’s attention and cause the Company to incur significant legal expense. Negative developments, findings or terms and conditions that the Company might agree to accept as part of a negotiated resolution of pending or future legal or regulatory matters, or have been forced upon the Company, could result in, among other things, harm to the Company’s or the Company’s medical providers’ reputation, substantial financial penalties or awards against the Company, substantial payments made by the Company, required changes to the Company’s business practices, impacts on the Company’s various relationships and/or contracts related to the Company’s business, exclusion from future participation in Medicare, Medicaid and other healthcare programs and, in certain cases, criminal penalties, any of which could have a material adverse effect on the Company.

 

42

 

 

Changes in the structure of and payment rates under private insurance, Medicare, Medicaid or other non-Medicare government-based programs or payment rates related to the Company’s business could have a material adverse effect on the Company’s business, results of operations, financial condition and cash flows.

 

Sleep center providers like SCN or other medical sleep providers the Company may acquire and manage or do business with rely on various forms of insurance held by patients for payment for products and services. These include private insurance, Medicare, Medicaid and other government programs. As such, the business of the medical sleep providers the Company manages and its business and results of operations could be adversely impacted by matters related to insurance coverage including, without limitation:

 

  ● The risk that reimbursement rates are reduced by private insurance carriers or government insurance providers;

 

  ● The risk that changes in insurance policies or regulatory mandates could limit the ability to either be paid for covered services or bill for treatments or services or otherwise impact reimbursement;

 

  ● The risk that interpretations of existing regulations, manual provisions and/or guidance, or the implementation or enforcement of new interpretations, will be inconsistent with how the Company and the medical sleep providers the Company manages have interpreted regulations, manual provisions and/or guidance;

 

  ● The risk that data and related reporting requirements are implemented that result in decreased reimbursement, increased technology and operational costs, or reputational harm;

 

  ● The risk that increases in the Company’s operating costs will outpace any Medicare or other rate increases the Company receives;

 

  ● The risk of federal budget sequestration cuts or other disruptions in federal government operations and funding; and

 

  ● The risk of ensuring that the sleep medical providers the Company manages remain compliant with applicable requirements, including marketing and education requirements and restrictions, as well as contractual terms with associated insurance plans.

 

If the Company is faced with these or similar risks, the Company could face material adverse consequences on its business, results of operations, financial condition and cash flows.

 

The Company’s business and the medical practices the Company manages are labor intensive. The Company’s inability to recruit qualified talent and manage labor costs or shortages could result in significant increases in the Company’s operating costs, decreases in productivity, and disruptions in the Company’s business operations.

 

The Company’s business and the business of the medical practices the Company manages is labor intensive. This is particularly true with respect to the Sleep Optimization (SO) teams the Company is putting in place at SCN, each consisting of one nurse practitioner (or physician’s assistant), two specially trained dentists, six dental assistants, six administrative support personnel, and one treatment navigator. Labor requirements also exist, albeit to a lesser extent, for contractual alliances with medical sleep providers the Company may enter into. The Company faces increased labor costs and the risk of difficulties in hiring skilled clinical personnel. The healthcare labor market for the talent the Company requires is challenging and experiences volatility, uncertainty and labor supply shortages. The Company may be unable to achieve the financial results the Company desires from the SCN acquisition, the acquisition of other medical sleep providers or the Company’s contractual alliances due to variations in labor-related costs and the productivity of the Company’s personnel.

 

43

 

 

The Company has incurred and, as the Company seeks to scale its business, expects to continue to incur increased labor costs, including through elevated compensation levels to the Company’s personnel, the ultimate extent of which will depend on the needs at SCN or other medical sleep providers the Company acquires as well as macroeconomic conditions and ancillary impacts on the labor market, among other things.

 

The Company competes for qualified talent with hospitals and other healthcare providers. Furthermore, changes in certification requirements could adversely impact the Company’s ability to maintain sufficient staff levels, including to the extent the Company’s personnel are not able to meet new requirements. In addition, if the Company experiences a higher than normal turnover rate for its skilled clinical personnel, the Company’s operations and ability to meet patient demand may be negatively impacted, which could adversely affect the Company’s business, results of operations, financial condition and cash flows.

 

Also, political or other efforts at the national or local level could result in actions or proposals that increase the likelihood of success of union organizing activities at the facilities the Company manages. If a significant portion of the Company’s personnel were to become unionized, the Company could experience, among other things, potential additional work stoppages or other business disruptions; adverse impacts to the Company’s financial results due to the costs of bargaining or implementing a grievance procedure and processing grievances, decreases in the Company’s operational flexibility and efficiency, or negative impacts on the Company’s employee culture. Any of these events or circumstances, including the Company’s responses to such events or circumstances, could have a material adverse effect on the Company’s employee relations, treatment growth, productivity, business, results of operations, financial condition, cash flows and reputation.

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

 

None, except as otherwise included in a Current Report on Form 8-K filed with the SEC. In addition, during the three months ended September 30, 2026, the Company issued 312,500 shares of common stock to consultants as compensation for services without registration under the Securities Act of 1933 in reliance on the exemption under Section 4(a)(2) thereof.

 

On August 4, 2026, the Company issued 1,812,031 shares of common stock and 2,500 shares of Series B Non-Convertible Preferred Stock to Streeterville Capital, LLC in exchange for $3,250,000 of principal of the Company’s secured promissory note held by Streeterville Capital, LLC under the Exchange Agreement dated June 5, 2026. On September 2, 2026, under twelve exchange agreements dated as of August 31, 2026, the Company issued an aggregate of 11,445,080 shares of common stock to Streeterville Capital, LLC in exchange for a further $2,861,270 of principal of that note, which was partitioned into twelve separate notes that Streeterville Capital, LLC surrendered for cancellation when the related shares became freely tradable. The Company received no proceeds from these exchanges. These securities were issued without registration under the Securities Act of 1933 in reliance on the exemption provided by Section 3(a)(9) thereof.

 

Item 3. Defaults Upon Senior Securities

 

None.

 

Item 4. Mine Safety Disclosures

 

Not applicable.

 

Item 5. Other Information

 

None.

 

Item 6. Exhibits, Financial Statement Schedules.

 

The following documents are filed , furnished or incorporated by reference as exhibits to this Quarterly Report on Form 10-Q.

 

Exhibit No.   Exhibit Description
     
3.1   Certificate of Incorporation of Vivos Therapeutics, Inc. filed with Delaware Secretary of State on August 12, 2020. (1)
     
3.2   Amended and Restated Bylaws of Vivos Therapeutics, Inc. (1)
     
3.3   Certificate of Conversion filed with Delaware Secretary of State on August 12, 2020. (1)
     
3.4   Certificate of Amendment to the Certificate of Incorporation of Vivos Therapeutics, Inc., dated October 25, 2023. (2)
     
3.5   Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Preferred Stock, filed with the Secretary of State of the State of Delaware on July 7, 2026. (3)
     
3.6   Certificate of Designations of Series C Convertible Preferred Stock of Vivos Therapeutics, Inc., filed with the Secretary of State of the State of Delaware on October 15, 2026. (10)
     
3.7   Form of Certificate of Designation of Preferences and Rights of Series B Non-Convertible Preferred Stock (filed as Exhibit A to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the SEC on June 8, 2026). (4)

 

44

 

 

4.1   Form of Common Stock Purchase Warrant, dated June 30, 2026, issued in connection with the Securities Purchase Agreement dated June 30, 2026. (3)
     
4.2   Registration Rights Agreement, dated June 30, 2026, by and among the Company, V-Co Investors 4 LLC and Bigger Capital Fund, LP. (3)
     
10.1   Exchange Agreement, dated June 5, 2026, by and between the Company and Streeterville Capital, LLC. (4)
     
10.2   Letter Agreement, dated June 18, 2026, by and between the Company and Streeterville Capital, LLC, amending the Exchange Agreement dated June 5, 2026. (5)
     
10.3   Securities Purchase Agreement, dated June 30, 2026, by and among the Company, V-Co Investors 4 LLC and Bigger Capital Fund, LP. (3)
     
10.4#   Master Services Agreement, dated July 31, 2026, by and between the Company and The CFO Portal, LLC. (6)
     
10.5#   Separation, Resignation and Executive Transition Agreement, dated July 31, 2026, by and between the Company and Bradford Amman. (6)
     
10.6   Form of Exchange Agreement, effective as of August 31, 2026, by and between the Company and Streeterville Capital, LLC. (7)
     
10.7   Collaboration Agreement, dated as of June 9, 2026, by and between the Company and South Palm Cardiovascular Associates, LLC. (8)
     
10.8   Mutual Stock Purchase and Asset Exchange Agreement, dated as of October 14, 2026, by and between the Company and SOD Sciences, Inc.† (9)
     
10.9   First Amendment to Mutual Stock Purchase and Asset Exchange Agreement, dated as of October 15, 2026, by and between the Company and SOD Sciences, Inc. (10)
     
10.10   Amendment No. 2 to Mutual Stock Purchase and Asset Exchange Agreement, dated as of October 16, 2026, by and between the Company and SOD Sciences, Inc. (10)
     
10.11   Assignment and Co-Ownership Agreement (Test Interest), dated as of October 16, 2026, by and between SOD Sciences, Inc. and the Company† (10)
     
31.1*   Certification of the Chief Executive Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
     
31.2*   Certification of the Chief Financial Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
     
32.1**   Certification of the Chief Executive Officer pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
     
32.2**   Certification of the Chief Financial Officer pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
     
101.INS*   Inline XBRL Instance Document
     
101.SCH*   Inline XBRL Taxonomy Extension Schema
     
101.CAL*   Inline XBRL Taxonomy Extension Calculation Linkbase
     
101.DEF*   Inline XBRL Taxonomy Extension Definition Linkbase
     
101.LAB*   Inline XBRL Taxonomy Extension Label Linkbase
     
101.PRE*   Inline XBRL Taxonomy Extension Presentation Linkbase
     
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)
     
*   Filed herewith.
**   Furnished herewith.
#   Management contract or compensatory plan or arrangement.
†   Certain schedules (and exhibits) have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company agrees to furnish supplementally a copy of any omitted schedule or exhibit to the SEC upon request.

 

(1) Incorporated by reference to the Company’s Registration Statement on Form S-1, filed with the SEC on October 9, 2020.
(2) Incorporated by reference to the Company’s Current Report on Form 8-K, filed with the SEC on October 27, 2023.
(3) Incorporated by reference to the Company’s Current Report on Form 8-K filed with the SEC on July 7, 2026.
(4) Incorporated by reference to the Company’s Current Report on Form 8-K filed with the SEC on June 8, 2026. The form of certificate filed as Exhibit A to Exhibit 10.1 was erroneously titled “Series A Preferred Stock,” but it is the form of Certificate of Designation for the Series B Non-Convertible Preferred Stock.
(5) Incorporated by reference to the Company’s Current Report on Form 8-K filed with the SEC on June 25, 2026.
(6) Incorporated by reference to the Company’s Current Report on Form 8-K filed with the SEC on August 3, 2026.
(7) Incorporated by reference to the Company’s Current Report on Form 8-K filed with the SEC on September 8, 2026.
(8) Incorporated by reference to the Company’s Current Report on Form 8-K filed with the SEC on June 16, 2026.
(9) Incorporated by reference to the Company’s Current Report on Form 8-K filed with the SEC on October 15, 2026.
(10) Incorporated by reference to the Company’s Current Report on Form 8-K filed with the SEC on October 19, 2026.

 

45

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  Vivos Therapeutics, Inc.
   
Date: November 16, 2026 By: /s/ R. Kirk Huntsman
    R. Kirk Huntsman
    Chairman of the Board and Chief Executive Officer
    (principal executive officer)
   
Date: November 16, 2026 By: /s/ Roman Franklin
    Roman Franklin
    Chief Financial Officer
    (principal financial officer)

 

46

 

Keep reading